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Introduction 
Mechanistic and therapeutic aspects of ischemic myocardial preconditioning 
Background 
Despite significant therapeutic advances at the end of the 20th century, cardiovascular 
disease accounted for almost half of all deaths in modem society and one fourth in the 
developing world.1,2 By the year 2020, cardiovascular disease is estimated to have surpassed 
infectious disease and to become the world's leading cause of death and disability.3A In the 
industrialized world, cardiovascular disease is responsible for approximately 45% of overall 
mortality of which 50% is due to acute myocardial infarction.2 The proportion of 
cardiovascular deaths in the industrialized world is expected to show a modest decline to 42% 
of total death by the year 2020.2 In the developing world however, 23% of total mortality was 
due to cardiovascular disease in 1990. By 2020 this figure will increase to 34% of total 
mortality, accounting for approximately 75% of all cardiovascular deaths worldwide.2 
In the middle of the 20th century both arrhythmias and pump failure were the major 
causes for both high early and late in-hospital mortality. In the early 1960s the development of 
the coronary care unit with continuous electrocardiographic monitoring and external 
defibrillation significantly decreased early arrhythmic deaths by acute myocardial infarction 
thereby reducing early mortality by 50%. Substantial use of thrombolytic therapy, aspirin, ~­
blockers and coronary angioplasty further improved mortality and survival rates of acute 
myocardial infarction.5 
Due to a reduced mortality from acute myocardial infarction, left ventricular 
remodeling and heart failure will become a major problem in cardiovascular disease. In the 
mid 20th century the major causes of heart failure were rheumatic fever and hypertension. With 
the application of antibiotics, valve repair surgery and the improved therapy of hypertension, 
the most important cause of heart failure was shifted to myocardial ischemia and infarction. As 
a consequence of the improved survival of acute myocardial infarction, ventricular remodeling 
associated with large infarct size is currently the major cause of chronic congestive heart 
failure. Development of new therapeutic strategies to control and prevent ischemic heart 
disease and limit infarct size in order to mitigate development of remodeling and heart failure 
remains therefore a major challenge in cardiovascular therapy. 6 
Many investigators have studied myocardial ischemia and searched for means of 
reducing it in order to limit cellular injury. In 1935, Tennant and Wiggers observed that 
dyskinetic contraction of the ischemic myocardium appeared within seconds after occlusion of 
a major coronary branch. When the occlusion lasted less then 2 minutes, normal myocardial 
contraction returned upon reperfusion. But when the occlusion lasted longer, dyskinetic 
contraction continued.7 In 1941, Blumgart and co-workers further observed in the dog that 
severe infarction occurred after coronary occlusions for 40 minutes or longer. However, 
occlusions of 5-20 minutes did not result in infarction. With occlusions of intermediate 
duration, the extent of necrosis was dependent on the time to reperfusion. 8 Many years later, 
during the late 1960s and early 1970s Braunwald en colleagues demonstrated that the extent 
and severity of ischemic injury could be extended by increasing myocardial oxygen demands. 
But more importantly, ischemic injury could be reduced by lowering oxygen demands by ~­
adrenergic blockers.9-11 However, many other studies were not able to reproduce these 
findings. 12 In the mid 1970s Reimer and Jennings documented in the dog the presence of a 
subepicardial zone of ischemic but viable myocardium which is available for pharmacological 
or surgical salvage for at least three hours following coronary occlusion.13 Since timely 
reperfusion was the only way to limit damage during evolving myocardial infarction, in the 
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mid 1970s and early 1980s several investigators focused on developing techniques for 
myocardial reperfusion in patients. With the exception of reperfusion therapy, much basic and 
clinical research efforts in the search for means to delay or prevent myocardial ischemic injury 
yielded disappointing results. Early attempts at tissue salvage with calcium antagonists and 13-
blockers showed a large number of both promising and disappointing results. 12•14 
However, in 1986 Murry and coworkers15 made a seemingly paradoxical observation 
that relined interest in pharmacological infarct size reduction. In dogs, Murry et al. exposed the 
myocardium to a "preconditioning protocol" with repetitive short periods of regional ischemia. 
Surprisingly, they found that this protocol induced resistance to a subsequent long-lasting 
ischemic period. Infarct size after 40 minutes of ischemia was limited from 29% without 
preconditioning to 7% with preconditioning. The investigators concluded that they had 
discovered a new phenomenon of cardioprotection that was initiated by ischemia. Ever since 
its first report, many efforts of investigation on this phenomenon has allowed a better 
understanding into myocardial ischemia and several ischemic syndromes. However, the exact 
mechanism of ischemic preconditioning is not fully elucidated and many aspects of its 
molecular cellular process are still incompletely understood. Moreover, therapeutical 
application is very promising but has so far been very slow. In order to better understand this 
phenomenon and to facilitate its translation from the experimental laboratory to the clinical 
setting, this thesis will discuss some of the mechanistic and therapeutic aspects of the most 
powerful endogenous cardioprotection against ischemia, the phenomenon termed "ischemic 
preconditioning". 
Myocardial ischemia 
Definition 
Ischemia is characterized by an imbalance between myocardial oxygen supply and demand. In 
most situations this imbalance is due to a reduction of blood flow and oxygen supply 
secondary to a coronary artery obstruction caused by vasospasm or intra-coronary platelet 
aggregation and thrombus formation at the site of an atherosclerotic lesion. Myocardial 
ischemia can be defined as an imbalance between the supply of oxygenated blood and the 
oxygen requirements of the myocardium leading to disturbance of cardiac function. 16 Complete 
abolition of blood flow to a myocardial region is termed ''total ischemia". When an imbalance 
between supply and demand results from increased myocardial metabolic requirements even 
though coronary blood flow is maintained we refer to "demand ischemia". The term 'regional 
ischemia" is used when myocardial ischemia is confined to a region of the heart. If the entire 
heart becomes ischemic as occurs during systemic hypotension or aortic cross-clamping 
necessitated by various cardiac surgical procedures, the term "global ischemia" is employed. 
Consequences of myocardial ischemia 
In order to retain normal function and to furnish the energy demands of the contracting 
muscle, the heart strongly depends on a sufficient oxygen and substrate supply. The energy that 
is required is derived from high-energy phosphates such as adenosine triphosphate (ATP), 
mainly produced by oxidative phosphorylation in the mitochondria. Subsequent to ischemia, 
oxidative phosphorylation is thought to stop within only 8 seconds after coronary occlusion 
leading to inhibited contractile function and anaerobic metabolism i.e. ATP production by 
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anaerobic glycolysis. 17 End products of anaerobic glycolysis are protons and lactate from 
glycolytic turnover.18 
Total coronary artery occlusion can elicit three responses of myocardial function 
depending upon the duration of ischemia. First, ischemia lasting less than 2 minutes does not 
result in any irreversible myocardial damage and both cardiac metabolism and contractile 
function return to baseline during reperfusion.7 Secondly, an occlusion lasting approximately 
between 2- and 20-min results in reversible damage characterized by a temporary impaired 
contractile function during restored normal myocardial blood flow with no evidence of cell 
death. During the 1970s Heyndrickx et al. first described this phenomenon of prolonged 
contractile dysfunction of fully reperfused viable myocardium.19,2o which was later termed 
"myocardial stunning" by Braunwald and Kloner.21 •22 In conscious dogs, contractile 
dysfunction after 15 min of coronary occlusion varies from less than 1 hour to several days?3 
Finally, when coronary blood flow is not restored and ischemia persists for more than 20 min, 
cardiomyocytes become irreversibly damaged leading to cell death either by apoptosis or 
necrosis. Myocardial cell death by ischemia is defined as "myocardial infarction". 
Determinants of myocardial infarct size 
A major determinant of infarct size is the time during which the myocardium is 
deprived from blood flow. Experiments in pigs have indicated that by 60 minutes occlusion the 
transmural extent of the infarct was 87%, increasing to 96% by 90 minutes and to maximum 
infarction at 24 hours?4 
In rats however, a full transmural myocardial infarction develops within 2 hours?5 In 
reviewing such interspecies differences Schaper and co-workers pointed out that infarct size 
depends upon the presence of collateral blood flow. 26 In rabbits, pigs and rats, collateral flow is 
virtually absent resulting in complete infarction after 1-1.5 hours ischemia. However, in guinea 
pigs in which collateral circulation is well developed, occlusion of a major coronary branch 
does not result in myocardial necrosis. Infarct size progression in humans is more gradual due 
to the presence of moderate collateral flow,26 two hours of ischemia results in 50% infarction 
of the area at risk, whereas infarction after 6 hours is complete (fig. 1).27 Next to duration of 
ischemia and collateral blood flow, an important determinant on the variability in infarct size is 
the myocardial area at risk zone. In dogs, the amount of necrosis after 40 min proximal 
coronary circumflex occlusion correlated closely with the size of the occluded coronary bed.28 
Therefore infarct size is typically expressed as percentage of area at risk zone. 
The role of myocardial oxygen demand at the onset of occlusion is controversial. In 
dogs a positive correlation has been reported between infarct size and myocardial oxygen 
demand estimated by the product of heart rate and left ventricular systolic pressure?9•30 
However, these studies used anesthetics that highly affected heart rate and ventricular pressure. 
An increase in heart rate can decrease collateral blood flow and redistribute collateral flow 
away from subendocardium, while an increase in blood pressure can increase collateral flow by 
increasing collateral driving pressure.31 In species with minimal collateral flow, infarct size is 
not significantly correlated with the rate-pressure product.32 However, the myocardium ceases 
to contract early after onset of occlusion so that energy utilization is confined mainly to 
maintenance of ionic homeostasis and basal metabolism. Under these conditions, the rate-
pressure may no longer reflect the energy demands of ischemic myocardium. 
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Finally, another important factor that contributes to infarct size variance is temperature. 
Hypothermia with temperatures below 30° C has shown to reduce infarct size.33,34 Heart rate is 
decreased by hypothermia, however the decrease of myocardial oxygen demand does not 
explain the correlation between infarct size and temperature.35-37 Proposed mechanisms 
responsible for protection by hypothermia include acidosis and maintenance of ion 
homeostasis during ischemia and reperfusion. Furthermore, a reduction of basal metabolic 
rates leading to slowing of high-energy phosphate depletion may be responsible. 
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Figure 1 Development of irreversible myocardial damage during total coronary occlusion in different species. 
(modified from Schaper et al26 and Arnold et al2) 
Reperfusion and reperfusion injury 
The concept of limiting infarct size was first developed based on studies involving 
human autopsies showing that infarct size was significantly smaller than the myocardial region 
supplied by the occluded coronary artery. In the early 1970s Braunwald and co- workers 
reported that ischemic injury could be limited by lowering myocardial Oz demands by beta 
adrenergic blockade.9-11 Early experimental studies occasionally showed an infarct size 
limiting effect by a drug, but others were often unable to reproduce these observations.38 To 
date, early coronary reperfusion is clinically the most effective means to limit the size of a 
myocardial infarct. To salvage ischemic or hypoxic myocardium, reinstatement of coronary 
flow is necessary. Timely reperfusion will limit cardiomyocyte damage and decrease cardiac 
mortality and morbidity. Current reperfusion therapy includes thrombolysis and percutaneous 
coronary intervention (PTCA), which are standard treatment in impending acute myocardial 
infarction. 
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Reperfusion itself may paradoxically lead to additional tissue injury beyond that 
generated by ischemia alone, a phenomenon termed repeifusion injury. Rosenkranz and 
Buckberg have provided a general definition of this term: "Reperfosion injury refers to those 
metabolic, jUnctional and structural consequences of restoring coronary flow that can be 
avoided or reversed by modification of the conditions of repeifusion. 39 The cellular damage 
that results from reperfusion can be reversible or irreversible, depending on the length of the 
ischemic insult. When reperfusion is initiated approximately within 20-min after the onset of 
ischemia, the resulting myocardial injury is reversible and is characterized by functional 
impairment of contractility that may persist for a variable period but eventually recovers 
completely. As mentioned earlier, this phenomenon is known as myocardial stunning.20 
Another manifestation of reversible reperfusion injury after less prolonged ischemia is the 
occurrence of reperfosion arrhythmias. In anesthetized dogs, ventricular fibrillation within the 
first few seconds of reperfusion is most likely to occur when the entire ischemic region is still 
viable (and excitable) and is progressively less likely to occur as the amount of potentially 
salvageable myocardium decreases by cell death.4° For any particular duration of ischemia, the 
major determinants ofreflow ventricular fibrillation are the severity of ischemia, the size ofthe 
area at risk and the heart rate.41 Ventricular tachyarrhythmias after myocardial 
revascularization are considered to be a benign transient event. In the clinical setting however, 
it appears to increase the risk of future life-threatening events in patients.42 Sustained 
ventricular tachycardia after coronary artery bypass grafting is uncommon but considered as a 
serious complication with an unsatisfactory prognosis.43 
Myocardial reperfusion, which is initiated after a duration of ischemia longer than 20-
min, results in irreversible myocardial injury or cell death. Tissue necrosis by reperfusion 
injury may occur within minutes of reperfusion and is additive to cell death due to the ischemic 
event itself.44 Moreover, the extent of cell death during reperfusion appears to be related to the 
duration of the ischemic event. 44 Increasing evidence indicates that lethal reperfusion possibly 
consists of two forms of cell death namely necrosis and apoptosis. Several studies strongly 
support the existence of reperfusion-induced necrosis.45•46 Moreover, it has been reported that 
the apoptotic process (programmed cell death) is initiated upon onset of ischemia but becomes 
markedly enhanced during reperfusion.47 Finally, when a coronary artery is occluded 
sufficiently long, detrimental changes occur in the cardiac capillaries and arterioles.48 After 
release of occlusion, blood flow to the ischemic tissue may still be impeded, a phenomenon 
known as "no rejlow". In a study by Kloner et al.,49 dogs were subjected either to 40- or 90 
minutes of coronary artery occlusion. When the coronary occlusion was restored after 40-min, 
blood flow to the ischemic myocardium was completely restored. In contrast, when blood flow 
was restored after 90-min occlusion, there was only partial restoration of blood flow to the 
myocardial tissue. It appears that the longer ischemia lasts, the more likely the "no-reflow" 
phenomenon is to occur. Further examination of the no-reflow areas revealed significant 
capillary damage in the form of swollen endothelium, intraluminal platelets and fibrine 
thrombi. These microcirculatory changes in combination with interstitial edema could 
compress the capillaries and may therefore be responsible for the no-reflow phenomenon. 48 
At least three major pathways have been proposed as possible mechanisms of lethal 
reperfusion injury. First, cellular acidosis could contribute to a calcium overload via 
sodium/hydrogen exchange and calcium/sodium exchange.50 When irreversibly injured 
myocytes are reperfused, the development of contraction band necrosis is well known to be 
associated with a major calcium overload resulting in mitochondrial calcification.51 In this 
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setting, a major calcium overload is the most likely cause of myofibrillar hypercontraction, and 
could contribute to rupture of the sarcolemma. Moreover, cellular calcium overload, 
particularly in association with oxidative stress, is followed by a mitochondrial calcium uptake 
which may trigger pathological states that lead to cell death. 52 Nevertheless, the importance of 
a modest calcium overload during ischemia and early reperfusion as a cause of myocardial cell 
injury remains a subject of debate. Second, ischemia is accompanied by an intracellular 
osmotic load of accumulated catabolites that could cause cell swelling when reperfusion 
provides an effectively unlimited supply of plasma water. This osmotic swelling coupled with 
an already weakened membrane, could result in membrane rupture. 53 Finally, oxygen derived 
free radicals such as superoxide anion, hydroxyl radicals and peroxynitrite may injure the 
sarcolemma. 54 Bolli and colleagues demonstrated that free radicals produced within the first 
few minutes of reflow play a significant role in myocardial stunning.55 Free radicals can be 
generated by several sources such as the mitochondrial respiratory, xanthine oxidase, 
metabolism of arachidonic acid, oxidation of catecholarnines and the NADPH oxidase of 
activated neutrophils. Reperfusion injury by free radicals can be induced by a reaction with 
polyunsaturated fatty acids, which results in the formation of lipid peroxides and 
hydroperoxides that damages the sarcolemma and impairs the function of several membrane-
bound enzyme systems. It remains however unclear whether free radicals contribute to lethal 
reperfusion injury. 
Cardiac adaptation to ischemia: Ischemic Myocardial Preconditioning. 
Much basic and clinical effort has been put into the quest for means to delay or prevent 
myocardial ischemic injury. Potential application of such therapy includes (i) preservation of 
myocardium during cardiac surgical procedures when transient periods of myocardial ischemia 
can occur during a substantial part of the procedure, and (ii) prevention or limitation of 
myocardial infarct size. During the 1970s and early 1980s considerable efforts in limiting 
myocardial infarct size had little success with the exception ofreperfusion therapy.38 
However, in 1979, Verdouw et al56 studied the effect of repeated local ischemia and 
reperfusion in pigs on myocardial metabolism and ventricular performance and observed that 
lactate and inosine release were much smaller during the second coronary occlusion period 
than during the first. Capitalizing on this apparent metabolic adaptation of the heart to repeated 
ischemic stress, Murry et al. 15 first demonstrated in 1986 that repeated brief episodes of non-
lethal ischemic myocardial stress elicit an increased resistance to infarction caused by a 
subsequent prolonged ischemic insult. Abundant evidence showed that this phenomenon 
known as "ischemic preconditioning" is the most powerful endogenous protective mechanism 
against ischemic-reperfusion injury in animals. An enormous amount of research over the last 
17 years has documented this phenomenon in all species including the pig,57 the rabbit58 and 
the rat.59•60 Most importantly, substantial evidence suggests that ischemic preconditioning 
occurs in human myocardium.61-65 Remarkable observations in the laboratory of this protective 
phenomenon have made extrapolation to the cardiology clinic or the operating room very 
attractive. However, since acute myocardial infarction in patients has usually already occurred 
when reaching the emergency room, application of preconditioning as a therapeutic strategy 
has so far been very prudent. 
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Definition of ischemic myocardial preconditioning 
In the in vivo open chest dog, Murry and co-workers observed that infarct size after 40-
min of coronary occlusion was reduced by 75% when preceded by 5-min episodes of coronary 
occlusion interspersed by 5-min reperfusion. 15 Thus, despite a longer cumulative duration of 
coronary occlusion, infarct size in preconditioned canine myocardium averaged only one 
fourth of that seen in controls. In the strict sense, ischemic preconditioning refers to the 
phenomenon that one or more brief non-lethal ischemic episode(s) initiates a cellular 
myocardial adaptation process that limits myocardial injury produced by a prolonged period 
of coronary artery occlusion and reperfosion. As a result, reduction of infarct size is regarded 
as "gold standard" of ischemic preconditioning.66 
TK 
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Figure 2 Schematic illustration of intracellular signal transduction pathway during ischemic preconditioning 
leading to an early "first window ofprotection"and a late "second window of protection". PIP2 indicates 
phosphatidyl inositol diphosphate; DAG, diacylglycerol; PLC, phospholipase C; PW, phospholipase D; IP3, 
inositol triphosphate; TK, tyrosine kinase; PKC, protein kinase C; MAPK, mitogen-activated kinase (modified 
from Cohen et al66) 
Ischemic preconditioning is not organ specific and has been demonstrated in several 
other organs including the kidney,67 brain,68 skeletal muscle,69 liver,70'71 lung72 and small 
intestine73• However, in these reports, endpoints were not always infarct size. 
Cardioprotection by an ischemic stimulus manifests itself in two different time 
windows. The first window of protection known as classic preconditioning appears a few 
minutes after initiation of the stimulus and disappears within approximately two hours.74-76 
Classic preconditioning is believed not to involve protein synthesis. The second window of 
protection known as delayed preconditioning reappears approximately 24 hours after the 
stimulus lasting for about 72-96 hours and requires transcription and protein synthesis. Both 
windows of protection partly share the same intracellular transduction pathway in which G-
linked sarcolemmal receptors, protein kinase C and ATP-sensitive K+- channels play a key role 
(Fig. 2). 
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Ischemic preconditiotring refers to delaying infarct development during ischemia. It is 
important to point out that the evolution of cell death is only delayed but not prevented. After 
prolonged (i.e. exceeding two hours) or permanent occlusion, infarct size in preconditioned 
myocardium is equally severe to non-preconditioned myocardium. Thus, cardioprotection by 
classic preconditiotring is limited to a time-window of protection (fig. 3). 
A possible explanation for the delay of cell death (either by necrosis or apoptosis) is that 
ischemic preconditiotring also reduces the energy demand during the early phase of a 
subsequent ischemic episode thereby resulting in less accumulation of glycolytic catabolites 
and slowing down of ATP depletion. The mechanism by which a decreased anaerobic 
glycolysis exactly determines the extent of ischemic injury remains unclear. 
Another possible characteristic of preconditiotring is the reduction in ischemia-
reperfusion arrhythmias in rats77"79 and rabbits. 80•81 In dogs however, results have been 
conflicting.79•82 The situation is further complicated in the pig model in which brief antecedent 
ischemia appears to be proarrhythmic.83 Nevertheless, there is evidence which demonstrate an 
antiarrhythmic protection in humans. 84-86 
Finally, ischemic preconditiotring also reduces postischemic contractile dysfunction87•88 
which is most likely reflected by reduced infarct size38•89 since it does not attenuate myocardial 
stuntring.90•91•92 Focusing on the heart as the target to protect, reduction of infarct size will 
remain as ''the gold standard" of protection. 
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Figure 3 Schematic illustration of the time window of protection showing that ischemic preconditioning 
results in a rightward shift of the infarct size - time relation indicating a delay in development of cell death. 
Infarct size by prolonged coronary occlusions exceeding two hours, is equally severe to non-preconditioned 
myocardium. 
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Ischemic- and non-ischemic myocardial preconditioning stimuli 
In the aforementioned study by Murry et al., 15 ischemic preconditioning was elicited by 
abrupt coronary occlusion and reperfusion in normal non pathologic arteries which does not 
reflect the clinical setting. However, Ovize et al. 93 demonstrated that partial stenosis causing 
50% coronary flow reduction for 15-min, was able to confer cardioprotection. In that study 
reperfusion between the ischemic stimulus and the prolonged total coronary occlusion was a 
necessity to obtain infarct size reduction. Using the Harris two-stage model, Koning et al.94 
observed in the pig that cardioprotection can be initiated without intermittent reperfusion 
provided that the ischemic stimulus is sufficiently severe. Thus a 70% coronary flow reduction 
lasting for 30-min innnediately followed by a 60-min total occlusion resulted in infarct size 
reduction. However, moderate flow reduction of 30% did not show any protective effect. 
Finally, Ito et al. reported cardioprotection after gradual progressive coronary flow reduction.95 
These findings clearly suggest that the severity and/or duration of the flow reduction play a 
pivotal role in triggering the protective effect. 
In addition to brief myocardial ischemia, several other non-ischemic triggers have been 
shown to initiate myocardial preconditioning. For instance, acute left ventricular volume 
overload leading to ventricular stretch protects the myocardium against a subsequent 
prolonged ischemia. Stretch-induced cardioprotection evolves most likely through protein 
kinase C and opening of ATP-sensitive K+ channels.96 In addition, Koning et al. increased 
heart rate up to 200 bpm in the porcine heart by electrical ventricular pacing which was also 
able to induce protection against myocardial ischemia. Pacing lasted for 30-min without 
developing ischemia. Cardioprotection was completely abrogated by pretreatment with the 
ATP-sensitive K+ blocker glibenclamide suggesting a K+ channel involved mechanism.97 Apart 
from changes in collateral flow and protein kinase C activation, preconditioning was mimicked 
by 5 brief episodes of tachycardia in the canine, which was mediated by adenosine. Finally, 
heat stress by a 15-min period of 42° C hyperthermia has also been shown to trigger 
myocardial preconditioning via opening of ATP-sensitive K+ channels. Thus, the mechanism 
by which non-ischemic stimuli elicit cardioprotection is very similar to the mechanism of 
ischemic stimuli. 
Many investigators have attempted to unravel the mechanism of this protective 
phenomenon for pharmacological exploitation in the clinical setting. Agents that activate 
components involved in the mechanism of ischemic preconditioning can also initiate 
cardioprotection after oral or intravenous administration. As part of unraveling the mechanism, 
several pharmacological agents like adenosine,98•99 bradykinin, 100 opioids 101 norepinephrine, 102 
protein kinase C activators103•104 and ATP-sensitive K+ channel openers105•106 have 
demonstrated a protective effect when administered before sustained ischemia which is 
confirmed in all species used for experimental study. 
Remote Preconditioning 
In the above-mentioned studies, both the ischemic stimulus and the sustained ischemia 
were applied to the same myocardial region. Therefore, Przyklenk et al. investigated the 
concept whether a brief ischemic stimulus applied in one coronary vascular bed protects 
adjacent naive myocardium from subsequent sustained ischemia.107 In this study, dogs were 
assigned to undergo 4 episodes of 5-min occlusions of the circumflex coronary artery followed 
by one hour of prolonged ischemia by occlusion of the left anterior descending artery. Indeed, 
infarct size was significantly reduced when compared to sustained occlusion in the non-
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preconditioned group. This concept of cardioprotection at a distance, further referred to as 
intra-cardiac remote preconditioning can be explained by the activation of stretch-activated 
channels, since severe myocardial dysfunction leads to stretch of the adjacent non-ischemia 
myocardium.96 However, it is also possible that the protection could be due to the transfer of 
protective factor(s) via collaterals connecting both territories.108 Other possible proposed 
means of transport are diffusion109 and communication via cardiac gap-junctions. Some reports 
suggest that gap-junction communication plays a role in conventional preconditioning.110•111 
Most interestingly, the second messenger IP3 which has been shown to be increased during 
classical ischemic preconditioning is also known to traverse gap-junctions. 112 
Since Przyklenk et al. were able to elicit cardioprotection in adjacent myocardium via 
remote coronary artery occlusion, other investigators extended the concept of preconditioning 
at a distance by applying the brief ischemic stimulus into a remote organ or vascular bed. This 
concept of inter-organ remote preconditioning was first suggested by a preliminary study of 
McClanahan and colleagues who reported that cardioprotection in the in vivo rabbit model by a 
transient 1 0-min occlusion of the left renal artery was similar in reducing infarct size to 
preconditioning by 5-min of brief coronary artery occlusion. 113 Subsequently, Gho et al. 114 
showed in the anesthetized rat model in which body core temperature was maintained constant, 
that remote preconditioning by brief 15-min mesenteric artery occlusion effectively limited 
infarct size caused by a 60-min sustained coronary occlusion. This inter-organ preconditioning 
of the heart has been further confirmed for the small intestine/ 15-119 kidney120-122 and skeletal 
muscle.123 Nevertheless, not all remote organs might be able to precondition the heart at a 
distance since de Zeeuw et al. 124 did not find any infarct size reduction after coronary artery 
occlusion when preceded by global cerebral ischemia. Although very limited, several reports 
demonstrate involvement of a delayed phase via endogenous calcitonin-gene-related peptide in 
a nitric oxide dependent pathway125 and the activation of capsaicin-sensitive sensory nerves.115 
The precise mechanism underlying inter-organ preconditioning is still incompletely 
understood. In the study by Gho et al. cardioprotection was abolished when the animals were 
pretreated with the ganglion blocker hexamethonium, indicating that the protective mechanism 
is transported via a neurogenic pathway rather than humoral factors. Another fundamental 
issue is the importance of intervening reperfusion of the remote organ after the ischemic and 
prior to the coronary artery occlusion. In the same study, Gho et al. observed that permanent 
mesenteric artery occlusion without interspersing reperfusion failed to limit infarct size to a 
subsequent 60-min coronary occlusion suggesting that reperfusion of the small intestine was 
mandatory, presumably to wash-out mediators from the remote organ to activate the 
neurogenic pathway. However, the specific mediators remain poorly characterized. There is 
emerging evidence that inter-organ preconditioning is triggered by the release of adenosine, 
bradykinin and/or endogenous opioids from the remote organ. Thus, recent studies suggest that 
cardiac preconditioning by brief renal and intestinal ischemia may be achieved via adenosine 
receptors/20' 121 activation/translocation of PKC, 118•119 and opening of mitochondrial and/or 
sarcolemmal KATP channels.120 Recent data on hind-limb ischemia by infra-renal aortic 
occlusion showed involvement of the ol-opioid receptor as well as PKC activation, but in 
contrast to small intestinal ischemia, cardiac preconditioning by brief hind-limb ischemia may 
be transmitted by a humoral pathway rather than a neurogenic pathway. 126 If humoral factors 
are able to elicit remote preconditioning, it may be possible to transfer the protection at a very 
great distance via collection and transfusion of coronary effluent. Dickson et al. 127•128 therefore 
explored in the isolated rabbit heart whether coronary effluent released during 3 brief ischemic 
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preconditioning stimuli of global ischemia when reoxygenated and administered to naive donor 
acceptor hearts can trigger cardioprotection. Indeed, Dickson observed that the acceptor hearts 
exhibited infarct size limitation after receiving donor coronary effluent released during 
preconditioning stimuli when compared to the donor control group. The mechanism 
responsible for transferred remote preconditioning, most likely humoral factors, remains 
incompletely understood. Both adenosine and/or norepinephrine have been proposed as the 
responsible humoral factors. 128 
Mechanism of the signal transduction pathway 
Since ischemic preconditioning exerts a very powerful anti-infarct effect, elucidation 
and manipulation of the signal transduction pathway could lead to development of anti-infarct 
therapy. By gaining substantial understanding of how cells can protect themselves against 
ischemic injury we may be able to develop agents capable of directly limiting cellular injury. 
Ever since its first report by Murry et al. in 1986, many efforts have attempted to unravel the 
mechanism behind the transduction pathway of preconditioning including triggers and 
mediators in the early phase, and potential end-effectors in the late phase of ischemic 
preconditioning. 129 Triggers may be important during preconditioning ischemia and 
reperfusion. Mediators may be important during the prolonged index ischemia. As 
aforementioned, mechanisms of the first window of protection and the second window are not 
entirely similar. This thesis will mainly focus on classic preconditioning i.e. the first window 
of protection. 
Trigger phase 
Protection by preconditioning is receptor mediated. Several humoral factors released 
during preconditioning ischemia initiate the cardioprotective effect by binding to their 
respective receptors. These metabolites and by products are adenosine, 130•131 
bradyldnine, 100•132•133 opioids, 134-136 acetylcholine, 137 norepinephrine, 138•139 angiotensine, 140 
endothelin141•142 and free radicals. 143•144 All receptors are linked to inhibitory G-proteins and 
phospholipases C and/or D. Phospholipase C catalyzes the hydrolyses membrane inositol-
containing phospholipids into inositol triphosphate and diacylglycerol which stimulates the 
translocation and activation of protein kinase C. Many investigators have reported that 
adenosine plays the major key role in triggering the preconditioning response, but it is 
hypothesized that bradykinin, opioids and free radicals share their triggering role in addition to 
adenosine reaching a threshold together.66 
The role of nitric oxide in ischemic preconditioning has not yet been precisely clarified, 
but it has been reported that blockade of nitric oxide synthase attenuates the increased 
functional recovery in ischemia/reperfusion injury in rats. 145•146 However, several studies in 
Bolli's laboratory demonstrated that nitric oxide seems to be of major importance in the second 
window of protection. 147 
The flux of calcium through L-type calcium channels has been in dispute as a potential 
trigger. Atrial muscle from patients with blockade of L-type calcium channels failed to be 
preconditioned by ischemia 148 Nevertheless, the calcium antagonist nisoldipine failed to 
abrogate cardioprotection in the anesthetized pig.149 
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The importance of each receptor may depend on the species and the induced stimulus. 
An increase of interstitial adenosine concentration occurs in rats, 150 rabbits, 151 dogs, 152 and 
pigs.133 Blockade of A1- and A3- but not A2-receptors abolishes the infarct size 
limitation.130•153•154 In the rat however, involvement of adenosine in ischemic preconditioning is 
still unclear. Kuzmin et al. demonstrated an increase of interstitial adenosine levels during 
regional ischemia and reperfusion in the rat.150 In contrast, several studies using adenosine-
receptor antagonists were not able to abrogate preconditioning in rats.60•155 A study by Li and 
Kloner, failed to block cardioprotection with the non-selective adenosine receptor antagonist 8-
SPT by a triple 3-min ischemic stimulus.156 Therefore Ganote and Armstrong recently 
concluded that there is now general agreement that, in contrast to other species used for 
experimental research, adenosine does not play a role in myocardial infarct size limitation in 
rats. 157 Bradykinin, clearly demonstrates an anti-infarct effect. The increase in the interstitial 
bradykinin concentration occurs earlier than the interstitial adenosine levels in pigs. 133 It is 
therefore a major trigger during ischemic stimuli of shorter durations while during more 
prolonged ischemic stimuli adenosine is more important.100•133 
During hypoxia or ischemia-reperfusion, mitochondrial respiration and oxidative 
phosphorylation are gradually uncoupled resulting in an increase of free radical production. 158 
Free radicals not only damage cardiac myocytes 159 but also act as triggers of ischemic 
preconditioning. Infusion of N-2-mercaptoglycerine an antioxidant or dimethylthiourea a 
radical scavenger both block the protection by ischemic preconditioning.143' 144 It is still elusive 
how exactly free radicals can trigger a preconditioning effect but they are known to activate G-
proteins, 160 protein kinases144 and ATP-sensitive potassium channels.161 
Mediator phase 
Studies in rabbits by Ytrehus et al. 103 and rats by Mitchell et al. 104 simultaneously 
concluded that protein kinase C activation is central to the protection by ischemic 
preconditioning. Activation of protein kinase C is physiologically mediated by liberation of 
diacylglycerol, which binds to the regulatory subunit of protein kinase C. In rabbits, blockade 
of protein kinase C alone with chelerythrine completely abolishes the infarct size reduction 
triggered by an ischemic stimulus.162 But in rats, dogs and pigs the results of pharmacological 
blockade are still controversial.163-165 In the pig, the selective protein kinase C inhibitor 
staurosporine was not able to block myocardial preconditioning.165 Ping et al. 166 identified 11 
protein kinase C isozymes in the rabbit heart. Using specific antibodies for each isozyme she 
demonstrated that 4 cycles of reperfusion interspersed by 6-min reperfusion caused 
translocation of only two isozymes namely e and 11 suggesting it was one of these two 
isozymes that contributed to cardioprotection. 163 It is now generally accepted that isozyme 
translocation of protein kinase C either to the sarcolemma or the surface of mitochondria, does 
occur during ischemic preconditioning further conducting the signal transduction pathway by a 
phosphorylation cascade. 
Events downstream have currently been the main focus of investigation. In the rabbit, 
administration of tyrosine kinase antagonists such as genistein or lavendustin A aborted 
ischemic preconditioning's protection in the rabbit.167 Since both genistein and lavendustin A 
can block the protection induced by PMA, a direct activator of protein kinase C, the involved 
tyrosine kinase is most likely downstream from protein kinase C.167 In rabbits, protein kinase c 
and tyrosine kinase appears to be in series. In other species however, tyrosine kinase may also 
act in a parallel pathway bypassing protein kinase C. Vahlhaus and coworkers failed to 
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abrogate cardioprotection from ischemic preconditioning with an antagonist of protein kinase 
C or tyrosine kinase alone. Yet, combined blockade with both genistein and staurosporin 
completely eliminated the protection, suggesting the existence of a parallel pathway next to 
protein kinase C containing at least on tyrosine kinase residue. This parallel pathway may be 
similar in rats and dogs. 168•169 In rats, multiple cycles of preconditioning can overcome the 
abrogation of protection by protein kinase C blockers. 168 
Another potential downstream target in addition to protein kinase C and tyrosine kinase 
are the mitogen-activated protein kinase (MAPK). Each subfamily: ERK, JNK and p38 have 
been suggested to play a major part in the preconditioning transductionpathway.170•171 The 
MAP-kinase family is activated by dual phosphorylation of a serine or threonine residue by a 
MAP kinase kinase and can translocate into the nucleus. 170 The MAP kinase kinase appears to 
be the tyrosine kinase in the signaling transduction pathway. 172 Most attention has focused on 
p38 MAP kinase. The selective inhibitor SB203580 can block the preconditioning effect in 
isolated rabbit cardiomyocytes suggesting p38 mediates its protection.172 However, in isolated 
rat hearts173 and pigs in vivo/74 blockade of p38 does not affect the infarct limiting effect by 
ischemic preconditioning. Following ischemic preconditioning, phophorylation of p38 during 
index ischemia has been reported to be increased in isolated rat- and rabbit hearts, unaltered in 
pig hearts in vivo and even decreased in dog hearts. Explanations for the controversial findings 
might be due to the different isoforms of p38 in different species. 
Potential end effectors 
Although many investigators have speculated on the elusive end-effector, to date this is 
still an ongoing debate. A possible mechanism for the infarct size limitation by ischemic 
preconditioning is the reduction of energy demand by slowing down ATP consumption during 
index ischemia.175 In addition, a reduced accumulation of ischemic catabolites such as lactate 
resulting in an decreased intracellular acidification reduction has been reported.176 This reflects 
a reduced anaerobic glycolysis. 
Whether protein synthesis is required to mediate the first window of protection in 
ischemic preconditioning is controversial. A transcriptional blockade seems not have any 
affect,177 but a blockade at the translational level was able to abolish preconditioning.178•179 
Furthermore, Xiao and Allen have suggested that the sodium-proton exchanger could be the 
end-effector. They noted that the sodium-proton exchanger was blocked during reperfusion 
when rat hearts were preconditioned.180 In rabbits, blockade of the sodium-proton exchanger 
limited infarct size to a similar extent as an ischemic stimulus.181 Both several kinase inhibitors 
and ATP-sensitive potassium channel blockers were able to abrogate this protection suggesting 
that the sodium-channel exchanger must be operational at a distant point in the signal 
transduction pathway. 
Prolonged ischemia can cause cytoskeletal disruption.182 The small heat shock protein 
HSP27 is known to regulate actin filament organization and stabilizes actin filaments during 
oxidative stress. 183 In isolated cardiac rat myocytes, overexpression of HSP27 confers 
protection to ischemia 184 It appears that redistribution of heat shock proteins from the cytosol 
to the sarcomere followed by alteration in the stability of the cytoskeleton is important for 
triggering cardioprotection by ischemic preconditioning.185•186 
During normal conditions the osmolarity of bodyfluid and cellular osmotic balance is 
maintained by matching the osmotic pull of proteins and nucleotides within the cell and by 
sodium outside the cell. During ischemia, ATP breaks down to AMP and inorganic phosphates 
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hereby tripling the osmotic pull leading to osmotic imbalance with cellular swelling of the 
ischemic cells. In preconditioned rat and pig hearts, the extent of myocardial edema is reduced 
along with infarct size. 187•188 Chloride channels are involved in volume regulation opening the 
possibility that opening of swelling induced chloride channels are responsible for the 
protection of ischemic preconditioning. 189 Furthermore, inhibition of the sodium-hydrogen 
exchanger may also prevent cell swelling. Finally, connexin 43 concentration, which regulates 
cell volume, may be maintained by preconditioning since loss of connexin 43 occurs during 
myocardial ischemia. 190 All the above-proposed end-effectors however, resulted in 
confounding results leading to speculation rather than clear conclusions. 
Gross and Auchampach were the first to propose that ATP-sensitive potassium 
channels mediate the effect of ischemic preconditioning based on pharmacological studies. In 
canine hearts ATP-sensitive channel openers like cromakalim and bimakalim mimicked 
cardioprotection whereas channel blockers, such as glibenclamide and 5-hydroxydecanoate 
abort the protection. 191 Two distinct ATP-sensitive potassium channels have been identified in 
cardiomyocytes: the sarcolemmal and mitochondrial channels each with a distinct 
pharmacological profile. Since Gross used glibenclamide blocking both channels, it was 
originally assumed that sarcolemmal ATP-sensitive potassium channel opening was the end-
effector by shortening of the action potential duration which can possibly lead to a lower 
metabolic demand and less Ca2+ overload. Subsequently, Grover and coworkers demonstrated 
that ATP-sensitive potassium channel opening by either BMS-180448 and cromakalim were 
also able to exert cardioprotection independent of any action potential shortening. 192•193 The 
class III antiarrhythmic agent dofetilide abolished action potential shortening without affecting 
the protection of preconditioning. 194 Additionally, HMR -1883 which selectively closes 
sarcolemmal potassium channels had no affect on infarct size limitation in preconditioned 
rabbit hearts. 195 Both Marban and Grover groups simultaneously provided convincing evidence 
that it was indeed not the surface potassium channel, but the mitochondrial ATP-sensitive 
potassium channel that was involved in the protection. 196-198 They found that the selective 
mitochondrial potassium channel opener diazoxide was as cardioprotective as ischemic 
preconditioning without affecting the sarcolemmal potassium channels. 5-hydroxydecanoate 
reversed this protection. For a while it was generally accepted that the mitochondrial ATP-
sensitive potassium channels were the end-effectors. Nevertheless, it has been difficult to 
understand how opening of mitochondrial ATP-sensitive potassium channels exerts 
cardioprotection, therefore many investigators are currently questioning whether these 
channels are indeed end-effectors rather than mediators or even triggers. 
Role of mitochondria in cardioprotection 
Mitochondrial function during normal conditions 
Under normal conditions, myocardial oxygen supply and expenditure are tightly 
coupled, from the point of energy production in the inner membrane of the mitochondria to the 
point of energy utilization within cellular sites. Reducing equivalents are generated from 
sequential breakdown of substrates and transferred in the form of NADH and F ADH2. Oxygen 
serves as the ultimate electron recipient in the electron transport chain, and the overall reaction 
results in 1.5 moles of A TP per mole of NADH and 2.5 moles of ATP per mole of F ADH2 
when transferred to 0 2• It is within the inner membrane of the mitochondria that the 
biochemical reactions of oxidative phosphorylation result in the transfer of electrons from 
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reducing agents, by virtue of differences in oxidation-reduction potentials. As electrons are 
transferred between complex I and complex IV, protons are translocated across the inner 
membrane of the mitochondria and a proton gradient is established. A total of 10 protons are 
"pumped" across the membrane in the transfer of two electrons from NADH to 0 2. It is by this 
series of proton pumps that the matrix becomes more alkaline relative to the external surface of 
the inner membrane, creating an electrochemical gradient (-A 'P). This electrochemical energy 
is sufficient to drive A TP synthesis from ADP in complex V (fig. 4). 
4H+ 2H+ 4H+ 
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I II III IV 
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Figure 4 Overview of the complexes I-V and pathways of electron transfer in mitochondrial electron transport 
chain. NQ indicates NADH-co-Q- reductase; GQ, glycerol-3-P co-enzyme Q reductase; co Q, co-enzyme Q; 
SQ, Succinate-co-enzyme Q reductase; CR, co-enzyme (!-cytochrome c reductase; CR, Cytochrome c; CO, 
cytochrome c oxydase 
Mitochondria and ischemic preconditioning 
The preservation of mitochondrial function in ischemic preconditioning has been well 
recognized by the observation that the rate of ATP loss was reduced during the subsequent 
prolonged period of ischemia versus control hearts.175 Similarly, a study by Fryer et al. 199 
demonstrated that isolated mitochondria from the area at risk of preconditioned hearts had 
higher rates of ATP synthesis compared to those of hearts subjected to prolonged ischemia 
without ischemic preconditioning stimulus. This preservation of mitochondrial function was 
abrogated by 5-hydroxydecanoate, supporting an improved ATP production as a common 
feature of ischemic preconditioning and mitochondrial ATP-sensitive potassium channel 
opening. In addition, ischemic preconditioning has been shown to suppress mitochondrial 
cytochrome-c release and apoptosis during ischernia-reperfusion.200 Most recently Baines et al. 
demonstrated that PKCe translocates to the surface of the mitochondria201 and can form 
physical interaction with the mitochondrial transition pore202 which are also important clues 
that the mitochondria play a critical role in the infarct-sparing effects of preconditioning. 
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Mitochondrial ATP-sensitive potassium channels 
No previous study had defined the timing for the opening of mitochondrial ATP-
sensitive potassium channels. Therefore, Pain et al. 203 determined the critical timing for these 
channels to open in order to protect the heart. Infarct size limitation by either diazoxide or an 
ischemic stimulus were both abolished by free radical scavenging or potassium channel 
blockade during the trigger phase, whereas when administered during the mediator phase (i.e. 
index ischemia) cardioprotection was still maintained. Pain subsequently proposed that 
opening of ATP-sensitive potassium channels during either preconditioning ischemia or 
diazoxide infusion generates free radicals, which then trigger cardioprotection most likely by 
activating several kinase proteins. The protective role of free radicals has also been striking in 
the role of various agonists activating cell surface receptors involved in the signaling cascade. 
Acetylcholine when added to chick cardiomyocytes exerted a burst of free radical production 
which was blocked by both myxothiazol, an inhibitor of mitochondrial electron transport, and 
by 5-hydroxydecanoate.204 The investigators suggested that acetylcholine leads to opening of 
mitochondrial ATP-sensitive potassium channels immediately followed by the release of free 
radicals which was further confirmed in intact hearts. 205-207 In addition, bradykinin, opioids and 
phenylephrine all appear to trigger ischemic preconditioning via a pathway that requires 
opening of mitochondrial ATP-sensitive potassium channels and release of free radicals.205 But 
in contrast to other agonists, the triggering action of adenosine seems to be independent of 
opening potassium channels and release of free radicals. Cohen et al. 205 showed that the 
protective action of exogenous adenosine was not affected by either mercapto propionyl 
glycerine or 5-hydroxydecanoate. It appears that all agonists are not equivalent and may work 
via separate pathways in order to exert myocardial preconditioning (fig. 5). 
The hypothesis that the mitochondrial ATP-sensitive potassium channels play a major 
role in both the first window- and the second window of protection has been well supported by 
an accumulating body of evidence.208 However, to date the mechanism in exerting 
cardioprotection has been incompletely understood. It seems paradoxical that the opening of an 
energy dissipating cation conductance on the mitochondrial inner membrane would be 
beneficial. Tight coupling between proton pumping and ATP production requires a relatively 
impermeable inner membrane and therefore opening of mitochondrial ATP sensitive potassium 
channels most likely lead to changes in mitochondrial function that compensate the loss of 
energy attributable to uncoupling. At least three mechanistic hypotheses have been proposed to 
explain the protective effect of mitochondrial ATP-sensitive potassium channel opening: (i) 
release of free radicals. Mitochondria are a source of free radical production because of 
leakage from the electron transport chain. Free radicals have been associated with cellular 
damage during ischemia and reperfusion.209 On the other hand, free radicals have also been 
demonstrated to trigger ischemic preconditioning.144 Therefore, opening of mitochondrial 
ATP-sensitive potassium channels could possibly enhance free radical production during early 
ischemia to trigger cardioprotection, or it could inhibit release during reperfusion. (ii) 
Reduction of mitochondrial Ca2+ overload. During ischemia or reperfusion, mitochondrial Ca2+ 
overload may be slowed down by depolarization of the mitochondrial membrane potential. In 
isolated mitochondria, ATP-sensitive potassium channel opening by diazoxide depolarized the 
mitochondrial baseline resting membrane potential by 15 to 20 mV which results in a 
decreased driving force for ci+ entry.210 (iii) Mitochondrial matrix swelling leading to an 
optimized energy production. Opening of mitochondrial ATP-sensitive potassium channels 
induces an influx of potassium, which is accompanied by the movement of diffusible weak 
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acids in order to maintain electro neutrality and water movement attributable to osmotic forces. 
The netto result of this process is matrix swelling_2ll Matrix swelling has been suggested to 
improve mitochondrial function by activating fatty acid oxidation, respiration and ATP 
production.212 In addition, it has also been theorized that that optimal efficiency of oxidative 
phosphorylation is achieved when mitochondria are partially uncoupled which may be induced 
by mitochondrial uncoupling proteins and opening of ATP-sensitive potassium channels.213.214 
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Figure 5 Hypothetical model for separate signal transduction pathways of pharmacological preconditioning. 
It appears that bradykinin, actylcholine and opioids somehow interact with mitochondria to produce free 
radicals that then go on to initiate a kinase cascade. However, adenosine seems to induce preconditioning 
independent of free radicals and mitochondrial ATP-sensitive potassium channels and may therefore activate 
phospholipases and protein kinase C. PLC indicates phospholipase C; PLD, phospholipase D; PKC, protein 
kinase C; TK, tyrosine kinase; JNK, c-Jun N-terminal kinase; MAPKAPK2, mitogen-activated protein kinase 2 
(modified from Cohen et az2°5) 
Tolerance to multiple episodes of ischemic preconditioning 
Pharmacological exploitation of ischemic preconditioning to limit myocardial infarct 
size in the clinical setting appears highly attractive. However, the therapeutical application may 
be limited by the development of tolerance to cardioprotection by repetitive brief ischemic 
stimuli. Most studies have demonstrated that repeated bouts of brief ischemic stimuli do not 
yield a cumulative cardioprotective e:ffect.215•216 Contrary to providing additive protection, 
there may be an apparent loss in efficacy of preconditioning with multiple cycles of ischemic 
stimuli. Thus in a conscious rabbit model, Cohen and coworkers217 demonstrated that 
myocardial protection to prolonged ischemia by a single ischemic stimulus of 5-min coronary 
artery occlusion is waned when preceded by 40 to 65 5-min occlusions over a three to four day 
period. 217 The study by Cohen did not discriminate between the first window of protection and 
the second window since induction period lasted for three days. However, development of 
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tolerance has been demonstrated to occur for the first window of protection. In the rabbit, six to 
eight repeated bouts of brief 5-min ischemia has been reported to result in a loss of e:fficacy.218 
The study by Cohen further showed that if the multiple ischemic stimuli were followed by a 3-
day rest interval, cardioprotection could be re-established.217 To date, the mechanism 
underlying development of tolerance to repetitive ischemic stimuli is poorly understood. 
Several studies either in rabbits or pigs suggested progressive loss of adenosine production219 
and /or reduced adenosine receptor responsiveness.220 
Aim and outline of the thesis 
To obtain a better understanding of myocardial ischemia-reperfusion injury and to 
advance therapeutical application of cardiac adaptation to ischemia, this thesis investigates 
several mechanistic aspects of ischemic preconditioning with respect to triggers, mediators and 
possible end-effectors. 
Adenosine is a well established trigger of ischemic preconditioning which is released 
during ischemia as a breakdown product of ATP. At least four adenosine receptor subtypes 
have been identified: A1-, A2a-, A2b- and A3- receptors.221 Both the A1- and the A3- receptor 
subtypes are believed to trigger myocardial preconditioning.131·153·222 The cardioprotective role 
of adenosine has been confirmed in all species used for experimental investigation.38 However, 
based on several studies using selective adenosine receptor antagonists which failed to block 
ischemic preconditioning, its role in rats is still controversial. 155•156 In these studies the duration 
of the ischemic stimuli were 3-5 min. Interestingly, Schulz et al. 133 demonstrated in the porcine 
heart that adenosine plays a significant role after 10-min of coronary artery occlusion. 
Therefore in chapter 2 we studied the role of adenosine in ischemic preconditioning in rats 
with respect to the duration of the ischemic stimulus. 
There are current indications that signal transduction pathway(s) exclusive of ATP 
sensitive potassium channel opening are able to induce ischemic preconditioning?05·223 In 
contrast to bradykinin, acetylcholine, opioids and phenylephrine, it appears that adenosine 
exerts myocardial preconditioning via a separate transduction pathway which does not involve 
opening of ATP sensitive potassium channels and release of free radicals.205 Since there are 
signs that separate pathways might co-exist upon triggering ischemic preconditioning, in 
chapter 3 we study whether an adenosine-dependent ischemic preconditioning stimulus exerts 
cardioprotection without opening ATP sensitive potassium channels and release of free radical, 
which are proximal to tyrosine kinase and protein kinase C. In addition, we further investigate 
whether an adenosine-independent ischemic stimulus. Moreover, it has recently been proposed 
that slight mitochondrial uncoupling may be a key event during myocardial protection.224 The 
aforementioned in vitro studies have demonstrated that not only ischemia, but also 
mitochondrial ATP-sensitive potassium channel opening resulted in slight uncoupling of 
mitochondria and cytoprotection. Additionally, superoxide has been reported to activate 
mitochondrial uncoupling proteins.225 Therefore in chapter 3, we further studied whether the 
adenosine dependent and/or the adenosine independent ischemic stimulus lead to an uncoupled 
state of mitochondria. 
Adenosine may also be involved in inter-organ remote preconditioning of the heart. 
Takaoka and co workers121 demonstrated that adenosine concentrations were 10 times higher 
after renal ischemia, implying that myocardial adenosine receptor stimulation might be 
involved. Based on the observation by Gho et al. that remote preconditioning is induced via 
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activation of a neurogenic pathway upon reperfusion, several investigators suggested that 
adenosine released in the ischemic kidney stimulate afferent nerves in order to protect the 
myocardium.120•205 In addition, both bradykinin and opioids have been shown to be involved in 
remote preconditioning. Nevertheless, the site(s) of action of these mediators has so far never 
been studied. Consequently in chapter 4 we investigated the involvement of adenosine 
receptors, and which of its subtypes, in myocardial protection by brief intestinal ischemia. 
Furthermore, we determined the location(s), i.e. myocardium and/or small intestine, of the 
involved adenosine receptors. 
Pharmacological exploitation of ischemic preconditioning to limit infarct size in a 
clinical setting is very promising. However, its therapeutical application may be limited by the 
development of tolerance to cardioprotection by repetitive brief ischemic stimuli. In isolated 
rabbit hearts it was shown that prolonged infusion with an A1-adenosine receptor agonist 
results in desensitization of its protective effect which is accompanied with a loss of protection 
from ischemic preconditioning. In addition, Hashimi et al. concluded that tolerance to ischemic 
preconditioning after prolonged infusion of adenosine must be due to down regulation or 
desensitization of A1 -adenosine receptors since both Gi and PKC components of the 
preconditioning pathways were still intact. Therefore it appears that tachyphylaxis may 
develop when many ischemic preconditioning stimuli are induced. In contrast to the loss of 
cardioprotection by Preconditioning after prolonged infusion with adenosine, the mechanism 
behind tolerance to ischemic preconditioning followed by multiple ischemic episodes has to 
date never been elucidated. In chapter 5 we therefore elucidate the phenomenon of tolerance to 
ischemic preconditioning in greater detail. 
Protein tyrosine phosphatase is known to trigger programmed cell death named 
apoptosis. Furthermore, apoptosis may play a pivotal role during myocardial ischemia-
reperfusion injury. Vanadate is an ortho-molecule that inhibits tyrosine phosphatases resulting 
in an enhanced tyrosine residue phosphorylation. We therefore study in chapter 6 whether the 
tyrosine phosphatase inhibitor vanadate induces cardioprotection to ischemia-reperfusion 
injury. 
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Role of adenosine in ischemic preconditioning in rats depends critically on the duration 
of the stimulus and involves both A1 and A3 receptors 
David A. Liem, Mirella A. van den Doe!, Sandra de Zeeuw, Pieter D. Verdouw, Dirk J. Duncker 
Summary 
Objectives: There is currently general agreement that adenosine is not involved in ischemic 
preconditioning (IP) in rat hearts. We hypothesized that the failure to show a role for adenosine 
is due to the use of brief preconditioning stimuli, and therefore investigated whether adenosine 
is involved when longer stimuli are employed and which receptor subtypes are involved. 
Methods and results: Infarct size (IS) was determined in anesthetized rats after 180 min of 
reperfusion (REP) following a 60-min coronary artery occlusion (CAO). IS was 69±2% of the 
risk area in control rats and 45±2% (P<0.05) following IP by a single 15-min CAO. The non-
selective adenosine receptor antagonist SPT, which itself had no effect on IS (74±1 %), blunted 
the protection by IP (IS =57±2%, P<0.05) in a dose of 2x5 mg/kg IV, and abolished the 
protection (IS=70±1%) at 2x25 mg/kg IV. Following IP by 3 cycles of3-min CAO and 3-min 
REP, IS was 24±6% (P<0.05), which was not affected by SPT in doses of 2xl0 and 2x25 
mg/kg IV. The A3 antagonist MRS-1191 (3.3 mg/kg, intraperitoneally), which itself did not 
affect IS (70±2%), blunted the protection by IP with a 15-min CAO (IS=54±2%, P<0.05). 
When 2x5 mg/kg SPT (a dose selective for A1-receptors, as it did not affect the protection by 
the A3 selective agonist IB-MECA, 51±3%) and MRS 1191 were combined the protection by 
IP was abolished (IS=67±2%). 
Conclusions: Involvement of adenosine in IP in rats depends critically on the duration of the 
stimulus. Thus, whereas adenosine was not involved when stimuli of 3-min duration were 
employed, activation of both A1 and A3 receptors contributed when a stimulus of 15-min was 
used. 
(Cardiovasc Res. 2001;701-708) 
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Introduction 
The cardioprotective role of adenosine has been firmly established in all species in 
which this has been investigated. Adenosine has also been shown to be one of the mediators 
involved in the protection afforded by ischemic preconditioning (IP). However, based on 
numerous studies including those in which the selective adenosine A1-receptor antagonist PD 
115,199 and the non-selective antagonist SPT failed to block IP,1•3 Ganote and Armstrong4 
conclude in a recent issue of this journal that there is now general agreement that adenosine 
does not play a role in the myocardial infarct size (IS) limitation by IP in rats. In these 
studies1-3 the duration of the (multiple) IP stimuli was 3-5 min. Interestingly, Schulz et al.5 
have shown that intracoronary adenosine deaminase was ineffective in attenuating IS limitation 
by a 3-min coronary artery occlusion (CAO), but abolished the cardioprotection by a 10-min 
CAO. We therefore hypothesized that adenosine could play a role in IP in rats when 
preconditioning stimuli of longer duration are used. Consequently, we investigated the role of 
adenosine in IP by a 15-min CAO, a stimulus which we have previously shown to protect the 
rat heart,6•7 and repeated the protocol of three cycles of 3-min CAO and 3-min REP used by Li 
and K.loner,Z to exclude that differences in results were caused by differences in breed, sex and 
experimental procedures. Our results not only confirmed the findings by Li and Kloner2 but 
also demonstrated that a high dose of SPT completely blocked the cardioprotection by a single 
15-min CAO stimulus. Because SPT is a non-selective adenosine receptor antagonist, we 
subsequently investigated which of the adenosine receptor subtypes are involved in IP. This is 
of interest, because evidence is accumulating that not only selective A1 but also selective A3 
agonists confer cardioprotection in a variety of animal models. For instance, the selective A3 
agonists APNEA and IB-MECA limit myocardial injury to a similar degree as IP in isolated 
rabbit cardiomyocytes8, and in isolated9 and in vivo10 rabbit hearts. Since the affinity of 
adenosine for the A3 receptor is 10-100 less than for the A1 receptor, it has been questioned 
whether A3 receptor activation is involved in the protection afforded by IP.11 Studies on the 
role of A3 receptors in IP in vivo have been hampered by lack of selective A3 receptor 
antagonists.4 However, MRS-1191 has recently been described as a highly selective A3 
receptor antagonist.4•11 Consequently, we studied the contributions of A1 and A3 receptor 
subtypes to the protection by IP in the in vivo rat heart. 
Methods 
Experiments were performed in ad libitum fed male Wistar rats (~300 g) in accordance 
with the Guide for the Care and Use of Laboratory Animals (NIH publication 86-23, revised 
1985) and with approval of the Animal Care Committee of the University. 
Drugs 
The following agents were used: the non-selective adenosine receptor antagonist 8-p-
sulfophenyltheophylline (SPT); the selective A1 agonist 2-chloro-~ -cyclopentyladenosine 
(CCPA); the selective A3 receptor agonist N-(3-iodobenzyl)adenosine-5'-N-methyluronamide 
(IB-MECA); the selective A3 receptor antagonist MRS-1191 (3-ethyl-5-benzyl-2-methyl-4-
phenylethynyl-6-phenyl-1 ,4,-[ ± ]-dihydro-pyridine-3 ,5-decarboxylase ); the histamine H1 
antagonist mepyramine (Mep), and N,N-dimethylacetamide (DMAC) in which MRS-1191 was 
dissolved. 
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Surgical and experimental procedures 
Pentobarbital-anesthetized (60 mg/kg) rats were intubated for positive pressure 
ventilation (Harvard rodent ventilator) with room air.6'7 Through the carotid artery a PE-50 
catheter was positioned in the thoracic aorta for measurement of arterial blood pressure and 
heart rate. In the inferior caval vein a PE-50 catheter was placed for infusion of Haemaccel 
(Behringwerke) to compensate for blood loss during surgery. After thoracotomy, via the left 
third intercostal space, the pericardium was opened and a silk 6-0 suture was looped under the 
left anterior descending coronary artery for later CAO. A catheter was positioned in the 
abdominal cavity to allow intraperitoneal administration of pentobarbital for maintenance of 
anesthesia. Rectal temperature was continuously measured and maintained at 36.5-37.5°C.6•7 
To prevent local heat loss from the thorax, the thoracotomy site was covered with aluminum 
foil. After completion of surgery, a 30-min stabilisation period was allowed before 
experimental protocols were carried out. 
Rats that fibrillated were allowed to complete the protocol, provided that conversion to 
normal sinus rhythm occurred spontaneously within 1 min, or that defibrillation by gently 
thumping on the thorax or with a 9V battery was successful within 2 min after onset of 
fibrillation. Occlusion and reperfusion were visually verified.6•7 
Experimental groups 
Fig. 1 depicts the experimental groups in which IS was determined after 180-min REP 
following a 60-min CAO. Area at risk (AR) and infarct area (lA) were determined using 
Trypan blue and nitro-blue-tetrazolium staining (Sigma Chemical).6•7 IS was expressed as 
WAR. 
Protocol I: Does adenosine contribute to ischemic preconditioning in the rat heart? 
One group underwent a 25-min sham period prior to the 60-min CAO followed by 180-
min of REP (Control). To determine whether adenosine contributed to IP when stimuli of 
longer duration are used, we preconditioned three groups with a 15-min CAO followed by 10-
min of REP. These groups received either no treatment (PC15), or were pretreated with 
intravenous (IV) SPT in doses of 2x5 mg/kg (PC15+10SPT) or 2x25 mg/kg (PC15+50SPT), 
respectively. To study the effects of SPT on IS per se, one group was pretreated with 2x25 
mg/kg SPT IV prior to the 60-min CAO (Contro1+50SPT). To exclude that confounding 
factors such as breed (Sprague-Dawlej versus Wistar), sex (females2 versus males) or 
experimental procedures (90-min CA02 versus 60-min CAO) contributed to differences 
between our observations and those by Li and Kloner, 2 we also determined in two groups 
whether 3 cycles of 3-min CAO followed by 3-min REP (PC3), protected the myocardium 
against infarction produced by a 60-min CAO and whether 2x10 mg/kg SPT (PC3+SPT20), the 
dose of SPT used by Li & Kloner,Z or the high dose of 2x25 mg/kg SPT affected this 
cardioprotection. 
Protocol II: Is A3 receptor stimulation cardioprotective and does SPT in the doses used 
possess Arreceptor antagonistic properties in the rat heart? 
In two groups the effect of A3 receptor stimulation on IS was studied by administration 
of IB-MECA in doses of 33 f.Lg/kg (IB-MECA33) or 100 f.Lg/kg (IB-MECA100), prior to the 
60-min CAO and compared to the Control group from Protocol I to which two animals were 
added (Fig. 1). Since IB-MECA releases histamine from mast cells in rats,10 another group was 
pretreated with 5 mg/kg Mep prior to IB-MECA and the 60-min CAO (IB-MECA100+Mep), 
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and compared to a group that received only 5 mg/kg Mep prior to the 60-min CAO 
(Control+Mep). To investigate whether SPT possesses A3 receptor antagonistic properties, we 
pretreated rats with 2x5 mg/kg SPT prior to administration of33 flg/kg IB-MECA (10SPT+IB-
MECA33) or 100 flg/kg IB-MECA with Mep (10SPT+Mep+IB-MECA100) and studied the 
effect of2x25 mg/kg SPT on the cardioprotection by 100 mg/kg IB-MECA in the presence of 
Mep (IB-MECA1 OO+Mep+50SPT). 
1. Control (n=1 0) 
2. PC15 (n=11) 
3. PC15+10SPT (n=8) 
4. PC15+50SPT (n=7) 
5. Controi+50SPT (n=5) 
6. PC3 (n=5) 
7. PC3+20SPT (n=5) 
1. Control (n=12) 
8. IB-MECA33 (n=7) 
9. IB-MECA100 (n=9) 
10. IB-MECA100+Mep (n=6) 
11. Controi+Mep (n=6) 
Protocol I 
60-rnin GAO 
• 
• 
••• 
Protocol II 
10 
180-min Rep 
14. IB-MECA100+Mep+50SPT (n=7) _ _.aiJ.w....,...,...._ ______ _ 
Protocol III 
1. Control (n=15) 
17. Controi+MRS (n=4) 
18. Controi+DMAC (n=5) 
-55 0 60 Time (min) 24( 
Figure I Overview of the study protocols. Numbers in parenthesis indicate number of animals that completed 
the protocol. 
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Protocol III: Are A;-receptors involved in ischemic preconditioning in the rat heart? 
Two groups received the 15-min CAO IP stimulus and 3.3 mg!kg MRS-1191 
(intraperitoneally) without (PC15+MRS) or with 2x5 mg!kg SPT (PC15+MRS+lOSPT). The 
results of these two groups were compared to the Control, PC15 and PC15+10SPT groups 
from Protocol I, to which a number of new animals were added (see Fig. 1). To exclude an 
effect ofMRS-1191 or its solvent DMAC on IS per se, one group received 3.3 mg/kg MRS-
1191 intraperitoneally (Control+MRS) and another group received the solvent DMAC 
(Control+DMAC) prior to the 60-min CAO. 
MRS-1191 has been reported to be a highly selective A3 antagonist, but in vivo 
experience with this compound is limited. Therefore, to exclude that At antagonistic properties 
contributed to the actions of MRS-1191, we studied the bradycardic reponses to the selective 
At agonist CCPA after treatment with MRS-1191 (n=6) or its solvent DMAC (n=5). Two 
consecutive doses (50 and 100 !lg!kg, IV) ofCCPA were administered. The second dose was 
given when heart rate had reached a stable level after administration ofthe first dose. 
Data analysis and presentation 
IS was analyzed by one-way ANOVA followed by Dunnett's test. Hemodynamic 
variables were compared by two-way ANOV A for repeated measures followed by the paired 
or unpaired t test. Statistical significance was accepted when P<0.05. Data are presented as 
mean±S.E.M. 
Results 
Mortality 
Eleven rats were excluded because of sustained ventricular fibrillation or pump failure 
(2 in Control, 1 in PC15, 1 in PC15+10SPT, 1 in PC3+20SPT, 1 in PC3+50SPT, 2 in IB-
MECA33, and 3 in Control+DMAC. 
Infarct size - Area at risk 
There were no differences (P=0.61) in AR (34±1%) between any of the experimental 
groups. 
Infarct size -Effect of duration of preconditioning stimuli on the involvement of adenosine 
Fig. 2 shows that IP by a 15-min CAO limited IS to 49±3% versus 70±2% in Control. 
SPT in a dose of 2x5 mg!kg attenuated the cardioprotection, while a 5 times higher dose, which 
by itself had no effect on IS, abolished the protection. Fig. 2 also shows that IP by 3-min 
CAO's limited IS to 24±6% and that SPT, not only in a dose of 2xl0 mg!kg (confirming the 
observations by Li and Kloner), but also in the high dose of 2x25 mglkg, did not attenuate the 
cardioprotection (18±3%). 
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Infarct size -Selectivity of SPT and IB-MECA for A1 and A3 receptor subtypes 
Pretreatment with IB-MECA limited IS to 59±1% and 51±3% at doses of33 and 100 
flg/kg, respectively (both P<0.05, Fig. 3). Mep blunted the IB-MECA-induced hypotension by 
35%, but had no effect on IS limitation, indicating that histamine release did not contribute to 
the cardioprotection by IB-MECA. IB-MECA, in either dose, had no effect on heart rate 
(Table), which indicates that IB-MECA, in the doses used, was selective for the A3 receptor. 
The low dose of SPT had no effect on the cardioprotection by either dose of IB-MECA, 
indicating that the low dose of SPT had no A3 antagonistic effects. In contrast, the high dose of 
SPT blunted the cardioprotection by IB-MECA100 (62±2%, P<0.05), suggesting that SPT 
possesses A3 antagonistic properties at this dose. For this reason, we employed the AI selective 
low dose of SPT in combination with MRS-1191 to study the role of AI and A3 subtypes in IP 
in protocol III. 
Infarct size -Adenosine subtypes involved in ischemic preconditioning 
Cardioprotection by IP was reduced by approximately 50%, when animals were 
pretreated with either 3.3 mg/kg MRS-1191 or the low dose of SPT (Fig. 4). Combining SPT 
and MRS-1191 completely abolished the cardioprotection by IP. 
To establish that the actions of MRS-1191 were indeed caused by A3 antagonism, we 
studied the bradycardic response to the selective AI agonist CCP A in the absence and presence 
ofMRS-1191. In the animals pretreated with DMAC, heart rate was lowered by 183±22 and 
261±21 bpm by the 50 and 100 !lglkg dose of CCPA, respectively (Fig. 5). After pretreatment 
with 3.3 mg!kg MRS-1191, the CCPA-induced heart rate reductions (191±23 and 275±11 bpm, 
respectively) were not different from those in the presence of DMAC, indicating that at the 
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Figure. 4 Infarct size limitation by PC15 is attenuated by the low dose of SPT as well as MRS-1191, and abolished 
by combined pretreatment with the A1 and A3 antagonists. *P<0.05 vs Control; tP<0.05 vs IP; :tP<0.05 vs 
IP+10SPTandiP+MRS. 
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dose used, MRS-1191 had no A1 antagonistic properties. In contrast, 3.3 mg/kg MRS-1191 
produced a high degree of A3 blockade as it attenuated the hypotension induced by 100 Jlg/kg 
IB-MECA by 70% (from 40±4 mmHg to 12±3 mmHg, n=7, P<0.05). 
Heart rate and arterial blood pressure during 60-min CAO and 180-min REP 
In all groups of Protocol I arterial blood pressure had decreased at the end of the 60-
min CAO and did not recover during reperfusion (Table). Heart rate remained virtually 
unchanged, although it decreased slightly (10-15 %) in some, but not all, groups treated with 
SPT. 
In the animals pretreated with IB-MECA, mean arterial pressure was lower than in the 
other groups of animals at the start of the 60-min CAO, which is most likely the reason for the 
smaller decrease in mean arterial pressure in these animals during the 60-min CAO, while 
heart rate remained virtually unchanged. In these animals, heart rate decreased slightly (5-10%) 
during 180-min REP. Mepyramine produced a 10% decrease in heart rate and blood pressure, 
but had no effect on blood pressure and heart rate response to the 60-min CAO and 180-min 
REP in any group. 
Animals pretreated with MRS-1191 behaved similarly as the other groups of animals 
during the 60-min CAO and 180-min REP procedure. In these animals heart rate increased 10-
15% after administration ofMRS-1191, which was mostly likely due to its solvent. 
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Figure 5 Bradycardic responses to CCPA are not modified by MRS-1191, implying that at this dose MRS-1191 is 
devoid of A1 antagonistic properties. *P<0.05 vs 0 pg/kg CCPA. 
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Table 
Heart rete and arterial blood pressure 
180-roin REP Baseline 60-roinCAO 
Before EJ:Jd EJ:Jd 
Contl'ol (n-15) 
HR 363 = 10 362 = 10 365 = 9 363 = 12 
MAP 101 = 5 100 = 4 90 : 4*T &3 : 4*T 
PC15 (n=19) 
HR 360 = 9 361 = 6 362 = 1 369 = 1 
MAP 107 = 3 100 = 3 95 = 3* &1 :, 4*T 
PC 15 + lOSPT(n=lO) 
HR 362 = 1 364 = 9 354 = 11 331 : 9*T 
MAP 102 = 5 101 = 1 &3 : 5*T 10 : 5*T 
PC15+50SPT(n=7) 
HR 369 = 10 360 "' 10 345 = 10 34& = 10 
MAP 119 = 6 111 = 6 96 : 4*T &6 : 5*T 
PC3 (n=5} 
HR 414 
"' 11 417 = 1& 431 = 16 435 "' 11 MAP 80 = 3 86 = 6 79 = 4 10 "' 1 
PC3 +20SPT(n=5) 
HR 400 "'23 395 = 9 410 = 14 391 "' 18 
MAP 8& 
"' 8 86 :11 15 = 8 60 "' lO*T 
PC3 +50SPT(n=4) 
HR 396 = 27 421 :44 392 "' 37 424 "' 9 MAP 89 
"' 11 110 "' 1 90 = 6 88 = 12 
Control +50 SPT (n=.5} 
HR 381 = 16 382 = 18 345 = 13* 326 = 8* 
MAP 98 = 4 133 = 5* &6 = & 11 = 9* 
IB-MECA.33 tn =7) 
HR 341 = 9 332 = 14 330 "' 12 293 : 7*T MAP 107 
"' 6 89 ="5* 77 "'4* 73 "' 7* 
1B-MECA.100 (n=9} 
HR 374 = 13 367 "' 13 357 = 17 331 "' 15*T 
MAP 113 
"' 1 66 = 6* 71 "' 8* 67 "'7* 
1B-MECA.100 +Mep (n=6) 
HR 419 = 6 369 = 12* 368 "' 10* 351 = 8* 
MAP 114 = 6 82 "' 7* 77 = 6* 19 "' 3* 
Contl'ol + Mep (n=6) 
HR 410 = 13 311 = 11* 366 "' 8* 360 "' 14* 
MAP 121 = & 10& = 6 102 = 5* &5 : 7*T 
1B-MECA.33 + 10SPT(n=5) 
HR 429 = 10 431 "' 19 39& "' 29 370 : 18*T 
MAP 83 = 4 14 = 1 66 "' 6 43 : 3*T 
1B-MECA.100 + Mep + 10SPT (n=8} 
HR 403 
"' 10 366 "' 14* 340 = 11* 336 : 9*T 
MAP 124 = 5 67 = 5* 72 = 1* 72 "' 7* 
lB-MECA.lOO + Mep +50 SPT (n=7) 
HR 390 = 9 367 = 14 341 "' 16* 316 : 10*T 
MAP 125 = 8 86 = 4 72 "' 1 65 = 6 
PC 15 +MRS (n=7) 
HR 356 
"' 11 419 = 9* 407 = 5* 402 = 5* MAP 109 = 3 99 = 3* 88 :, 4*T &3 : 4*T 
PC 15 +MRS+ 10SPT(n=7) 
HR 341 = 9 404 = 6* 408 = 9"' 400 "' 16"' 
MAP 112 "'4 116 
"' 5 101 : 5T 82 : 6*T 
Contl'ol +MRS (n=4) 
HR 328 
"' 10 363 = 10* 315 "' 7* 3&8 ± 15* 
MAP 91 = 6 103 = 3 96 = 4 84 "' 3 
Contl'ol + DMAC (n=5) 
HR 311 
"' 13 413 = 14* 421 "' 6* 422 
"' 
4* 
MAP 115 = 3 104 = 4 99 = 3* &1 = 5* 
Data are me~S.E.M.; *P.:0.05vs Baseline; TP.:0.05vsbefore CAO. 
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Discussion 
Major findings in the present study in the rat heart were that (i) the non-selective 
adenosine receptor antagonist SPT had no effect on cardioprotection produced by 3 cycles of 
3-min CAO and 3-min REP, confirming observations by Li and Kloner [2], but attenuated (low 
dose) and abolished (high dose) the protection afforded by a single 15-min CAO and 10-min 
REP; (ii) The selective A3 receptor agonist IB-MECA limited infarct size dose-dependently, 
which was not affected by pretreatment with the low dose, but was blunted by the high dose of 
SPT, and (iii) the selective A3 receptor antagonist MRS-1191 attenuated IP and together with 
the low dose ofSPT abolished the protection by IP. 
Involvement of adenosine in IP in the rat heart 
Since the original observation by Downey and co-workers12 in an in vivo rabbit model, 
that the adenosine receptor blockers SPT and PD115,199 were able to abolish cardioprotection 
afforded by ischemic preconditioning, the role of adenosine in ischemic preconditioning has 
been confirmed in other species such as dogs13 and swine.14•15 However, the evaluation of the 
contribution of adenosine to IS limitation by IP has led to negative results in the rat, although 
several studies have shown that pretreatment with exogenous adenosine can be 
cardioprotective in this species. 4 Capitalizing on observations by Schulz et al. 5 we 
hypothesized that the failure to establish the role of adenosine in the aforementioned studies in 
rats4 could be due to the fact that the duration of the IP stimulus may have been too short. In 
the present study we not only confirmed the findings by Li and Klone? that protection 
afforded by 3 cycles of 3-min CAO and 3-min REP was not amenable to adenosine receptor 
blockade with SPT in a dose of 2x10 mg!kg/ but also in the high dose of 2x25 mg/kg which 
antagonized both A1 and A3 receptors. However, when a preconditioning stimulus of longer 
duration was used (15-min CAO), the protection was blunted by a dose of SPT that was half 
(2x5 mg/kg) and abolished by a dose that was 2.5 times (2x25 mg/kg) that used by these 
investigators. These observations imply that adenosine receptor activation is involved in the 
protection by IP, provided that the duration of the preconditioning stimulus is sufficiently long. 
Headrick16 reported that in interstitial fluid collected between 1 and 6 min of a 6-min of 
global normothermic ischemia in isolated hearts, myocardial interstitial adenosine 
concentrations increased from 0.25 to 6.8 ~Min rats and only from 0.33 to 2.0 ~in rabbits. 
The Ki value of adenosine for the A1 receptor is 10-100 nM in rats and 28 nM in rabbits.4'11 
These findings of higher interstitial adenosine levels together with a similar affinity for A1 
receptors in rat and rabbit hearts are difficult to reconcile with a contribution of adenosine to IP 
by brief stimuli in the rabbit, but not the rat heart.4 Since Headrick16 used a 6-min CAO, the 
different results obtained in rats and rabbits can only be explained by an early increase in 
adenosine in the rabbits, whereas in rats, similar to pigs, 5 interstitial adenosine levels do not 
increase during the initial 3 min of occlusion. 
Adenosine subtype receptor activation and cardioprotection 
SPT is a non-selective adenosine receptor antagonist which is only five-fold more 
potent for A1 receptors than for A3 receptors. 11 Consequently, the SPT-induced dose-dependent 
attenuation of the cardioprotection by IP may therefore have been the result of adenosine A1 as 
well as A3 antagonism. The cardioprotection by the selective A3 agonist IB-MECA, 
demonstrates the presence of cardioprotective A3 receptors in the rat heart, similar to the rabbit 
heart.9•10 However, SPT in a dose of 2x5 mg/kg did not modify the cardioprotection by IB-
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MECA in a dose of 33 and 100 !lg/kg, which indicates that this low dose of SPT was selective 
for A1 receptors. Therefore, the attenuation of cardioprotection by IP with the low dose of SPT 
can be attributed to A1 blockade. In contrast, the high dose of SPT blunted the protection by 
IB-MECA, indicating that SPT possesses A3 antagonistic properties at this dose. These 
findings suggest that the abolition of protection by IP with the high dose of SPT may have 
been caused by combined A1 and A3 blockade. Alternatively, the abolition of the protection by 
IP by the high dose of SPT may also have been the result of a higher degree of A1 blockade. 
Consequently, additional studies using the selective A3 antagonist MRS-1191 were pivotal. We 
observed that at a dose of 3.3 mg/kg MRS-1191 produced a high degree of A3 blockade 
without any A1 blockade, confirming its reported 28-fold selectivity for A3 over A1 receptors in 
the rat heart.11 Single treatment with either MRS-1191 or the A1 selective low dose of SPT 
attenuated IS limitation by the 15-min CAO by approximately 50%, while the combination of 
these two agents completely abolished the cardioprotection by IP. These findings indicate that 
adenosine A1 and A3 receptors both contribute to cardioprotection by the 15-min CAO 
preconditioning stimulus. 
Conclusions and therapeutic implications 
The present study demonstrates for the first time that adenosine is involved in ischemic 
preconditioning in rat hearts in vivo but only when the duration of the stimulus is sufficiently 
long. The study also shows that in vivo that A3 receptors contribute to ischemic 
preconditioning. It is not yet clear whether A3 receptors also contribute to IP in species other 
than the rat in which interstitial adenosine levels may rise to higher levels than in other species, 
during IP stimuli of >5-min. 16 Since endogenous adenosine has a 10-100 fold higher affinity 
for the A1 receptors over A3 receptors, it is possible that in other species the A3 receptor may 
not contribute to the same extent. Interestingly, the protection by hypoxic preconditioning 
against hypoxia-induced damage in isolated rabbit cardiomyocytes could only be partially 
blocked by the adenosine A1 selective antagonist DPCD:X, and required a combination of 
DPCPX with either the adenosine A1/A3 antagonist BWA1433 or with SPT, for complete 
blockade, suggesting that also in the rabbit heart both adenosine A1 and A3 receptors might 
contribute to ischemic preconditioning in vivo.17 
Stimulation of A3 receptors on mast cells produces histamine release in rats but not in 
rabbits or humans. 10•11 Consequently, in the latter species A3 receptor stimulation does not 
result in hemodynamic alterations, 10 contrasting with the bradycardia and hypotension that 
results from A1 and A2 receptor stimulation, which suggests that A3 receptor agonists are of 
potential interest for clinical application as cardioprotective agents. However, Lee and Emala 18 
reported that pretreating the kidney with IB-MECA added to the loss of renal function 
produced by renal ischemia. Although the authors used a ten-fold higher dose of IB-MECA 
than in the present study, the observation that A3 receptor blockade with MRS-1191 enhanced 
the protection by IP in the kidney suggests that also A3 receptor stimulation by endogenous 
adenosine levels during brief renal ischemia exerts a deleterious effect in the kidney. 
Consequently, systemic treatment of myocardial ischemia with A3 receptor agonists would 
appear premature. 
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Ischemic Preconditioning Stimuli can Activate Different 
Signal Transduction Pathways but Converge into 
Mitochondrial U nco up ling 
Mechanistic and therapeutic aspects of ischemic myocardial preconditioning 
Summary 
In the present study we tested in vivo the hypothesis that different signal transduction pathways 
contribute to ischemic preconditioning which converge in eliciting mitochondrial uncoupling. 
A single 15-min coronary artery occlusion elicited cardioprotection in the in vivo rat heart 
which was triggered by adenosine receptor stimulation, followed by PKC and tyrosine kinase 
activation and then K+ ATP channel opening. In contrast, the cardioprotection by 3 cycles of 3-
min coronary artery occlusions involved the release of reactive oxygen species followed by 
PKC and tyrosine kinase activation. Both stimuli resulted in mitochondrial uncoupling. 
Blockade of each signal transduction pathway was paralleled by concomitant blunting of 
uncoupling, which is consistent with the concept that mitochondrial uncoupling contributes to 
infarct size reduction. In conclusion, while ischemic preconditioning can activate different 
signal transduction pathways, mitochondrial uncoupling appears to a unifying step in the signal 
transduction pathway that results in cardioprotection. 
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Introduction 
The original studies investigating the mechanism of ischemic preconditioning (IPC) did 
not consider that the signal transduction pathways leading to the infarct size limitation might 
depend on the employed preconditioning stimulus. Recent evidence, however, indicates that 
activation of the signal transduction pathway depends critically on the IPC stimulus. Thus, in 
swine adenosine was not involved in the infarct size limitation produced by a single 3-min 
coronary artery occlusion (CAO), but contributed to the cardioprotection by a single 10-min 
CA0.1 Similarly, in the in vivo rat heart adenosine receptor stimulation mediates 
cardioprotection by a single 15-min CAO (1CA015),2 whereas a triple 3-min CAO 
interspersed by 5-min of reperfusion (3CA03) did not require adenosine receptor 
stimulation.2•3 Moreover, Cohen et a/.4 reported that cardioprotection in the rabbit produced by 
bradykinin and acetylcholine, but not adenosine, involved K+ ATP channel activation and 
production of reactive oxygen species (ROS). However, while these studies suggest that 
different signal transduction pathways can be activated by varying stimuli, the question 
remains whether and where these different pathways converge into a common (end-)point. In 
human Girardi cells and murine skeletal myotubes, Minners et al. 5•6 recently demonstrated that 
not only simulated ischemia, but also adenosine and the K+ ATP channel opener diazoxide 
resulted in mild mitochondrial uncoupling and cytoprotection. Furthermore, a low dose of the 
mitochondrial uncoupler dinitrophenol (DNP), afforded protection in isolated rat 
cardiomyocytes7 and the isolated rat heart.5 
In view of these observations, the aim of the present study was two-fold. First, we 
explored the signaling pathways of the adenosine-independent (3CA03) and adenosine-
dependent (1CA015) preconditioning stimuli to test the hypothesis that the signal transduction 
pathway of 3CA03 but not 1CA015 involves release of ROS and activation of K+ATP channel 
in the in vivo rat heart? The second aim of the study was to test the hypothesis that the signal 
transduction pathways of these two stimuli converge into mitochondrial uncoupling. 
Methods 
Experiments were performed in male Wistar rats (300-380 g) in accordance with the 
Guide for the Care and Use of Laboratory Animals (NIH publication 86-23, revised 1985) and 
with approval of the Erasmus University Rotterdam Care Committee. 
Surgical and Experimental Procedures 
Pentobarbital-anesthetized (60 mglkg) rats were intubated for positive pressure 
ventilation with oxygen-enriched room air. Through the carotid artery a PE-50 catheter was 
positioned in the thoracic aorta for measurement of arterial blood pressure and heart rate. In the 
inferior caval vein aPE-50 catheter was placed for infusion of Haemaccel (Behringwerke) to 
compensate for blood loss during surgery, and for drug infusion during the experiments. After 
thoracotomy, via the left third intercostal space, the pericardium was opened and a silk 6-0 
suture was looped under the left anterior descending coronary artery for later CAO. A catheter 
was positioned in the abdominal cavity to allow intraperitoneal administration of pentobarbital 
for maintenance of anesthesia. Rectal temperature was continuously measured and maintained 
at 36.5-37.5 °C. To prevent local heat loss from the thorax, the thoracotomy site was covered 
with aluminum foil. After completion of surgery, a 30-min stabilisation period was allowed 
before experimental protocols were carried out. 
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Rats that fibrillated were allowed to complete the protocol, provided that conversion to 
normal sinus rhythm occurred spontaneously within 1 min, or that defibrillation by gently 
thumping on the thorax or with a 9V battery was successful within 2 min after onset of 
fibrillation. Occlusion and reperfusion were visually verified. 
Experimental protocols 
Infarct size 
All animals, in which a myocardial infarction was produced, underwent a 60-min CAO 
followed by 120 min of reperfusion (Fig. 1 ). Then, area at risk (AR) and infarct area (lA) were 
determined using Trypan blue and nitro-blue-tetrazolium staining.2 In view of the 
proportionality of the area at risk and infarct area in the rat heart, infarct size was expressed as 
INAR.8•9 
Preconditioning stimuli 
Preceding the 60-min CAO, animals underwent either a 25 min sham period, a 15-min 
CAO followed by 10-min ofreperfusion (1CA015), or three cycles of3-min CAO interspersed 
by 5-min ofreperfusion (3CA03; Fig. 1). 
Components of signal transduction pathway 
To study the involvement ofROS in the two preconditioning stimuli, several groups of 
rats that underwent the sham or either one of the preconditioning protocols, were pretreated 
with a continuous intravenous (IV) infusion of 1 mg!kg/min of the free radical scavenger n-(-2-
mercaptopropionyl)glycine (MPG, Figure 1). To study the involvement of K+ATP""channels in 
the two PC stimuli, various groups of animals were intravenously pretreated with K+ ATP 
channel inhibitor glibenclamide (3 mg!kg), the mitochondrial K+ ATP channel inhibitor 5-
hydroxydecanoic acid (5-HD, 20 mg!kg + 20 mg/kg!h), or the sarcolemmal K+ATP channel 
inhibitor HMR-1098 (6 mg/kg). Finally, to study the contribution of TyK and PKC, several 
groups of animals were pretreated intravenously with the TyK inhibitor genistein (2 x 5 
mg/kg), the PKC inhibitor chelerythrine (5 mg!kg), or their combination. 
Order of involvement of components of signal transduction pathway 
To study the sequence of adenosine receptor stimulation, activation of TyK and PKC, 
generation of ROS and activation of IC" ATP channels in 1 CAO 15 and 3CA03, several groups of 
animals received either adenosine (ADO, 200 mg/kg infused IV over 15 min), the 
mitochondrial K+ ATP opener diazo xi de (1 0 mg!kg), or the mitochondrial free radical generating 
compound menadione (37.5 mg/kg).10 
Afuochondrialfunction 
To study the role of mitochondrial ROS production and mitochondrial uncoupling in 
the cardioprotection by the various cardioprotective stimuli, groups of rats were subjected to 
sham procedure, 3CA03, 1CA015 (Fig. 2). In several of these groups, animals were pretreated 
with glibenclamide or MPG. At a time point corresponding with the onset of the 60-miri CAO, 
the preconditioned LAD area was dissected out and mitochondria were isolated. In isolated 
mitochondria, 0 2 consumption (nmoles/min/mg protein) was measured using standard Clark 
electrodes in state 2 (using succinate as a complex II substrate) and in state 3 (succinate + 
ADP). Respiratory control index was computed as state 3 I state 2. In our hands, isolated 
mitochondria display a respiratory control index greater than 4 in the presence of complex I 
substrates malate/glutamate. 
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Adenosine depedent- and independent ischemic stimuli 
Sham 
CA015 ~ fi#''""'G4·' 
3CA03 
' II fi#''""IG4·' 
0 30 55 
Involvement of mediators 
8-SPT (2x 25mg/kg) 
MPG (1mg/kg/min over 35min) 
Genistein (5mg/kg) 
Chelerythrine (5mg/kg) 
Genistein + Chelerythrine 
Glibenclamide (3mg/kg) 
5-HD (20mg/kg + 20mg/kg/h) 
HMR-1098 (6mg/kg) I 
0 
Sequence of signal transduction 
Adenosine (200J..ig/min over 15min) 
Diazoxide (10mg/kg) 
Menadione (37.5mg/kg) I 
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120-min Reperfusion 
120-min Reperfusion 
Figure I Experimental protocols in the infarct-size studies. Shown are the preconditioning protocols and the 
protocols for administering the various pharmacological agents to inhibit or stimulate the signal transduction 
pathways. 
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Mitochondrial funtion 
Sham 
T sacrifice 
CA015 
3CA03 
Glibenclamide (3mg/kg) II t I 
MPG (1 mg/kg/min) .~ 
0 30 55 
Figure 2 Experimental protocols in the mitochondrial jUnction studies. Shown are the preconditioning 
protocols and the protocols for administering the various pharmacological agents to inhibit or stimulate the 
signal transduction pathways. 
Data Analysis and Presentation 
IS was analyzed by one-way ANOVA followed by Student-Newman-Keuls test. 
Hemodynamic variables were compared by two-way ANOV A for repeated measures followed 
by Dunnett's test. Statistical significance was accepted when P<0.05. Data are presented as 
mean±SEM. 
Drugs 
HMR-1098 was a generous gift from Dr. Gogelein (Aventis Pharma Deutschland 
GmbH). All other compounds were purchased from Sigma. Fresh drug solutions were prepared 
daily. 
Results 
Mortality 
Five rats in the myocardial infarction studies were excluded due intractable ventricular 
fibrillation (no more than one rat per group). 
Hemodynamics 
There were no significant differences between baseline heart rate (365±3 bpm) and 
mean arterial blood pressure (101±1 mmHg) in the various experimental groups. Similar to 
previous reports,2'11 there was no significant correlation between the rate-pressure product of 
the individual animals at the onset of the 60-min CAO and their corresponding infarct size (r2= 
0.001; P=0.66). 
Infarct Size 
Preconditioning stimuli. 
Infarct-size produced by a 60-min CAO (69±2%) was limited by 1CA015 and 3CA03 
to 45±3% and 28±4%, respectively (Fig. 3). 
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Figure 3 Components of signal transduction pathways in the two preconditioning stimuli. Shown are the effects 
of the inhibitors of the various components in the signal transduction pathway. *P<0.05 vs corresponding Sham; 
1P<0.05 vs corresponding untreated JCA015 or 3CA03 
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Components of signal transduction pathway 
Adenosine receptor blockade with 8-SPT abolished the cardioprotection by ICA015, 
but had no effect on the protection by 3CA03 (Fig. 3; historic data2). Conversely, the ROS 
scavenger MPG had no effect on the protection by 1CA015 but blunted the protection by 
3CA03. Neither PKC blockade with chelerytrine, nor TyK blockade with genistein had any 
effect on cardioprotection by ICA015 when administered alone, whereas combined 
administration blunted the cardioprotection by 1CA015. Also, genistein and chelerythrine each 
tended to blunt the cardioprotection by 3CA03 (P>0.05), but only combined administration 
significantly attenuated the cardioprotection by 3CA03. The mitochondrial K+ ATP-channel 
inlnbitor 5-HD and the general K+ ATP-channel inhibitor glibenclamide, but not the sarcolemmal 
K+ATP-channel inhibitor HMR-1098, abolished the protection by 1CA015. In contrast, none of 
these K+ ATP-channel inhibitors affected IPC by 3CA03, suggesting that its cardioprotection 
does not require opening ofK+ ATP-channels. 
Order of involvement of components of signal transduction pathway 
Either glibenclamide or combined chelerythrine and genistein abolished 
cardioprotection by adenosine (Fig. 4). In contrast, the protection by the mitochondrial K+ ATP-
channel opener diazoxide was not affected by chelerythrine and genistein. These findings 
suggest that in ICA015 adenosine activates TyK and PKC which then leads to opening of 
mitochondrial K+ ATP channels. Finally, the infarct size limitation by menadione was abolished 
by combined administration of genistein and chelerythrine, consistent with the concept that in 
3CA03 ROS lead to activation ofTyK and PKC. 
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Figure 4 Mitochondrial respiratory control index (RCI) in mitochondria subjected to sham procedure or either 
ICA015 or 3CA03. *P<0.05 vs Sham; tp<0.05 vs ICA015 or 3CA03 
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Mitochondrial function studies 
Both IPC stimuli 1CA015 and 3CA03 resulted in mitochondrial uncoupling (Fig. 5). 
The uncoupling produced by 1CA015 was blocked by in vivo administration of glibenclamide 
but not MPG, while the reverse was true for 3CA03. The respiratory control index (RCI) was 
significantly correlated with infarct size (Fig. 6). 
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Figure 5 Relation between mitochondrial respiratory control index (RC/) and myocardial infarct size. Shown 
are mean±SEMfor all experimental groups disph:yed in Fig. 5. 
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Figure 6 Relation between mitochondrial respiratory control index (RCI) and myocardial infarct size. Shown 
are mean±SEM for all experimental groups displayed in Fig. 5. 
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Discussion 
The major findings of the present study are that: (i) 1CA015 elicits protection via 
adenosine receptor stimulation, TyK and PKC and subsequently activation of mitochondrial 
K+ ATP channels, without any involvement of ROS; (ii) 3CA03 elicits protection involving the 
release of ROS which subsequently activate TyK and PKC, without any involvement of K+ ATP 
channel opening; (iiz) Despite employing different signal transduction pathways, both stimuli 
resulted in mitochondrial uncoupling. (iv) Blockade of the signal transduction pathways 
abolished not only their infarct size reduction, but also the stimulus-induced mitochondrial 
uncoupling. The implications of these findings will be discussed in detail. 
The existence of different ischemic preconditioning stimuli was first demonstrated by 
Schulz et al. 1 who reported in the porcine heart that intracoronary adenosine deaminase was 
ineffective in attenuating IS limitation by a 3-min CAO, but abolished the cardioprotection by 
a 10-min CAO. Subsequently, we demonstrated in the in vivo rat heart that preconditioning by 
3CA03 did not involve adenosine, whereas in 11CA015 adenosine plays a pivotal role.2 
Moreover, Cohen et al. demonstrated in the intact rabbit heart that pharmacological 
cardioprotection by bradykinin and opioids, but not by adenosine involved K+ ATP channel 
activation and release of ROS.4 In accordance with the latter findings, we observed in the in 
vivo rat heart that the adenosine-dependent stimulus 1CA015 did not involve production of 
ROS, but found in contrast, that the adenosine-dependent stimulus involved activation of 
mitochondrial ~ ATP channels. 
Several studies have reported an important contribution of ROS in triggering IPC, as 
infusion of pro-oxidants has been shown to induce cardioprotection in rabbit hearts, 12 whereas 
radical scavengers can block IPC.13•14 Moreover, in hypoxic chick cardiomyocytes an early 
increase of ROS during the IPC period was shown by VandenHoek et al. 15 Xanthine oxidase 
reaction have been suggested as a possible source of ROS in order to open K+ ATP channels.16 
During myocardial preconditioning, the mitochondrial electron transport chain at site III may 
be the source of ROS.17 The mechanistic link between opening of of mito~hondrial K+ ATP 
channels and release of ROS remains poorly understood. Several reports have shown that 
opening of mitochondrial K+ ATP channels leads to release of ROS.18-20 However, in contrast to 
these findings, several other reports have shown that ROS are able to open the mitochondrial 
.K+ ATP channels.16•21 Zhang et al., reported in mitochondria from bovine ventricular 
myocardium that ROS, possibly from xanthine oxidase reaction, can lead to opening of 
mitochondrial K+ATP channels?1• Finally, Lebuffe et a1.22 recently concluded that ROS can 
trigger preconditioning by causing activation of the K+ ATP channel, which then induces 
generation of ROS and nitric oxide that are required for preconditioning protection. In contrast 
to other G-protein linked receptor agonists, adenosine has been reported to trigger IPC 
independently of mitochondriali<A.TP and generation of ROS.4 The present study shows that IS-
limitation by 3CA03, which could not be blocked by KATP inhibition, was markedly blunted 
by free radical scavenging, suggesting an adenosine-independent ischemic preconditioning 
stimulus in which generation of ROS play a key role without any involvement of mito KATP 
activation. In contrast, IS-reduction by 1CA015 was completely abolished by KATP inhibition, 
but was not affected by the free radical scavenger MPG, demonstrating an adenosine 
dependent ischemia stimulus, which does not involve generation of ROS. Since 
preconditioning by 3CA03 was not abrogated by glibenclamide, we exclude mitochondrial 
K+ ATP channels as a source of ROS. Moreover, cardioprotection by menadione which generates 
mitochondrial ROS, could not be abrogated by glibenclamide demonstrating an insignificant 
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role ofK+ATP channel activation. Conversely, cardioprotection by 1CA015 was not affected by 
MPG implying multiple short bursts of ischemia-reperfusion augment generation of ROS. It is 
still not clear in what way ROS can precondition myocardium, but they are known to activate 
G-proteins and protein kinases.23 Both P38 MAPkinase and TyK can be activated, whereas 
PKC seems to be independent of radical signaling.14 
Early studies indicated that cardioprotection by a single 10-min CAO in the pig could 
be abolished by glibenclamide, implicating a critical role for K+ ATP channel opening in IPC in 
swine.24•25 In contrast, Schwartz et al.26 recently reported that glibenclamide failed to block 
cardioprotection after preconditioning by two 5-min ischemic preconditioning stimuli. The 
latter authors did not consider different preconditioning stimuli as a cause for the different 
results regarding the role of K+ ATP channels. However, the results from the present study 
clearly suggest that the different observations in pigs may have been due to multiple brief 
(2CA05) versus long (lCAOlO) ischaemia stimuli. Thus, it appears that opening of K+ATP 
channels in IPC may depend on the preconditioning stimulus. 
Preconditioning by either 1CA015 or 3CA03 was abolished when PKC and TyK were 
inhibited. These findings not only confirm a major contribution for both PKC and TyK in 
ischemic preconditioning either by single- or multiple stimuli, 27-32 but also demonstrate their 
activation either without KATP opening in 3CA03, or ROS in 11CA015. Similar to the 
findings of Valhaus et al/3 cardioprotection by both preconditioning stimuli was only 
abolished by simultaneous inhibition. Single inhibition of either PKC or TyK did not affect IS-
reduction implying their parallel activation. Since IS-reduction by diazoxide was unaffected by 
PKC- and TyK-inhibition, mitochondrial K+ ATP opening in 1CA015 most likely occurs 
downstream as an end-effector.34 In addition, cardioprotection by menadione was completely 
abolished by combined treatment with chelerythrine and genistein. Thus, during 
preconditioning by 3CA03, both PKC and TyK are most likely activated in parallel pathways 
after generation ofROS. 
The present study clearly demonstrates that the adenosine-dependent preconditioning 
stimulus 1CA015 involves mitochondrial K+ATP channels but not ROS, whereas in the 
adenosine-independent preconditioning stimulus 3CA03, ROS play a pivotal role but does not 
involve K+ ATP channel activation demonstrating potent cardioprotection by two separate 
pathways. However, despite their markedly different signaling pathways, both stimuli resulted 
in mitochondrial uncoupling, as reflected in the decrease of RCI. In vitro evidence is 
accumulating that mild uncoupling of mitochondria may increase cardiomyocytes survival 
during sustained ischaemia and reperfusion. It cannot be determined from the present study 
how the two stimuli produced uncoupling, but there is evidence that both opening of K+ ATP 
channels in the inner mitochondrial membrane and ROS can cause mitochondrial 
uncoupling.35-37 Conversely, the exact mechanism by which uncoupling protects against 
cardiomyocytes death is also incompletely understood and may involve reduced mitochondrial 
matrix calcium overload,38 mitochondrial swelling,37•39 and reduced oxidative stress40 during 
prolonged ischaemia and reperfusion and possibly augmentation of glucose uptake.41 
In conclusion we clearly demonstrate the diversity of IPC stimuli regarding the 
involvement of adenosine, activation of K+ ATP channels and the generation of ROS. 
Furthermore, while different IPC stimuli can induce cardioprotection by separate pathways, the 
protective signaling pathway converges into mitochondrial uncoupling. 
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On the sites of action of adenosine in interorgan preconditioning of the heart 
Liem David A., Pieter D. Verdouw, Harald Ploeg, Shahla Kazim and Dirk J. Duncker 
Summary 
The mechanism underlying interorgan preconditioning of the heart remains elusive, although a 
role for adenosine and activation of a neurogenic pathway have been postulated We tested in 
rats the hypothesis that adenosine released by the remote ischemic organ stimulates local 
afferent nerves, which leads to activation of myocardial adenosine receptors. Preconditioning 
with a 15-min mesenteric artery occlusion (MA015) reduced infarct size produced by a 60-
min coronary artery occlusion (60-min CAO) from 68±2% to 49±4% (P<0.05). Pretreatment 
with ganglion blocker hexamethonium or 8-(p-sulfophenyl)theophylline (8-SPT) abolished the 
protection by MA015. Intramesenteric artery (but not intraportal vein) infusion of adenosine 
10 J.lg/min was as cardioprotective as MA015, which was also abolished by hexamethonium. 
Whereas administration of hexamethonium at 5 min reperfusion following MA015 had no 
effect, 8-SPT at 5 min reperfusion abolished the protection. Permanent reocclusion of the 
mesenteric artery before the 60-min CAO enhanced the cardioprotection by MA015 (30±5%) 
but all protection was abolished when 8-SPT was administered after reocclusion of the 
mesenteric artery. Together these findings demonstrate the involvement of myocardial 
adenosine receptors. In conclusion, locally released adenosine during small intestinal ischemia, 
stimulates afferent nerves in the mesenteric bed during early reperfusion, initiating a 
neurogenic pathway that leads to activation of myocardial adenosine receptors. 
(Am J Physiol Heart Circ Physiol 283:H29-H37) 
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Introduction 
Ischemic preconditioning is not organ specific as it has not only been demonstrated for 
the heart,1 but also for the kidneys, liver, brain, skeletal muscle and the lung.2 Przyklenk et aL3 
expanded the concept of ischemic preconditioning from intraregional to interregional 
myocardial protection by showing that a brief coronary artery occlusion (CAO) not only 
preconditioned the myocardium nourished by that coronary artery but also protected the 
adjacent virgin myocardium. Gho et aL4 subsequently showed that 15 min of small intestinal or 
renal ischemia preceding a 60-min CAO by 10 min was also capable of limiting myocardial 
infarct size. This interorgan preconditioning (IOPC, remote myocardial preconditioning; 
preconditioning at a distance) of the heart by preceding transient ischemia in remote organs has 
been confrrmed for the small intestine, 5•6 kidney7·9 and skeletal muscle. 10 However, not all 
remote organs may be able to protect the myocardium as De Zeeuw et aL 11 did not find any 
infarct size limitation when a 60-min CAO was preceded by global cerebral ischemia. 
Although not yet extensively studied, IOPC of the heart also appears to involve a delayed 
phase.5'6 
The mechanism underlying classical ischemic myocardial preconditioning is still 
incompletely understood, but there is now consensus that it involves the release of a number of 
local mediators such as adenosine, norepinephrine and bradykinin during the preconditioning 
stimulus, which, most likely via different signal transduction pathways, 12 activate the 
mitochondrial K+ ATP channels. 13 The mechanism underlying interorgan preconditioning is less 
clear. Gho et aL4 showed the involvement of a neurogenic pathway in IOPC by preceding 
small intestinal ischemia, as pretreatment with the ganglion blocker hexamethonium abolished 
the cardioprotection. In that study it was also shown that reperfusion of the occluded 
mesenteric artery, responsible for small intestinal ischemia, was mandatory (an observation 
confirmed for the renal bed9). The latter suggests that activation of the neurogenic pathway 
occurs upon reperfusion4 or that reperfusion facilitates the transfer of hormonal 
preconditioning factors from the ischemic organ to the heart.14 Bradykinin15 and adenosine8•9 
may also be involved in IOPC of the heart but the site(s) of action of these mediators, i.e. the 
ischemic organ or the heart or both, has not been investigated. Takaoka et aL9 suggested that 
myocardial adenosine receptors might be involved because the adenosine concentrations in the 
carotid artery were ten times higher after renal ischemia than after regional myocardial 
ischemia. However, based on the hypotension following renal artery reperfusion, Pell et aL 8 
proposed that adenosine release from the kidney was insufficient to produce cardioprotection 
via the circulation and suggested, based on the observations by Gho et aL,4 that adenosine 
released in the ischemic kidney stimulated the afferent renal nerves and thereby protected the 
myocardium. The latter hypothesis was recently confirmed by Ding et al. 7 in anesthetized 
rabbits. 
To further elucidate the mechanism of IOPC, we not only investigated whether 
activation of adenosine receptors (and which of its subtypes) is involved in the protection by 
small intestinal ischemia, but we also determined the location(s) (myocardium and/or small 
intestine) of the adenosine receptors involved. Studies were performed in anesthetized rats. 
Until recently it has been assumed that adenosine, is not involved in ischemic preconditioning 
in the rat, 16•17 despite its capability to limit infarct size in this species. 18 We have recently 
shown, however, that adenosine is involved classic ischemic preconditioning in the rat, but that 
its role depends critically on the duration of the preconditioning stimulus. 19 Capitalizing on our 
earlier observation that hexamethonium abolished the cardioprotection by small intestinal 
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ischemia, 4 we hypothesized that adenosine released in the small intestine during small 
intestinal ischemia stimulates afferent nerves within the mesenteric bed, which via a 
neurogenic pathway leads to activation of myocardial adenosine receptors prior to the coronary 
artery occlusion, thereby preconditioning the heart. This hypothesis also implies that once the 
myocardial adenosine receptors have been activated, blockade of the neurogenic pathway, 
which occurs upstream from activation of the myocardial adenosine receptors will not abolish 
the cardioprotection by small intestinal ischemia. 
Methods 
Experiments were performed in 228 ad libitum fed male Wistar rats (280-360 g) in 
accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication 86-
23, revised 1985) and with approval of the Erasmus University Rotterdam Animal Care 
Committee. 
Experimental procedures 
Pentobarbital anesthetized (60 mg/kg, ip) rats were intubated (PE-240) for positive 
pressure ventilation (Harvard rodent ventilator) with room air.4•19•20 The thoracic aorta was 
cannulated via the carotid artery with a PE-50 catheter for measurement of arterial blood 
pressure and computation of heart rate. A catheter was positioned in the femoral vein for 
infusion of Haemaccel (Behringwerke) to maintain fluid balance. After thoracotomy via the 
left third intercostal space and opening of the pericardium, a silk 6-0 suture was looped under 
the coronary artery for later occlusion. Following laparotomy, the anterior mesenteric artery 
was dissected free and looped by a loose suture to allow later mesenteric artery occlusion with 
an atraumatic clamp. Pentobarbital was suffused in the abdominal cavity to maintain 
anesthesia. Rectal temperature was continuously measured with an electronic thermometer 
(Electromedics Inc.) and was maintained at 36.5-37.5 °C.4•19•20 
Rats that fibrillated during occlusion or reperfusion were allowed to complete the 
protocol when conversion to normal sinus rhythm occurred spontaneously within 1 min, or 
when resuscitation by gently thumping on the thorax or defibrillation with a modified battery 
of 9V was successful within 2 min after onset of fibrillation. Occlusion and reperfusion were 
visually verified by appearance and disappearance of myocardial cyanosis. 
Experimental design 
After surgery, a 30-min stabilization period was allowed before the start of the 
experimental protocol. All animals were subjected to a 60-min CAO followed by 120 min of 
reperfusion, after which area at risk (AR) and infarct area (IA) were determined using trypan 
blue and nitro-blue-tetrazolium staining.4•19,2° Infarct size (IS) was defined as 100 x WAR 
(%). 
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Protocol/: Choice of interorgan preconditioning stimulus 
Sham (n=15, historic data)19 120-min Rep 
CA015 (n=19, historicdata)19 • 
3-CA03 (n=5, historic data)19 Ill 
MA015 ( n=10, historicdata)4 • 
1. 3-MA03 ( n=4) Ill 
Protocol//: Involvement of adenosine receptors 
2. Sham (n=12) 
3. MA015 ( n=12) 
• 
4. 50SPT + Sham (n=5) --[H] 
5. 50SPT + MA015 (n=8) 
--lWJ 
6. 10SPT +Sham (n=4) ---[]-{] 
7. 10SPT + MA015 (n=9) 
--1WJ 
8. MRS + Sham (n=4) 
9. MRS+ MA015 (n=8) 
•• 
10. 10SPT + MRS+ MA015 (n=5) 
--11111 
Protocol II/: Involvement of small intestinal adenosine receptors 
2. Sham (n=12) 
11. Saline IMA (n=5) 
12. ADO IMA (n=8) 
13. Hex+ ADO IMA (n=4) 
14. ADO IV (n=5) 
15. ADO IPV (n=5) 
y 
II 
----------
-r--.11------
Figure 1 Schematic overview of experimental protocols I, II and III. For details see text. 
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Protocol I: Choice of IOPC stimulus 
Using the identical protocol of Li and Kloner14 we recently observed, 19 that 3 cycles of 
3-min CAO interspersed by 5 min of reperfusion (3-CA03) provided a greater degree of 
myocardial protection than a 15-min CAO (CA015, Fig. 1). Therefore, we first investigated 
the cardioprotection afforded by IOPC elicited by 3 cycles of 3-min MAO interspersed by 5 
min ofreperfusion (3-MA03, group 1), and compared it to the protection afforded by a single 
15-min mesenteric artery occlusion followed by 10 min ofreperfusion (MA015, historic data.4 
Because, 3-MA03 failed to afford cardioprotection (see results), we selected MA015 as the 
IOPC stimulus. 
Protocol II: Involvement of adenosine receptor stimulation in IOPC 
To investigate the role of adenosine in IOPC, four groups of rats were studied (Fig. 1), 
in which the effect of a single MA015 on infarct size by 60-min CAO was determined in the 
absence (Sham, group 2; MA015, group 3) and presence (50SPT+Sham, group 4; 
50SPT+MA015, group 5) of a non-selective dose (2 x 25 mg/kg iv, 50SPT) ofthe adenosine 
receptor antagonist 8-SPT [8-(p-sulfophenyl)theophylline ]. Since we established the 
involvement of adenosine in this model of IOPC (see results), we further investigated whether 
the A1- and A3-receptor subtypes are involved. For this purpose, Sham and IOPC animals were 
pretreated with either an A1-selective dose (2 x 5 mg/kg iv) of 8-SPT (10SPT, groups 6 and 7) 
or an A3-selective dose (3.3 mg/kg iv) of the adenosine receptor antagonist MRS 1191 (MRS, 
groups 8 and 9).19 Finally, IOPC animals were pretreated with a combination of 10SPT and 
MRS (group 10). 
Protocol III: Effect of small intestinal adenosine receptor stimulation on myocardial infarct 
size 
To investigate whether activation of adenosine receptors in the small intestine 
contributes to IOPC, we employed intramesenteric artery infusions of vehicle (saline 50 
~1/min, group 11) and adenosine (10 ~g/min, ADO IMA, group 12). This dose of adenosine 
has been shown to stimulate intestinal afferent nerves.21 The involvement of the neurogenic 
pathway in the cardioprotection by intramesenteric adenosine was verified by pretreating 
animals with hexamethonium (Hex+ ADO IMA, group 13). To exclude that the intramesenteric 
artery infusion of adenosine protected the myocardium by direct stimulation of myocardial 
adenosine receptors (after recirculation), we also infused this dose of adenosine intravenously 
(ADO IV, group 14). Finally, to exclude that stimulation of the afferent nerves in the liver 
contributed to the cardioprotection, we also studied the effect of infusion of 10 ~g/min 
adenosine into the portal vein (ADO IPV, group 15). 
Protocol IV: Involvement of myocardial adenosine receptor stimulation in IOPC 
It is well established that adenosine receptor blockade between the preconditioning 
stimulus and the sustained CAO abolishes the cardioprotection in ischemic myocardial 
preconditioning.Z2 We therefore followed two approaches to study the involvement of 
myocardial adenosine receptors in IOPC. Firstly, we established that the neurogenic pathway 
(required for IOPC of the heart Hex+MA015, see reference4 was no longer required for IOPC 
5 min after mesenteric artery reperfusion (MA015+Hex, group 16), indicating that the 
neurogenic pathway had already activated cardiac adenosine receptors. Subsequently, we 
determined the role of myocardial adenosine receptors by administering 50SPT at 5 min of 
mesenteric artery reperfusion (MA015+50SPT, group 17). The second approach involved 
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reocclusion of the mesenteric artery 5 min prior to the 60-min CAO in order to prevent that the 
subsequently administered 8-SPT would, we also occluded in a number of animals the 
collaterals in the mesenteric vascular bed reach the small intestine. To exclude that 8-SPT 
would reach the small intestine via collaterals 23• We first confirmed that a permanent MAO 
(MAO-P, group 18) was not cardioprotective,4 and then studied IOPC produced by 
MA015+MAO-P (group 19). These experiments revealed a potentation of the cardioprotection 
by MA015+MAO-P (see results). To establish whether this potentiated cardioprotection also 
involved the neurogenic pathway, we determined the effects of treatment with hexamethonium 
administered prior to MA015 (Hex+MA015+MAO-P, group 20) and more importantly when 
administered after 5-min of mesenteric reperfusionjust prior to MAO-P (MA015+Hex+MAO-
P, group 21). We then studied the effect of 8-SPT administered after re-occlusion of the 
mesenteric artery (MA015+MAO-P+50SPT, group 22) to obtain further evidence for the 
involvement of myocardial adenosine receptor activation in IOPC. Finally, we studied the role 
of myocardial A1 (MA015+MAO-P+IOSPT, group 23) and A3 (MA015+MAO-P+MRS, 
group 24) adenosine receptors in IOPC. 
Protocol IV: Involvement of myocardial adenosine receptors 
60-minCAO 
2. Sham (n=15) 120-min Rep 
3. MA015 ( n=15) 
111111 
Hex+ MA015 (n=7, historic data)4 y 
111111 
16. MA015 +Hex (n=S) 
111111 
y 
5. SOSPT + MA015 (n=S) 
-1W)-------
17. MA015 + SOSPT (n=S) 
18. MAO·P (n=S) 
19. MA015 + MAO-P (n=17) 
20. Hex+ MA015 + MAO-P (n=6) 
21. MA015 +Hex+ MAO-P (n=8) 
22. MA015 + MAO·P + SOSPT (n=10) 
23. MA015 + MAO-P + 10SPT (n=8) 
24. MA015 + MAO·P +MRS (n=7) 
Small intestinal collateral blood flow 
Megison et al.23 reported that after mesenteric artery occlusion in rats, small intestinal 
collateral blood flow amounted 17±6% of basal flow, an after subsequent occlusion of 
collateral blood vessel amounted 2±1% of basal flow. To determine small intestinal blood flow 
in our model, radioactive microspheres were injected in 4 additional rats at baseline, after 
Figure 2 Schematic overview of experimental protocol IV. For details see text. 
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mesenteric artery occlusion and after additional occlusion of collateral vessels (i.e. arcades 
between right colic artery and ileocolic artery and between jejunal branches just proximal and 
distal to the point of the superior mesenteric artery occlusion. 23 
Data analysis and presentation 
Infarct size was analyzed by one-way analysis of variance for all groups, followed by 
one-way analysis of variance within each protocol and Student-Newman-Keuls test. 
Hemodynamic variables were compared by two-way (time and treatment) analysis of variance 
for repeated measures followed by the paired or unpaired t-test with Bonferroni correction for 
multiple comparisons. Statistical significance was accepted when P<0.05. Data are 
mean±SEM. 
Results 
Mortality 
Of the 224 rats that entered the IOPC study 30 animals were excluded, because of 
sustained ventricular fibrillation during the 60-min CAO or cardiac pump failure. Because the 
excluded rats were equally distributed over the various groups, the exclusion did not cause a 
bias towards any intervention. In 13 animals the area at risk was less than 15% of total left 
ventricular mass and were therefore also excluded. Data are presented for 181 animals. 
100 
2" 80 t (/) 
·;:: 
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-0 
~ 
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"§ 
ro 
-..!: 
20 
0 
Sham CA015 3-CA03 MA015 3-MA03 
Figure 3 Cardioprotection by classical and interorgan preconditioning (IOPC). Note that whereas 3-CA03 was 
more cardioprotective than CA015 in classical preconditioning, 3-MA03 was ineffective in IOPC. Historic data 
have been presented for Sham, CA015 and 3-CA03, and for MA015. *P<0.05 vs Sham; tp<o.05 vs 
corresponding 15-min stimulus. 
Area at risk 
There were no differences between the area at risk of the experimental groups 
(30.5±0.7%, n=181, P=0.16). 
Infarct size 
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Protocol I: Choice of IOPC stimulus 
Figure 3 shows that MA015 and CA015 afford similar cardioprotection. However, in 
contrast to 3-CA03, 3-MA03 failed to protect the myocardiwn. Consequently, MA015 was 
selected as the stimulus for IOPC. 
Protocol II: Involvement of adenosine receptor stimulation in IOPC 
Pretreatment with a non-selective dose of 8-SPT (50SPT) abolished the 
cardioprotection by MA015 (Fig. 4). The A1-selective dose of 8-SPT (IOSPT) and the A3-
selective dose of MRS 1191 each attenuated the cardioprotection by MA015. Combined 
pretreatment with the A1- and A3-selective doses of these antagonists (IOSPT + MRS) 
abolished the cardioprotection. 
Control 
100 
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A-receptor blockade 
2' 80 en 
·.:: c8> 
-ro 
ctS 
1'0 ~ 
ctS 60 
0 c:e 
~ 0 cg! * ~ 
·c;; 40 8 
~ 0 
c£• ;. t 
0 
.E1 
£ 
20 
0 
0 
Sham MA015 50SPT 50SPT 
+ + 
Sham MA015 
A1-receptor A3-receptor 
blockade blockade 
cS. 0 Q)!~ <%• *t cP Qj! 
co Ol t 
0 
10SPT 10SPT MRS MRS 
+ + + + 
Sham MA015 Sham MA015 
A1- and A,- receptor 
blockade 
8 
co !t 
0 
10SPT 
+ 
MRS 
+ 
MA015 
Figure 4 Involvement of adenosine receptor stimulation and of A1 and Arreceptor subtypes in IOPC by 
MA015. *P<0.05 vs corresponding Sham; fp<0.05 vs MA015.15-min stimulus. 
Protocol III: Effect of small intestinal adenosine receptor stimulation on myocardial infarct 
size 
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lntramesenteric artery infusion of 10 J.lg/min adenosine (ADO IMA), but not of its 
vehicle, limited infarct size (IS=47±4%) to the same extent as MA015 (Fig. 5). Pretreatment 
100 
0 
80 
os:> § o ~! 
........ ({~}, .......... 9 .. .!................. . ....... g .!.t .... . 
§ ~ 0 60 0 
0 
40 0 
8 
20 
0 
Figure 5 Involvement of small intestinal adenosine receptor stimulation in IOPC. Intramesenteric artery 
infUsion of 10 p.g/min adenosine (ADO IMA) limited infarct size to the same extent as MA015 (see Figure 
4). The protection by ADO IMA is under neurogenic control as pretreatment with hexamethonium 
(Hex+ ADO IMA) abolished the protection and intravenous adenosine infusion (ADO IV) was ineffective. 
Stimulation of adenosine receptors in the liver by spillover of adenosine during ADO IMA does not 
contribute to the protection by ADO IMA, as adenosine infUsion into the portal vein (ADO IPV) was 
ineffective. *P<0.05 vs Sham. tP<0.05 Hex+ ADO IMA vs ADO IMA. 
with hexamethonium abolished the cardioprotection by ADO IMA (Hex+ADO IMA), 
implying involvement of a neurogenic pathway in the cardioprotection by locally administered 
adenosine. This is also confirmed by the lack of effect of intravenous adenosine infusion (ADO 
IV), excluding that recirculation of adenosine during ADO IMA stimulated cardiac adenosine 
receptors directly. Finally, infusion of adenosine into the portal vein (ADO IPV) did not limit 
myocardial infarct size, excluding that spillover of adenosine during ADO IMA stimulated 
adenosine receptors in the liver and contnbuted to the cardioprotection by ADO IMA. 
Protocol W: Involvement of myocardial adenosine receptor stimulation in IOPC 
Figure 6 shows that whereas pretreatment with hexamethonium abolished IOPC 
(Hex+MA015, IS=74±2%), hexamethonium did not abrogate IOPC when administered at 5 
min of mesenteric artery reperfusion (MA015+Hex, IS=54±2%). In contrast, both 
pretreatment (50SPT+MA015, IS=73±2%) and treatment at 5 min of mesenteric reperfusion 
with 8-SPT (MA015+50SPT, IS=67±3%) abolished IOPC. Figure 6 also confirms that 
permanent occlusion of the MAO (MAO-P) did not confer significant cardioprotection 
(18=63±2%). However, MAO-P potentiated the cardioprotection protection by MA015 as IS 
was only 30±5% after MA015+MAO-P vs 49±4% after MA015 (P<0.05). This enhanced 
protection was also mediated via a neurogenic pathway as (i) pretreatment with 
hexamethonium (Hex+MA015+MAO-P) completely abrogated all cardioprotection and (ii) 
posttreatment, selectively abolished the potentation leaving the protection by MA015 
unperturbed (MA015+MAO-P+Hex). Administration of 8-SPT after the mesenteric artery was 
reoccluded following MA015 (MA015+MAO-P+50SPT) entirely abolished the protection. In 
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several of these experiments, the collaterals of the mesenteric vascular bed were also occluded 
to minimize the adenosine antagonist from entering the mesenteric bed via these collaterals and 
blocking the adenosine receptors in the small intestine (Fig. 6). Both selective A1 and A3 
receptor blockade blunted the cardioprotection by MA015+MAO-P as IS was 61±2% after 
10SPT and 53±3% after MRS, respectively. 
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Figure 6 Involvement of myocardial adenosine receptor stimulation in IOPC by MAO 15. Notice that, whereas 
posttreatment with hexamethonium (MA015+Hex) had no effect on IOPC, post-treatment with 8-SPT 
(MA015+50SPT) abolished IOPC. To prevent that 8-SPTwould reach the adenosine receptors in the small 
intestine, 8-SPT (50 mglkg iv) was administered after the mesenteric artery was permanently occluded (MAO-
P) following the 15-min MAO (MA015+MAO-P+50SPT). The figure shows that MAO-P potentiated the 
cardioprotection by MA015 and that this enhanced protection was also under neurogenic control 
(MA015+Hex+MAO-P). IOPC involved myocardial adenosine receptor stimulation as cardioprotection was 
abolished in MA015+MAO-P+50SPT. Infarct size was not different in animals in which the small intestine 
collateral vessels were occluded (animals indicated by triangles). *P<0.05 vs Sham; tP<0.05 vs MA015; 
tP<0.05 vs MA015+MAO-P. 
Heart rate and blood pressure 
Baseline heart rate and mean arterial blood pressure for all 181 animals were 381±3 
bpm and 93±2 mmHg, with minimal differences between the experimental groups with the 
exception of 50SPT+MA015 in which baseline mean arterial blood pressure was 135±4 
mmHg. Similar to earlier reports/0 there was no correlation between the product of heart rate 
and mean aortic pressure of the individual animals at the onset of the 60-min CAO and their 
infarct size (linear regression: ?= 0.01; P= 0.88). 
Small intestinal collateral blood flow 
Following occlusion of the mesenteric artery small intestinal blood flow was reduced to 
5±2% (range 0-10%) of baseline. Subsequent ligation of the collateral vessels further reduced 
flow to 0. 7±0. 7% (range 0-2%) of baseline, confirming previous observations.23 
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Discussion 
The major findings of the present study are: (i) In contrast to classical ischemic 
myocardial preconditioning, in which 3-CA03 provided greater cardioprotection than CA015, 
3-MA03 was unable to limit myocardial infarct size. (ii) Pretreatment with a non-selective 
dose of the adenosine receptor antagonist 8-SPT abolished the cardioprotection by MA015, 
while pretreatment with an A1-selective dose of 8-SPT or the A3-selective antagonist 
MRS1191 attenuated cardioprotection by MA015. (iii) Intramesenteric artery infusion of a 
dose of adenosine, that was ineffective when infused into either the portal or inferior caval 
vein, mimics the IOPC by MA015 which was also abolished by pretreatment with 
hexamethonium. (iv) Hexamethonium abolished IOPC by MA015, but only when 
administered before the mesenteric artery occlusion, and not when administered after 5-min of 
mesenteric artery reperfusion. In contrast, 8-SPT abolished IOPC also when administered after 
5-min of mesenteric artery reperfusion. (v) Whereas a permanent mesenteric artery occlusion 
was not cardioprotective by itself, it potentiated the protection by MA015; this enhanced 
protection was also abolished by ganglion blockade. (vi) After the myocardium was 
preconditioned by MA015, administration of 8-SPT, at a time point that the mesenteric artery 
was permanently reoccluded to prevent 8-SPT to reach the small intestine, abolished all 
cardioprotection IOPC. 
IOPC stimulus 
In our original study,4 MA015 was as effective as a CA015 in limiting myocardial 
infarct size produced by a subsequent 60-min CAO. Because 3-CA03 afforded greater 
protection than CA015/9 we investigated whether 3-MA03 was also more effective than 
MA015 in eliciting cardioprotection. Our data showed that these multiple brief MAO's were 
unable to precondition the myocardium. In this respect it is of interest, that Tang et al.5 recently 
showed that a single 10-min episode of small intestinal ischemia was equally effective in 
producing early and delayed (24-72 h) IOPC. The latter could also be elicited by 6 cycles of 4-
min small intestinal ischemia and 4 min of reperfusion.6 Although in this latter study, 6 only the 
delayed preconditioning phase was investigated, it cannot be excluded that a larger number 
and/or longer duration than the 3-min periods of small intestinal ischemia used in the present 
study might have provided an effective stimulus for IOPC. 
That MA015 does not yet provide optimal protection was shown when we reoccluded 
the mesenteric artery permanently after the MA015. Thus, while MAO-P alone was not 
cardioprotective, we observed that MAO-P potentiated the cardioprotection by MA015. The 
reason for the activation of the neurogenic pathway during MAO-P by the preceding of 
MA015 is not clear. However, it is likely that the MA015 not only preconditioned the heart 
but also the small intestine itself possibly via adenosine, calcitonin-gene related peptide or 
endogenous opioids. 24'25 It may then be postulated that, while the virgin small intestine is 
unable to activate the neurogenic pathway during mesenteric artery occlusion and requires 
reperfusion (10), the preconditioned small intestine is capable of activating the neurogenic 
pathway during occlusion and thereby enhances the protection by the MA015. Future studies, 
involving measurement of interstitial adenosine concentrations in the small intestine and 
discharge rate of the small intestinal afferent nerves, are needed to test this hypothesis. 
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Involvement of adenosine receptor stimulation 
The cardioprotection by small intestinal ischemia was completely prevented by 
pretreating rats with a high non-selective dose of 8-SPT (50 mg/kg), implying that adenosine is 
at least one of the mediators leading to cardioprotection in this model of IOPC. The present 
study also reveals that, at least with the currently used stimulus, both the A1 and A3 receptor 
subtypes contribute. A role for adenosine has also been suggested for the IOPC by renal 
ischemia, 7.9 but in none of these studies the site of location or the subtype of the involved 
adenosine receptors was investigated. 
Myocardial adenosine receptors 
Because in Protocol II the adenosine receptor antagonists were administered 
intravenously and prior to both MA015 and 60-min CAO, the data in Fig. 4 do not reveal the 
site of action of adenosine. In order to investigate whether the myocardial adenosine receptors 
were involved, we administered 8-SPT (i) after 5 min of mesenteric reperfusion at a time when 
the cardioprotective mechanism no longer required continued activation of the neurogenic 
pathway, and (ii) after the mesenteric artery had been reoccluded following MA015 to prevent 
that 8-SPT would reach the small intestine. In several animals, we additionally ligated the 
collaterals in the mesenteric vascular be<f3 to exclude that 8-SPT would still reach the small 
intestine via these vessels during MAO-P in sufficient amounts to prevent activation of the 
neurogenic pathway. In this situation (MA015+MAO-P+50SPT), 8-SPT abolished all 
cardioprotection by IOPC (and not only the potentation by MAO-P), implying that the 
myocardial adenosine receptors must be involved in the mechanism underlying this 
phenomenon. The myocardial adenosine receptors involved are of both of the A1 and A3 
subtypes. This observation is in agreement with earlier studies in which a role for both receptor 
subtypes was established when CA015 was used to precondition the myocardium. 19 
Small intestinal adenosine receptors 
Intramesenteric infusion of 10 !J.glmin of adenosine limited myocardial infarct size to 
the same extent as MA015. Moreover, because infusion of the same dose of adenosine in the 
portal vein or inferior caval vein did not protect the myocardium, the adenosine must have 
acted in the small intestine. The action of locally administered adenosine was abolished when 
rats were pretreated with hexamethonium, which implies that the neurogenic pathway was also 
involved in this model of pharmacological IOPC. The intramesenteric artery infusion rate of 
adenosine was chosen such that only the adenosine receptors in the small intestine were 
activated. However, we do not know how the adenosine concentrations in the small intestine 
achieved by this route of administration compare to the adenosine concentrations that are 
achieved during MA015. It cannot be excluded that in the portal vein higher concentrations 
were reached upon reperfusion of the ischemic small intestine than during the direct infusion of 
adenosine into the portal vein. If true, these higher concentrations might have been sufficient to 
stimulate afferent nerves in the liver and thereby have contributed to the cardioprotection by 
small intestine ischemia. That the concentrations during intramesenteric adenosine infusion 
and MA015 were similar is suggested by the observation that the protection by the 
intramesenteric artery infusion of adenosine was very similar to the protection by MA015. 
To definitively demonstrate the involvement of adenosine receptor stimulation in the 
small intestine in IOPC requires blockade these receptors, while leaving the myocardial 
receptors unaffected. In view of the half-life of the antagonists used, which would result in 
recirculation and concomitant adenosine receptor blockade in the heart, this is technically not 
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feasible. Nevertheless, the present observations are consistent with the hypothesis that in IOPC 
by small intestinal ischemia, locally released adenosine triggers afferent nerves which in turn 
lead to stimulation of myocardial adenosine receptors. 
The findings in the present study do not exclude that mediators other than adenosine 
may also contribute to IOPC similar to classical ischemic myocardial preconditioning. For 
example, Schoemaker and Van Heijningen15 showed, without determining the site(s) of action, 
that the cardioprotection by transient small intestinal ischemia could be mimicked by 
intramesenteric artery infusion of bradykinin and abolished by pretreatment with the 
bradykinin antagonist HOE-140. Similarly, a role for calcitonin-gene related peptide, of which 
the release can be modulated by adenosine/6 has been implicated in the cardioprotection by 
small intestinal ischemia.5•6 
Conclusions 
Small intestinal ischemia results in local release of adenosine that activates a 
neurogenic pathway during the first few minutes of mesenteric artery reperfusion, which then 
leads to stimulation of A1 and A3 adenosine receptors in the heart prior to the coronary artery 
occlusion, 4 thereby preconditioning the heart. Adenosine is currently under investigation for its 
purported ischemic reperfusion-damage limiting effects.27 The results of the present study 
suggest that the cardioprotective effects of intravenous adenosine may not only be due to direct 
effects in the heart but could in part result from adenosine receptor activation in remote tissues 
which via neurogenic pathways increase interstitial adenosine levels in the heart.27 Such a role 
for adenosine complies with a paraphrase of the statement by Ribeiro28: "adenosine in its 
'obsession' to protect cells from insults uses as many receptor systems in as many tissues as 
possible in order to exert what seems to be the 'destiny' of this nucleoside: protection of the 
cardiac myocytes". 
Acknowledgements 
The present study was supported by the Netherlands Heart Foundation (NHS 99.135). 
Dr Duncker is the recipient for an "Established Investigator" Stipend (2000 D038) from the 
Netherlands Heart Foundation. 
References 
1. Murry CE, Jennings RB, Reimer K.A. Preconditioning with ischemia: a delay of lethal cell 
injury in ischemic myocardium. Circulation. 1986;74:1124-36. 
2. DeZeeuw S, Van den Doel MA, Duncker DJ, Verdouw PD. New insights into cardioprotection 
by ischemic preconditioning and other forms of stress. Ann NY Acad Sci. 1999;874:178-91. 
3. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' 
protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 
1993;87:893-9. 
4. Gho BC, Schoemaker RG, Van den Doel MA, Duncker DJ, Verdouw PD. Myocardial 
protection by brief ischemia in noncardiac tissue. Circulation. 1996;94:2193-200. 
5. Tang ZL, Dai W, Li YJ, Deng HW. Involvement of capsaicin-sensitive sensory nerves in early 
and delayed cardioprotection induced by a brief ischaemia of the small intestine. Naunyn 
Schmiedebergs Arch Pharmacal. 1999;359:243-7. 
6. Xiao L, Lu R, Hu C, Deng H, Li Y. Delayed cardioprotection by intestinal preconditioning is 
mediated by calcitonin gene-related peptide. Eur J Pharmacal. 2001 ;427: 131-5. 
7. Ding YF, Zhang MM, He RR. Role of renal nerve in cardioprotection provided by renal 
ischemic preconditioning in anesthetized rabbits. Sheng Li Xue Bao. 2001 ;53:7 -12. 
-78-
Cha ter4 
8. Pell TJ, Baxter GF, Yellon DM, Drew GM. Renal ischemia preconditions myocardium: role of 
adenosine receptors and ATP-sensitive potassium channels. Am J Physiol. 1998;275:H1542-7. 
9. Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, lnubushi T, Kinoshita M. Renal 
ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial 
ischemia via adenosine receptors in rabbits: effects of "remote preconditioning". JAm Col/ 
Cardiol. 1999;33:556-64. 
10. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of 
myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of 
the gastrocnemius muscle in the rabbit Circulation. 1997;96:1641-6. 
11. De Zeeuw S, Lameris TW, Duncker DJ, Hasan D, Boomsma F, Van den Meiracker AH, 
Verdouw PD. Cardioprotection in pigs by exogenous norepinephrine but not by cerebral 
ischemia-induced release of endogenous norepinephrine. Stroke. 2001 ;32:7 67-7 4. 
12. Cohen MV, Yang :x::t\1, Liu GS, Reusch G, Downey JM. Acetylcholine, bradykinin, opioids, 
and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and 
opening mitochondrial K+ATP channels. Circ Res. 2001;89:273-8. 
13. Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and 
myocardial preconditioning. Circ Res. 1999;84:973-9. 
14. Dickson EW, Lorbar M, Porcaro WA, Fenton RA, Reinhardt CP, Gysembergh A, Przyklenk K. 
Rabbit heart can be "preconditioned" via transfer of coronary effluent Am J Physiol. 
1999;277:H2451-7. 
15. Schoemaker RG, Van Heijningen CL. Bradykinin mediates cardiac preconditioning at a 
distance. Am J Physiol Heart Circ Physiol. 2000;278:H1571-6. 
16. Li Y, Kloner RA. The cardioprotective effects of ischemic 'preconditioning' are not mediated 
by adenosine receptors in rat hearts. Circulation. 1993;87: 1642-8. 
17. Ganote CE, Armstrong SC. Adenosine and preconditioning in the rat heart Cardiovasc Res. 
2000;45:134-40. 
18. Whittaker P, Kloner RA, Przyklenk K. lntramyocardial injections and protection against 
myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine. 
Circulation. 1996;93:2043-57. 
19. Liem DA, Van den Doel MA, DeZeeuw S, Verdouw PD, Duncker DJ. Role of adenosine in 
ischemic preconditioning in rats heart depends critically on the duration of the stimulus and 
involves both A1 and A3-receptors. Cardiovasc Res. 2001 ;51 :701-708. 
20. Van den Doel MA, Gho BC, Duval SY, Schoemaker RG, Duncker DJ, Verdouw PD. 
Hypothermia extends the cardioprotection by ischaemic preconditioning to coronary artery 
occlusions oflonger duration. Cardiovasc Res. 1998;37:76-81. 
21. Janssen BJ, Van Essen H, Struyker Boudier HA, Smits JF. Hemodynamic effects of activation 
of renal and mesenteric sensory nerves in rats. Am J Physiol. 1989;257:R29-36. 
22. Thornton JD, Thornton CS, Downey JM. Effect of adenosine receptor blockade: preventing 
protective preconditioning depends on time of initiation. Am J Physiol. 1993;265:H504-8. 
23. Megison SM, Horton JW, Chao H, Walker PB. A new model for intestinal ischemia in the rat. J 
Surg Res. 1990;49:168-73. 
24. Davis JM, Gute DC, Jones S, Krsmanovic A, Korthuis RJ. Ischemic preconditioning prevents 
postischemic P-selectin expression in the rat small intestine. Am J Physiol. 1999;277:H2476-
81. 
25. Christofi FL. Unlocking mysteries of gut sensory transmission: is adenosine the key? News 
Physiol Sci. 2001;16:201-7. 
26. Sebastiao AM, Ribeiro JA. Fine-tuning neuromodulation by adenosine. Trends Pharmacal Sci. 
2000;21:341-6. 
27. Kloner RA, Jennings RB. Consequences ofbriefischemia: stunning, preconditioning, and their 
clinical implications: part 2. Circulation. 2001;104:3158-3167. 
28. Ribeiro JA. Adenosine A2A receptor interactions with receptors for other neurotransmitters and 
neuromodulators. Eur J Pharmacal. 1999;3 75: 101-13. 
-79-

Does tolerance to classic ischemic preconditioning cause 
cross-tolerance to other preconditioning stimuli? 
Mechanistic and therapeutic aspects of ischemic myocardial preconditioning 
Summary 
Objectives 
To test the hypothesis that development of tolerance to the first window of cardioprotection by 
ischemic preconditioning does not cause cross-tolerance to preconditioning stimuli that employ 
a different signaling pathway. 
Background 
The mechanism of myocardial tolerance to preconditioning remains incompletely understood, 
but may involve loss of adenosine production, reduced adenosine receptor responsiveness or 
modifications in downstream signaling pathways. However, not all preconditioning stimuli use 
signaling pathways involving adenosine. 
Methods 
Anesthetized rats underwent classical, remote or pharmacological preconditioning of the heart. 
Size of the myocardial infarction, produced by a 60-min coronary artery occlusion (CAO) was 
determined using tetrazolium staining. Myocardial interstitial adenosine concentrations were 
measured using microdialysis. 
Results 
Preconditioning by either a single 15-min CAO (CA015) or by two CA015 resulted in a 
potent cardioprotection against a subsequent 60-min CAO. However, preconditioning with six 
CA015 did not limit infarct size, demonstrating that the myocardium had become tolerant to 
this stimulus when repetitively applied. During consecutive 15-min CAO, interstitial adenosine 
levels did not increase after the second CAO. In this tolerant myocardium, cardioprotection by 
exogenous adenosine was unperturbed, suggesting that development of tolerance is not due to 
blunting of adenosine receptor responsiveness or a signal transduction pathway downstream of 
the adenosine receptor. In corroboration with these findings, we observed that inter-organ 
preconditioning by small intestinal ischemia or preconditioning by an adenosine-independent 
classic preconditioning stimulus consisting of 3 cycles of 3-min CAO still produced protection. 
Finally, multiple episodes of 15-min exogenous adenosine infusions resulted in blunting of the 
infarct size limiting effects, indicating that responsiveness of adenosine receptors (or 
downstream components) can be attenuated. 
Conclusions 
The in vivo rat heart is susceptible to the induction of tolerance to preconditioning by repetitive 
stimulation with brief periods of ischemia. Although repeated adenosine infusions can also 
blunt adenosine's cardioprotective effects, the tolerance to ischemic preconditioning was most 
likely due to a loss of adenosine production, as cross-tolerance to preconditioning by 
exogenous adenosine, remote and a classic but adenosine-independent stimulus did not occur. 
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Introduction 
Ischemic preconditioning, the phenomenon whereby brief periods of ischemia and 
reperfusion render the heart more resistant to infarction by a subsequent prolonged period of 
ischemia, 1 has been identified as the most powerful means of endogenous cardioprotection to 
irreversible cell injury.2 Although the mechanism underlying ischemic preconditioning may 
involve activation of adenosine receptors, intravenous infusion of adenosine can enhance 
cardioprotection, even when hearts are already preconditioned by brief episodes of ischemia.3 
Abundant evidence has been presented that ischemic preconditioning also occurs in man.4-<i 
Nevertheless, the demonstration of infarct size limitation by brief anginal episodes in patients 
with an acute myocardial infarction or the benefit of pharmacological exploitation of ischemic 
preconditioning by administration of adenosine is still not convincing?-9 One of the reasons 
may be the development of tolerance to cardioprotection by repetitive applying the same 
stimulus, has been described for both the first and second window of protection. 10-12 Hence, 
without a detailed knowledge of the number and type of preconditioning stimuli (anginal 
episodes) preceding a myocardial infarction it will be next to impossible to classifY hearts as 
preconditioned or tolerant to ischemic preconditioning stimuli. 
It has become apparent that not all preconditioning stimuli activate the same signaling 
pathway to exert their cardioprotective action. 13-16 For instance, we have shown that in the rat 
the cardioprotection by a 15-min coronary artery occlusion (CA015) involves activation of 
adenosine receptors ultimately leading to opening of K+ ATP channels, whereas in the more 
potent cardioprotection by 3 cycles of 3-min coronary artery occlusion interspersed by 5-min 
of reperfusion (3CA03) neither adenosine nor the K+ ATP channel play a role. 16 It is currently 
unknown whether tolerance to an ischemic preconditioning stimulus also implies tolerance to a 
cardioprotective stimulus that employs a different signal transduction pathway. The 
myocardium can also be preconditioned by brief ischemia in non-cardiac tissue such as the 
small intestine, kidneys and skeletal muscle, 17-20 which, at least for the small intestine involves 
a neurogenic pathway. 17' 18 However, whether cross-tolerance occurs between a classical 
ischemic preconditioning stimulus and a remote myocardial preconditioning stimulus has not 
been investigated. The purpose of the first part of the present study was therefore to investigate 
whether tolerance to a particular ischemic preconditioning stimulus (adenosine-dependent 
CA015) also affects the cardioprotection by a classical ischemic preconditioning stimulus that 
involves a different mechanism (adenosine-independent 3CA03) and that by a non-cardiac 
ischemia stimulus (15-min mesenteric artery occlusion, MA015) in the rat. 
The mechanism underlying tolerance to ischemic preconditioning remains unclear. 
However, studies in rabbits and pigs indicate that refractoriness and tolerance to protection or 
may involve a progressive loss of adenosine production21 and/or reduced adenosine receptor 
responsiveness.22 Since we observed in the first part of the study that the ischemia-induced 
increase in myocardial interstitial adenosine concentrations was no longer significant during 
the development of tolerance, we hypothesized that administration of exogenous adenosine 
could still be cardioprotective. 
Chronic administration of adenosine receptor agonists produces tolerance to the 
cardioprotection by adenosine as well as ischemic preconditioning,22 which may involve a 
defect at the A, receptor.23 In contrast, the involvement of adenosine receptor desensitization in 
the development of tolerance to the first window of cardioprotection by adenosine has not been 
investigated. However, Iliodromitis et al., 11 proposed that the time course of development of 
tolerance to the first window of protection by ischemic preconditioning (<2 hours) was too fast 
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to be explained by alterations in the number of adenosine receptors or responsiveness to 
adenosine.24 To assess whether adenosine receptor responsiveness can be attenuated during the 
first window of protection, we additionally investigated whether repetitive 15-min adenosine 
infusions produce tolerance to the cardioprotection by adenosine. 
Methods 
Experiments were performed in ad libitum fed male Wistar rats (300-380 g, n=l58) in 
accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication 86-
23, revised 1996) and with approval of the Erasmus University Rotterdam Animal Care 
Committee 
Surgical and Experimental Procedures 
Pentobarbital-anesthetized (60 mg!kg) rats were intubated for positive pressure 
ventilation with oxygen-enriched room air. Through the carotid artery a PE-50 catheter was 
positioned in the thoracic aorta for measurement of arterial blood pressure and heart rate. 18,25 In 
the inferior caval vein aPE-50 catheter was placed for infusion of Haemaccel (Bebringwerke) 
to compensate for blood loss during surgery, and for drug infusion during the experiments. 
After thoracotomy, via the left third intercostal space, the pericardium was opened and a silk 6-
0 suture was looped under the left anterior descending coronary artery for later coronary artery 
occlusion. A catheter was positioned in the abdominal cavity to allow intraperitoneal 
administration of pentobarbital for maintenance of anesthesia. Rectal temperature was 
continuously measured and maintained at 36.5-37.5° C.18'25 To prevent local heat loss from the 
thorax, the thoracotomy site was covered with aluminum foil. After completion of surgery, a 
30-min stabilisation period was allowed before experimental protocols were carried out. Rats 
that fibrillated were allowed to complete the protocol, provided that conversion to normal sinus 
rhythm occurred spontaneously within 1 min, or that defibrillation by gently thumping on the 
thorax or with a 9V battery was successful within 2 min after onset of fibrillation. Occlusion 
and reperfusion were visually verified. 
To measure myocardial interstitial adenosine levels during the development of tolerance, a 
CMA/20 microdialysis probe (Carnegie Medicine AB, Stockholm, Sweden; membrane 4 mm x 
0.5 mm, cut-off: 20 kD) was implanted into myocardial area at risk of 5 rats.26 After 90 min of 
stabilization, baseline measurements were obtained and rats were subjected to four 15-min 
episodes of coronary artery occlusion. Samples were collected during each 15-min period of 
myocardial ischemia at a rate of 2 J.LVmin. At the conclusion of each experiment probe recovery 
was determined ex vivo using a solution containing 100 J.1M adenosine, and found to be 
14±1%. All samples were stored at -50° C for later analysis. The adenosine concentration in 
dialysate samples was determined by reversed phase high-performance liquid 
chromatography. 27 
Experimental design 
Rat hearts were preconditioned with either one or multiple 15-min coronary artery 
occlusions separated by 15 min of reperfusion (nCA015, adenosine-dependent stimuli), a 
sequence of 3 coronary artery occlusions of 3 min interspersed by 5 min of reperfusion 
(3CA03, adenosine-independent stimulus) or 2 mesenteric artery occlusions of 15 min 
separated by 15 min of reperfusion (2MA015, remote myocardial preconditioning stimulus). 
Pharmacological cardioprotection was produced by either one or multiple 15-min intravenous 
-84-
Cha ter5 
infusions of 200 !lg/min adenosine separated by 15 min (nADO). Myocardial infarcts were 
produced by a 60-min CAO (index ischemia) and infarct size (IS) was determined after 120-
min ofreperfusion.28 The area at risk and infarct area were determined using Trypan blue and 
nitro-blue-tetrazolium staining, respectively.15•17•18•25 Infarct size was expressed as the ratio of 
infarct area and the area at risk. 
Development of tolerance to classical ischemic preconditioning by an adenosine-dependent 
stimulus 
In a control group of rats, infarct size was determined after 120 min of reperfusion 
following the 60-min index ischemia. Subsequently, we determined the duration of the frrst 
window of protection by the adenosine-independent stimulus single CA015 (1CA015) by 
varying the duration of the reperfusion period between the preconditioning stimulus and the 
60-min index ischemia from 10 min to 180 min. Other groups of rats were subjected to either 
two or six episodes of CA015 (2CA015 and 6CA015, respectively) preceding the 60-min 
CAO. The reperfusion period between the last CA015 and the 60-min CAO lasted 10 min. To 
determine the course of the myocardial interstitial adenosine concentration during development 
of tolerance to ischemic preconditioning, a group of ten rats underwent only four episodes of 
CA015 without the 60-min period of index ischemia (4CA015). In separate rats we 
determined the irreversible damage produced by 4CA015. 
Cross-tolerance between adenosine-dependent and adenosine-independent classical 
ischemic myocardial preconditioning 
To investigate whether the adenosine-independent preconditioning stimulus 3CA03 can still 
produce cardioprotection after myocardium has become tolerant to an adenosine-dependent 
stimulus, we replaced the fifth and sixth CA015 by sham periods (4CA015+2Sham) or by 
3CA03 (4CA015+3CA03). 
Cross-tolerance between classical ischemic myocardial preconditioning and remote 
myocardial preconditioning 
We recently reported that a single MA015 limits myocardial infarct size by local 
release of endogenous myocardial adenosine. 17 Consequently, we investigated whether 
intramyocardial release of adenosine by remote preconditioning can still produce protection of 
myocardium that has become tolerant to ischemic myocardial preconditioning by 4CA015 or 
that cross-tolerance to protection by MA015 had also developed. For this purpose, we replaced 
the fifth and sixth CA015 by two episodes ofMA015 (4CA015+2MA015). 
Effect of exogenous adenosine on myocardium tolerant to an adenosine-dependent ischemic 
preconditioning stimulus 
To determine whether an exogenous adenosine infusion will reinstate protection in 
myocardium that has become tolerant to ischemic preconditioning by 4CA015, we replaced 
the fifth and sixth CA015 by two episodes of AD015 (4CA015+2AD015). 
Development of tolerance to cardioprotection by exogenous adenosine 
To investigate whether multiple infusions of adenosine also affected cardioprotection, 
three groups of rats received either one, two or six adenosine infusions (1AD015, 2AD015 
and 6AD015, respectively) before index ischemia. 
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Data Analysis and Presentation 
Infarct size was analyzed by one-way ANOVA followed by Student-Newman-Keuls 
test. Hemodynamic variables were compared by two-way ANOV A for repeated measures 
followed by Dunnett's test. Statistical significance was accepted when p<0.05. Data are 
presented as mean±SEM. 
Results 
Mortality and exclusions 
Of the 158 rats that entered the study, 18 rats were excluded because of sustained 
ventricular fibrillation during CAO or pump failure. Seven rats were excluded due to an area at 
risk <15% of the left ventricle. 
Heart rate and arterial blood pressure 
Baseline heart rate and mean arterial blood pressure for all 106 animals were 353±5 
bpm and 96±2 mmHg, with no significant differences in heart rate (p=0.17) and mean arterial 
blood pressure (p=0.24) between the experimental groups. Similar to previous reports, there 
was no significant linear correlation between the heart rate-pressure product at the onset of the 
60-min CAO and their corresponding infarct size (linear regression:?= 0.001; p=0.78). 
Area at risk 
There were no differences in area at risk (33±1% of the left ventricle; p=0.15) between 
the experimental groups. 
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Figure 1 Time window of protection by JCA015. *p<0.05 versus Control. 
Infarct size 
Figure 1 shows that the cardioprotection by 1CA015 was unmitigated after 70 min but 
was lost after 90 min ofreperfusion. 1CA015 and 2CA015limited infarct size to 43±5% and 
to 37±6%, respectively, compared to 69±2% in control rats (p<0.05; Fig. 2). In contrast, 
6CA015 failed to elicit cardioprotection (68±1 %), demonstrating development of tolerance. 
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The loss of cardioprotection was not caused by the development of irreversible damage during 
the period that the myocardium became resistant to the classical ischemic preconditioning 
stimuli as infarct size was 10±4% after 4CA015. 
1. 
2. 
3. 
4. 
5. 
IA/AR% 
Control (n = 11) i§•f•lieiittel 12(J.minRep 69 ± 2% 
1CA015 (n = 11) • 43 ± 5%* 
2CA015 (n = 8) 
• • 37 ± 6%* 
6CA015 (n= 7) • • • • • • 68 ±1% 
4CA015+Rep (n = 8) ~ ~ ~ ~ 10 ± 4%* I I 
Time(mln) 
-30 30 eo 90 120 175 
Figure 2 Loss of cardioprotection with multiple CA015. *p<0.05 versus control; fp<0.05 versus JCA015; 
fp<0.05 versus 2CA015. 
Ninety min after insertion of the microdialysis probe, adenosine concentrations had 
reached a stable level. Baseline levels, measured 120-min after probe-insertion, were 3.8±0.6 
f,lM. During the first and second CA015 the average interstitial adenosine concentrations 
increased to 27.6±9.8 and 6.4±1.0 f,lM, respectively (both p<0.05 vs baseline), but during the 
third and fourth CA015 the adenosine concentrations were no longer different from baseline 
(Fig. 3). 
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Figure 3 Interstitial adenosine concentrations during 4CA015. Adenosine concentrations represent 
averages for each 15-min period. *p<O. 05 versus baseline. 
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Cross-tolerance between adenosine-dependent and adenosine-independent classical 
ischemic myocardial preconditioning stimuli 
After 4CA015 followed by a sham period (4CA015+2Sham), infarct size (69±2%) 
was not different from that of the control group (69±2%, Fig. 4) or the 6CA015 (68±1%, Fig. 
1). When 4CA015 preceded the adenosine-independent 3CA03 ischemic preconditioning 
stimulus, limitation of infarct size was still present, although less than the limitation produced 
by 3CA03 alone (Fig. 4). Taking into account that after 4CA015 alone infarct size was 
10±4%, it can be calculated that 44±9% of the area at risk that was viable at the onset of 
3CA03 became infarcted. These findings indicate that at a time when the myocardium has 
become tolerant to the protection produced by an adenosine-dependent stimulus protection, 
albeit less, can still be elicited by an adenosine-independent classical ischemic preconditioning 
stimulus. 
IAIAR% 
1. Control (n = 11) i§•+m;•+·Sel 12()..min Rep 69 ± 2% 
9. 4CA015+2Sham (n=7) 
• • • • 69 ± 2% 
13. 3CA03 (n = 14) Ill 29 ± 5% * 
14. 4CA015+3CA03 (n = 9) • • • • Ill 50 ± 8% •t 
11. 2MAO (n = 7) ,. Ill 49 ± 6%*t 
12. 4CA015+2MAO (n = 7) Ill .. .. .. • 
Ill I 49±6%*t I 
-30 30 60 90 120 175 Tlme{mln) 
Figure 4 Cardioprotection by 3CA03 and by 2MA015 is still present in myocardium that has become tolerant 
by 4CAOI5 to the protection by 2CA015. *p<0.05 versus Control; fp<0.05 versus 4CA015+2Sham; 
fp<0.05 3CA03 versus 4CA015+3CA03. 
Cross-tolerance to classical ischemic myocardial preconditioning and remote myocardial 
preconditioning 
Remote myocardial preconditioning by 2MA015 limited infarct size to 49±6% versus 
69±2% in control rats (p<0.05; Fig. 4). When 4CA015 preceded the 2MA015 
(4CA015+2MA015), infarct size was limited to 49±4% (43±7% of the area at risk viable at 
the onset of2MA015) which was not different from the cardioprotection by 2MA015. 
Effect of exogenous adenosine on myocardium tolerant to classical ischemic 
preconditioning by an adenosine-dependent stimulus 
When 4CA015 was followed by 2AD015, infarct size was limited to 40±4% (33±6% 
of the viable area at risk; both p<0.05 vs 4CA015+2Sham), which was not different from the 
infarct size limitation produced by 2AD015 alone. These findings indicate that exogenous 
adenosine can still produce cardioprotection at a time when the myocardium has become 
tolerant to the protection by the adenosine-dependent stimulus 2CA015. 
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Development of tolerance to cardioprotection by exogenous adenosine 
IAD015 and 2AD015 limited infarct size to 26±7% and 35±8%, respectively, while 
after 6AD015 infarct size was 50±6% (p<0.05 vs IAD015) compared to 69±2% in the control 
group (Fig. 6). These data demonstrate that repetitive adenosine infusions can induce, at least 
partial, tolerance to the pharmacological cardioprotection by adenosine. 
IAIAR% 
1. Control (n = 11) i§•ijuile@el 120·min Rep 69 ± 2% 
9. 4CA015+2Sham (n=7) 
• • • • 69 ± 2% 
7. 2ADO (n = 7) 
• • 
35 ± 8% * 
10. 4CA015+2ADO (n=7) 
• • • I • • • I 
40 ± 4% * t 
-30 30 60 90 120 175 nme(mln) 
Figure 5 Cardioprotection by 2AD015 is maintained in myocardium that has become tolerant by 4CA015 to 
the protection by 2CA015. *p<0.05 versus control; p<0.05 versus 6CA015. 
1. 
6. 
7. 
8. 
IAIAR% 
Control (n=9) ijiui!rllt•Sel 120-min Rep 69 ± 2% 
1ADO (n=S) 
• 26 ± 7%* 
2ADO (n=6) • • 39 ± 7%* 
6ADO (n=7) 
• • • I • • • I 
50 ± 6%. t 
-30 30 60 90 120 175 Tlme(mln) 
Figure 6 Progressive loss of cardioprotection with increasing number of AD015. *p<0.05 versus control; 
p<0.05 versus JAD015; tp<0.05 versus 2AD015. 
Discussion 
The major findings of this study can be summarized as follows: (i) Ischemic 
preconditioning by 2CA015 resulted in potent cardioprotection to subsequent 60-min index 
ischemia. However, 6CA015 did not limit infarct size, demonstrating that the myocardium had 
become tolerant to the protection by 2CA015 after fuur episodes ofCA015 were applied. (ii) 
Interstitial adenosine levels were progressively reduced during repetitive episodes of CA015. 
(iii) After tolerance to preconditioning had been produced by 4CA015, cardioprotection could 
still be obtained with the adenosine-independent classic preconditioning stimulus 3CA03 and 
by remote preconditioning with 2MA015. (iv) Similarly, when tolerance had occurred 
cardioprotection could still be produced by 2AD015, suggesting that development of tolerance 
to ischemic preconditioning was not due to blunting of the myocardial responsiveness to 
adenosine. (v) After 4AD015, the protection by 2AD015 was attenuated, indicating that 
myocardial responsiveness to adenosine can be blunted. The implications of these findings 
will be discussed. 
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Refractoriness and tolerance to classical ischemic myocardial preconditioning 
Refractoriness to ischemic preconditioning was first descnbed by Sack et al., t2 who 
preconditioned pigs by 2CA010 interspersed by 30 min of reperfusion. They observed that 
cardioprotection was lost when the duration of the reperfusion period between the second 
CAOlO and the index ischemia was extended from 30 min to 60 min. Interestingly, when after 
60 min the 2CA010 stimulus was again applied, preconditioning could not be recaptured. This 
so called myocardial "refractoriness" to cardioprotection by brief episodes of ischemia was 
later shown to be the result of progressive loss of adenosine production during multiple brief 
ischemic episodes.2 t In contrast, in rabbit;9 and rats30 the early phase of preconditioning can 
be reinstated by applying the same stimulus when protection from the first period has waned 
indicating that, unlike the pig, trne refractoriness does not occur in rodent species.3t However, 
multiple repeated brief coronary artery occlusions preceding a sustained coronary artery 
occlusion can result in tolerance to protection in the rabbit heart, in the first as well as the 
second window of protectionY The present study demonstrates that multiple brief coronary 
artery occlusions can also elicit tolerance to ischemic preconditioning in the rat heart. 
Mechanism of tolerance to cardioprotection 
The mechanism of development of tolerance in the rabbit heart is presently unknown. 
However, based on the mechanism of myocardial refractoriness in the porcine heart, as well as 
the prominent role of adenosine in preconditioning in both rabbits and pigs, a role for 
progressive loss of adenosine production during repeated occlusions also appears a likely 
explanation for tolerance in the rabbit heart. Alternatively, a reduced adenosine receptor 
responsiveness could also contribute. For example, in rabbit hearts, cardioprotection from 
ischemic preconditioning was lost after 72 hours of administration of the adenosine At agonist 
CCP A in a high dose of 1 OOJ.lglkg/h. 22,23 The latter effect may depend on the dose-regimen of 
CCPA, since a lower dose of 40 J.lg/kg administered at 48 hr intervals over 10 days did not 
induce tolerance.32 
The mechanism underlying the development of tolerance in the rat heart has not been 
fully elucidated. Although in this species, a role for adenosine in ischemic preconditioning has 
been questioned,33 we recently showed that not only classical preconditioning by CA015,t5 but 
also remote preconditioning by MA015t7 involves the activation of myocardial adenosine 
receptors. Consequently, we hypothesized that tolerance could be due to a progressive 
exhaustion of adenosine production during 4CA015, and/or a blunted myocardial 
responsiveness to adenosine, stemming from adenosine receptor exposure to repeated 
elevations of intramyocardial adenosine levels. Using microdialysis, we observed that 
interstitial adenosine increased only during the first two episodes of CA015 but was not 
different from baseline during the third and fourth CA015. These observations are in 
agreement with observations regarding refractory myocardium in the pig heart,Zt and suggest 
that both myocardial tolerance and refractoriness are caused by exhaustion of intracellular 
adenosine pools. Alternatively, attenuation of myocardial responsiveness to adenosine could 
have contributed to tolerance, as this has been described in rabbits for the second window of 
protection produced by a high dose of the adenosine At receptor agonist CCPA.22 However, 
based on the fast time course of tolerance development, other investigators have questioned the 
probability of involvement of adenosine responsiveness in the development of tolerance to the 
first window of protection.tt,z4 In the present study multiple infusions of intravenous adenosine 
(administered over a period of 2 hours) induced blunting of the protective effect of adenosine, 
indicating that a reduction of responsiveness to adenosine can already occur during within the 
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first window of protection. From the present study we cannot determine at what level (i.e. 
which subtype of adenosine receptor or their downstream signaling pathways) tolerance was 
induced, but there is evidence that chronic adenosine administration can cause desensitization 
of the A1 receptor.22•23 We have shown earlier that in the rat heart not only A1- but also A3 
receptors are involved in ischemic preconditioning, 15 and can therefore not exclude that a 
reduced responsiveness to A3 receptor stimulation may also have contributed to the 
development of tolerance in the rat heart. 
Although exogenous adenosine was capable of inducing myocardial tolerance to its 
own protection, a loss in responsiveness of adenosine receptor or the downstream signaling 
pathway did not contribute to the development of tolerance by 4CA015. Thus, the 
cardioprotection by 2AD015 was not affected after pretreating hearts with 4CA015, which is 
in agreement with data regarding refractoriness in swine. 12 Cross-tolerance did also not occur 
to remote preconditioning of the heart by mesenteric ischemia, as 2MA015 was capable of 
producing a preconditioned state in myocardium that had become tolerant to the protection by 
2CA015. We have previously shown that MA015 elicits protection in the heart via activation 
of a neurogenic pathway that ultimately leads to adenosine receptor stimulation in the heart.17 
The present findings suggest that 2MA015 may have protected the heart via release of 
adenosine from a source that was not exhausted by 4CA015. Finally, tolerance by 4CA015 
produced partial cross-tolerance to the classical, but adenosine-independent, preconditioning 
stimulus 3CA03. This observation is difficult to explain in view of the unmitigated protection 
to remote and pharmacologic stimuli, as well as the different signal transduction pathway 
involved in 3CA03 versus CA015. Future studies, involving other mediators such as 
bradykinin, 13"16 are required to determine the biochemical basis for this partial cross-tolerance 
to other classical preconditioning stimuli. Taken together, the observations that exogenous 
adenosine, release of endogenous adenosine via remote preconditioning and classical 
preconditioning via an adenosine-independent stimulus were all still capable of protecting 
myocardium that had become fully tolerant to the protection by 2CA015, indicates that 
adenosine receptor responsiveness and the various downstream signaling pathways were still 
intact. 
Clinical relevance 
The results of this study show that tolerance to the first window of cardioprotection by 
ischemic preconditioning can occur within hours when the same stimulus is repeatedly applied. 
However, stimuli that operate through a different signaling pathway may still be effective. In 
studies evaluating the effect of pre-infarction angina on infarct size in patients this has to be 
taken into account as pooling of all pre-infarction angina data might result in a mix of data 
from preconditioned hearts and hearts that have become tolerant to ischemic preconditioning. 
The observation that administration of exogenous adenosine was still protective in hearts that 
had become tolerant to ischemic preconditioning, suggests that in patients with unstable angina 
administration of pharmacological agents that mimic preconditioning can still afford 
cardioprotection. However, observations that repeated administration of adenosine or selective 
agonists can induce (at least partial) tolerance, warrants future studies to determine whether 
chronic administration of cardioprotective agents that act downstream of the adenosine 
receptor, such as K+ ATP channel openers, also induce tolerance. 
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Attenuation of myocardial reperfusion injury by the tyrosine phosphatase inhibitor 
bis(maltolato )-oxovanadium involves the opening of K+ ATP channels 
Summary 
Objectives 
David A. Liem, Coen C. Gho, Ben C. Gho, Shah/a Kazim, 
Pieter D. Verdouw and DirkJ Duncker 
To test the hypothesis that the organic vanadate compound bis(maltolato)-oxovanadium 
(BMOV) limits myocardial infarct size by attenuating reperfusion injury and to investigate the 
underlying mechanism. 
Background 
Vanadate has been shown to inhibit tyrosine phosphatase, leading to an increased tyrosine 
phosphorylation state. The latter has been demonstrated to be involved in the signal 
transduction pathway of ischemic preconditioning, the most potent endogenous mechanism to 
limit myocardial infarct size. Furthermore, there is evidence that phosphatase inhibition may be 
cardioprotective when given late after the onset of ischemia, but the mechanism of protection 
is unknown. 
Methods 
Myocardial infarction was produced in 94 anesthetized rats by a 60-min coronary artery 
occlusion and infarct size was determined histochemically after 180 min of reperfusion. 
Results 
Intravenous infusion of BMOV in doses of 3.3, 7.5 and 15 mg/kg iv decreased infarct size 
dose-dependently from 70±2% of the area at risk in vehicle-treated rats down to 41±5% 
(P<0.05 vs control), when administered prior to occlusion. Administration of the low dose just 
prior to reperfusion was ineffective, but administration of the higher doses was equally 
cardioprotective as compared to administration before occlusion. The cardioprotection by 
BMOV was abolished by the tyrosine kinase inhibitor genistein and by the K+ ATP channel 
blocker glibenclamide, but was not affected by the ganglion blocker hexamethonium. 
Conclusions 
We conclude that BMOV (i) afforded significant cardioprotection; (ii) exerted its benefits 
principally by limiting reperfusion injury, and (iii) appeared to act directly on the heart by 
increasing tyrosine phosphorylation and opening ofK+ ATP channels. 
(Submitted) 
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Introduction 
An increase in tyrosine residue phosphorylation via increased tyrosine kinase activity 
has been implicated in the signal transduction pathway of cardioprotection produced by 
ischemic preconditioning, 1-3 which is the most potent endogenous mechanism to limit 
myocardial infarct size. There is evidence that increased tyrosine residue phosphorylation, 
produced by a shift in the balance between tyrosine kinase and tyrosine phosphatase, increases 
cell survivaL 4-6 Vanadate enhances tyrosine residue phosphorylation by inhibition of tyrosine 
phosphatase.7•8 Consequently, we postulated that vanadate might limit myocardial infarct size. 
To test this hypothesis, we administered different doses of bis(maltolato)-oxovanadium 
(BMOV) to anesthetized rats before a coronary artery was occluded for 60 min and reperfused 
for 3 hours. Interestingly, Armstrong et aL9 reported that serine threonine phosphatase 
inhibitors were highly effective in protecting isolated cardiomyocytes subjected to ischemia, 
when administered late (75 min) after onset of ischemia. Since those findings suggest that 
these phosphatase inhibitors do not require administration prior to the onset of ischemia, we 
also evaluated whether limitation of reperfusion injury contributed to the infarct size limitation 
by administration of BMOV just before reperfusion. To establish whether the limitation of 
infarct size indeed involved an increase in tyrosine phosphorylation, we investigated the effect 
of BMOV on infarct size in the presence of tyrosine kinase inhibition. K+ ATP channels are 
downstream targets or tyrosine kinase in the signalling pathway of ischemic preconditioning. 1'2 
Hence, we determined the involvement of K+ ATP channel opening in the protection by BMOV. 
Finally, a brief period of ischemia in a remote organ can precondition the myocardium by 
stimulation of afferent nerves in the remote ischemic organ that results in activation of a 
neurogenic pathway10 ultimately leading to myocardial adenosine release.11 To study whether 
activation of a neurogenic pathway by BMOV also contributed to the cardioprotection, we 
determined the effect of BMOV on infarct size in the presence of the ganglion blocker 
hexamethonium. 
Material and methods 
Experiments were performed in ad libitum fed male Wistar rats (-300 g) in accordance 
with the Guide for the Care and Use of Laboratory Animals (NIH publication 86-23, revised 
1996) and with approval of the Animal Care Committee of the University. 
Surgical and experimental procedures. Pentobarbital-anesthetized ( 60 mg!kg) rats were 
intubated for positive pressure ventilation (Servo ventilator) with oxygen enriched room 
air.12' 13 Through the carotid artery a PE-50 catheter was positioned in the thoracic aorta for 
measurement of arterial blood pressure and heart rate. In the inferior caval vein a PE-50 
catheter was placed for infusion of physiological saline to maintain fluid balance. Following 
thoracotomy, via the left third intercostal space, the pericardium was opened and a silk 6-0 
suture was looped under the left anterior descending coronary artery for later coronary artery 
occlusion (CAO). A catheter was positioned in the abdominal cavity to allow intraperitoneal 
administration of pentobarbital for maintenance of anesthesia. Rectal temperature was 
continuously measured and maintained at 36.5-37.5° C.14 To prevent local heat loss from the 
thorax, the thoracotomy site was covered with aluminium foiL After completion of surgery, a 
30-min stabilisation period was allowed before experimental protocols were carried out. 
-97-
Mechanistic and therapeutic aspects of ischemic myocardial preconditioning 
Rats that fibrillated were allowed to complete the protocol, provided that conversion to 
normal sinus rhythm occurred spontaneously within 1 min, or that defibrillation by gently 
thumping on the thorax or with a 9V battery was successful within 2 min after onset of 
fibrillation. Occlusion and reperfusion were visually verified.10·12-14 
Experimental protocols 
All rats were subjected to index ischemia consisting of a 60-min CAO followed by 180 
min of reperfusion. At the end of reperfusion the left anterior descending coronary artery was 
reoccluded and the area at risk determined with negative trypan blue staining, after which the 
heart was excised and infarct size determined with negative nitro-blue-tetrazolium 
staining.'O,IZ-14 
To determine whether BMOV had any effect on infarct size 3 doses ofBMOV (3.3 mg/kg, 7.5 
mg!kg and 15 mg/kg) or its vehicle (up to 2.5 ml phosphate buffered saline (PBS)) were 
administered over 10 min, starting 20 min before the 60-min CAO. We subsequently 
investigated whether attenuation of reperfusion injury contributed to the limitation of infarct 
size. Since the former experiments established a dose-dependent limitation of infarct size by 
BMOV, the same doses ofBMOV or its vehicle were again administered over 10 min, but now 
starting 10 min prior to reperfusion. 
To establish whether the limitation of infarct size/reperfusion injury by BMOV 
required an increased state in tyrosine phosphorylation during reperfusion, we investigated 
whether the cardioprotection by BMOV, in a dose of 7.5 mg!kg iv, administered either prior to 
occlusion or prior to reperfusion was affected by the presence of the tyrosine kinase inhibitor 
genistein. Genistein was administered intravenously in a dose of 10 mglkg over 5 min, starting 
15 min prior to reperfusion. To investigate the involvement of K+ ATP channel opening in the 
protection by BMOV, we determined whether the K+ ATP channel blocker glibenclamide 
affected the cardioprotection by BMOV (7.5 mglkg) administered prior to reperfusion. 
Glibenclamide was administered in two doses of 3 mglkg each and infused over a 5 min 
period, the first infusion starting 20 min prior to occlusion and the second infusion starting at 
45 min after the onset of occlusion. Finally, we investigated the involvement of activation of a 
neurogenic pathway in the protection by BMOV by studying the effect of BMOV (7.5 mglkg, 
prior to reperfusion) in the presence of the ganglion blocker hexamethonium (20 mglkg iv) 
administered over 15 min starting 35 min after the onset of occlusion. We and others have 
previously shown that genistein (2,12,15), glibenclamide12•16 and hexamethonium10'11 per se do 
not affect myocardial infarct size. 
Data analysis and presentation 
Infarct size was analysed by one-way ANOV A followed by Dunnett's test. 
Hemodynamic variables were compared by two-way ANOV A for repeated measures followed 
by paired or unpaired t testing. Statistical significance was accepted when P<0.05. Data are 
presented as mean±SEM. 
Drugs. BMOV (GH0-1®, GHO-Pharma, Maastricht, The Netherlands) was dissolved in 1 ml 
(3.3 and 7.5 mg/kg) or 2.5 ml (15 mg/kg) phosphate buffered saline (PBS, modified Sorensen). 
Genistein (10 mglkg, Sigma Chemicals) was dissolved in 0.3 ml of 95% ethanol and alkamuls 
EL-620 (a generous gift from Rhodia) to which 0.3 ml physiologic saline was added. 
Glibenclamide (3 mglkg, Sigma Chemicals) was dissolved in 1 ml of deionized H20 at a pH of 
10. Hexamethonium (20 mg/kg, Sigma Chemicals) was dissolved in 1 ml physiologic saline. 
Fresh drug solutions were prepared on each day. 
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Results 
Exclusion criteria. Of the 107 rats that entered the study, 10 rats were excluded because 
of sustained ventricular fibrillation (no more than 3 rats in one group) and 3 rats were excluded 
because the area at risk comprised less than 10% of the left ventricular mass. 
Infarct size 
There were no differences (P=0.71) between the areas at risk of the various 
experimental groups (41±1%, n=94). Infarct size, which was 70±2% in vehicle-treated rats, 
was limited in a dose-dependent manner to 41±5% by administration ofBMOV prior to the 60-
min CAO (P<0.05; Fig. 1, left panel). When administered just prior to reperfusion, BMOV in 
the dose of 3.3 mg/kg was ineffective, but the doses of 7.5 and 15 mg/kg were equally 
cardioprotective as the comparative doses when administered before the 60-min CAO (Fig. 1, 
right panel). 
The cardioprotection by BMOV in a dose of 7.5 mg/kg was abolished when rats were 
treated with genistein, independent of whether BMOV was administered prior to the 60-min 
CAO (Fig. 2, left panel) or the 180-min reperfusion period (Fig. 2, right panel). The 
cardioprotection by BMOV, administered prior to reperfusion, was also abolished by 
glibenclarnide but not by hexamethonium (Fig. 3). 
Heart rate and arterial blood pressure 
There were no significant baseline differences in heart rate (P=0.24) and mean arterial 
blood pressure (P=0.35) between any of the experimental groups (Table). In the PBS-treated 
groups, heart rate and mean aortic blood pressure remained virtually unchanged throughout the 
60-min CAO. During the subsequent 180-min reperfusion period, blood pressure slightly 
decreased and heart rate slightly increased. BMOV, administered either prior to occlusion or 
prior to reperfusion, produced transient and dose-dependent increases in mean arterial pressure 
(37±4 mrnHg), which were accompanied by decreases in heart rate. Apart from these transient 
effects the hemodynamic responses tot occlusion and reperfusion were not different from the 
responses in the vehicle-treated animals. 
Pretreatment with genistein markedly attenuated the pressor response induced by 7.5 
mg/kg BMOV (14±5 mmHg compared to 37±4 mmHg, P<0.05; Table). In contrast, the 
BMOV-induced increase in blood pressure was not altered by pretreatment with either 
glibenclamide (28±10 mmHg) or hexamethonium (53±12 mmHg). 
Infarct size limitation by pre-occlusion treatment with BMOV was not related to alterations in 
the product of heart rate and mean arterial blood pressure at the onset of occlusion (Fig. 4, left 
panel), which is in line with previous observations that infarct size is not correlated with 
oxygen demand at the onset of occlusion.10' 14' 17' 18 In addition, the cardioprotection by BMOV 
administered prior to reperfusion was also not correlated with the rate-pressure product at the 
onset of reperfusion (Fig. 4, right panel). 
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Figure I Effects of BMOV administered prior to ischemia (left panel) or repeljitsion (right panel) on 
myocardial infarct size produced by a 60-min CAO. *P<0.05 vs corresponding vehicle (PBS); tP<0.05 BMOV 
vre-reverfusion vs BMOV vre-CAO. 
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Figure 2 Effects of the tyrosine-kinase inhibitor genistein (1 0 mg!kg) iv, administered 15 min prior to 
repeljitsion, on the cardioprotection by intravenous administration of 7.5 mg/kg BMOV administered 
either prior to ischemia (left panel) or prior to reperfosion (right panel). *P<O. 05 vs corresponding vehicle 
(PBS); fP<0.05 vs BMOV. 
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Figure 3 Effects of the K + ATP channel blocker glibenclamide (2 x 3 mg/kg iv) or the ganglion blocker 
hexamemethonium (20 mg/kg iv) on the cardioprotection by 7.5 mg!kg BMOV intravenously administered 
vrior to reverfusion. *P<0.05 vs vehicle {PBS!: tP<0.05 vs BMOV. 
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Table Heart rate and arterial blood pressure 
Pre-Coronary Artery Occlusion (min) Coronary Artery Occlusion (min) Rep erfusion (min) 
-25 -10 -1 30 50 60 15 60 120 180 
1. PBS ore-CAO (n=14l 
HR 360±8 357±9 359±8 368±8 368±8 367±8 369±9 379±13 390±11*1 397±9*1 
MAP 95±3 100±3 98±2 95±3 95±3 96±3 90±4 92±3 86±4 91±4 
2. BMOV 3.3 pre-CAO (n=7) 
HR 385±12 297±16* 367±15 380±14 378±17 379±17 382±18 396±15*1 398±12*1 407±9*1 
MAP 99±3 123±4* 100±3 92±5 94±4 95±3 89±5 93±5 88±6 87±4 
3. BMOV 7.5 pre-CAO (n=5) 
HR 347±11 251±15*1 310±15 362±71 359±121 362±141 370±141 370±161 393±17*1 391±10*1 
MAP 91±1 134±5* 100±5 101±5 102±3 96±1 93±3 91±4 88±3 80±61 
4. BMOV 15 pre-CAO (n=5) 
HR 340±9 298±11 *I 334±11 358±9 360±8 346±14 360±8 375±61 409±13*1 400±17*1 
MAP 94±3 138±10*1 102±10 87±12 84±101 84±101 83±71 85±91 84±61 72±11*1 
5. PBS pre-REP (u=S) 
HR 374±7 342±10* 338±6* 344±11 * 341±7* 341±7* 349±8* 355±9* 373±131 383±81 
MAP 97±2 99±3 97±3 95±4 96±5 100±5 94±4 92±5 89±7 89±3 
6. BMOV3.3 pre-REP (u=S) 
HR 387±11 367±11 361±10 361±5 363±4 340±11 * 371±9 371±8 382±11 404±111 
MAP 99±5 95±3 84±4* 84±6* 92±4 106±511 94±6 83±7* 76±6* 78±7* 
7. BMOV 7.5 pre-REP (u=12) 
HR 371±7 335±7* 331±9* 340±11* 335±11* 286±8*11 333±10* 333±12* 361±111 363±191 
MAP 104±2 98±2 97±2 96±3 98±3 134±4*11 97±2 91±6 83±3* 84±3* 
8. BMOV15 pre-REP (u=9) 
HR 367±6 338±6* 333±3* 339±5* 339±5 274±5*11 314±7* 344±9* 357±61 379±41 
MAP 101±3 97±3 95±2 97±3 102±2 135±5*11 96± 3 93±4* 83±2*1 88±4*1 
9. BMOV 7.5 +Genistein (u=6) 
HR 351±16 249±9* 295±10* 330±10 300±13* 355±91 357±121 345±91 332±20 348±151 
MAP 108±2 161±3*1 115±5 95±51 75±8*1 101±51 88± 4*1 86±5*1 89±71 83±9*1 
10. Genideiu + BMOV7.5 (u=6) 
HR 375±13 353±14 333±9* 369±12 356±18 330±6 358±26 395±151 402±151 387±171 
MAP 101±5 100±3 106±2 88±41 91±8 105±81 86±61 83±21 94±6 81±51 
11. Glibeuclami(le + BMOV 7.5 (u=7) 
HR 341±14 343±8 349±11 345±10 351±11 281±20*11 328±12 373±15 372±15 385±17*1 
MAP 104±7 124±3 126±2 104±5 117±4 145±8*1 105±7 98±61 87±101 94±71 
12. Hexametlronimn + BMOV 7.5 (n= 7) 
HR 363±16 365±13 367±13 365±10 334±101 298±14*11 327±9*1 351±13 357±14 378±11 
MAP 103±6 101±4 105±3 100±1 71±4*1 124±14*1 83±3*1 86±3 84±41 87±3 
HR= heart rate (bpm); mean arterial blood pressure (mmHg); -10 min of occlusion corresponds to the end of infusion of vehicle. Data are mean±SEM; * P<0.05 vs Baseline; IP<0.05 vs pre-CAO (-I 
min); IP<0.05 60 min CAO vs 50 min CAO. 
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Figure 4 Lack of relation between the rate-pressure product at the onset coronary artery occlusion (left panel) 
and the onset of reperfosion (right panel) and myocardial infarct size in rats receiving PBS or BMOV prior to 
occlusion (open symbols) or prior to reperfitsion (solid symbols). Circles denote PBS, squares denote 3.3 
mg!kg BMOV, while upward and downward triangles denote 7.5 and 15 mg/kg BMOV, respectively. 
Discussion 
The major findings in the present study in the in vivo rat heart are that (i) pretreatment 
with BMOV limited myocardial infarct size in a dose-dependent manner, (ii) at sufficiently 
high doses, BMOV was equally cardioprotective when administered prior to reperfusion as 
compared to administration prior to coronary artery occlusion, (iil) tyrosine kinase inlubition 
and K+ ATP channel blockade abolished the cardioprotection by BMOV, and (iv) ganglion 
blockade had no effect on BMOV's cardioprotection. The implications of these findings will 
be discussed below. 
Importance of dosage and timing of administration of BMOV 
Previous in vitro studies have indicated that vanadate possesses cardioprotective 
properties. For example, vanadate limited acidosis and lactate accumulation during global 
ischemia in isolated buffer perfused rat hearts, although post-ischemic recovery of left 
ventricular-developed pressure was only minimally improved.19 These data are difficult to 
interpret, because vanadate was administered in a high dose of 40 1-1M that produced marked 
cardiodepression at baseline, as reflected in the more than 50% reduction in left ventricular-
developed pressure.19 Furthermore, ischemia lasted up to 15 min, which in buffer-perfused 
rodent hearts may already result in significant necrosis.2° Consequently, without measurement 
of infarct size, no distinction can be made between a vanadate-induced attenuation of 
reversible contractile dysfunction (stunning) versus limitation of myocardial infarct size. 
In rabbits with pressure-overload induced left ventricular hypertrophy, vanadate was 
administered for a period of 3-4 weeks in a dose of 7.5 mg/kg PO per day dissolved in drinking 
water. When hearts were subsequently isolated and buffer perfused, glycolytic flux in the 
hypertrophied compared to normal hearts was depressed but glucose transport was enhance<f1• 
Furthermore, during a 40 min period of global ischemia, these vanadate-treated hypertrophic 
hearts showed reduced lactate release and improved post-ischemic recovery of left ventricular-
developed pressure compared to vehicle- treated hypertrophied rabbit hearts.21 However, since 
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the duration of ischemia exceeded 15-20 min, again no distinction can be made between a 
vanadate-induced attenuation of reversible contractile dysfunction (stunning) versus limitation 
of myocardial infarct size. 22 
The present in vivo study is the first to demonstrate that BMOV, in a dose-dependent 
manner, limits myocardial infarct size in vivo. At a low dose of 3.3 mg/kg only pre-ischemia 
treatment was effective in limiting infarct size, suggesting either that the compound exerts 
principally anti-ischemic actions or that tissue concentrations were too low at the onset of 
reperfusion. Rats lack a significant collateral circulation in the coronary vascular bed, so that 
administration of BMOV may not have reached the jeopardized myocardium in sufficient 
concentrations prior to the onset of reperfusion. However, at sufficiently high doses, BMOV 
was equally effective when administered prior to reperfusion as compared to administration 
prior to coronary artery occlusion. Taken together these findings suggest that BMOV exerts its 
effects principally during reperfusion, with minimal effect on ischemia-related injury, but that 
sufficiently high concentrations need to be present in the blood at the onset of reperfusion. It is 
of interest to note that in the same rat model the degree of cardioprotection by the highest dose 
of BMOV, i.e. a reduction in infarct size from 70±2% to 40±3%, is similar to the protection 
afforded by a adenosine-dependent ischemic preconditioning stimulus consisting of a single 
15-min coronary artery occlusion (from 70±2% to 49±3%) but less than the protection afforded 
by the adenosine-independent stimulus consisting of three cycles of 3-min occlusion and 5 min 
ofreperfusion (from 70±2% to 24±6%).13 
Mechanism of cardioprotection by BMOV 
The cardioprotective effect of vanadate has been proposed to be in part mediated by its 
apparent free radical scavenging properties. Thus, vanadate has been reported to inhibit the 
generation of superoxide produced by 5 min of perfusion with a mixture of xanthine and 
xanthine oxidase resulting in a blunting of the superoxide-induced loss of sarcolemmal Ca2+-
pump activity and Na+-dependent ci+-uptake in isolated rat hearts.23 In contrast, under certain 
conditions in vitro, vanadate has been shown to be capable of generating free radicals.Z4 
However, this does not account for all its actions, because other investigators failed to observe 
any action of reductants or antioxidants on vanadate-induced expression of actin and c-Ha-
ras.25 Importantly, the role of reactive oxygen species in lethal reperfusion injury is still poorly 
understood, as studies on efficacy of scavengers of reactive oxygen species against reperfusion 
injury have been highly equivocal. 26·27 
In the present study, the tyrosine kinase-inhibitor genistein markedly attenuated the 
cardioprotection by BMOV even when BMOV was administered before ischemia and 
genistein was administered after 45 min of ischemia (i.e. just before reperfusion). These 
findings reflect the strong dependency of BMOV on an intact tyrosine kinase activity during 
reperfusion, and indicate the importance of tyrosine phosphorylation status in the pathogenesis 
of ischemia-reperfusion damage. An increased phosphorylation of tyrosine residues has been 
proposed to afford protection against ischemia-reperfusion damage via a number of subcellular 
actions. First, vanadate exerts insulin-like effects including enhanced stimulation of glucose 
transport and oxidation in the isolated rat heart, which might be due to its tyrosine phosphatase 
inhibitory actions.21 Interestingly, recent clinical trials indicate that a combination of glucose 
and insulin might increase the salvage of cardiomyocytes during early reperfusion. 28 The 
mechanism by which enhanced glucose utilization produces protection might be related to 
increased ATP production at the site of the sarcolemma (and perhaps the mitochondria) during 
the first few min of reperfusion (at a time when mitochondria have not yet resumed ATP 
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production) thereby maintaining ion homeostasis and chaperoning the vulnerable 
cardiomyocytes into a phase in which the mitochondria resume ATP generation.29 Another 
mechanism by which an increase in tyrosine phosphorylation may exert cardioprotection could 
involve in opening of K+ ATP channels. Thus, ischemic preconditioning has been shown to 
involve activation of tyrosine kinase and opening of K+ ATP channels_2,3 In accordance with the 
concept that tyrosine kinase can activate K" ATP channels, we observed that the cardioprotection 
by BMOV was abolished by pretreatment with the K" ATP channel blocker glibenclamide. 
We have previously shown that a brief episode of intestinal ischemia can elicit remote 
preconditioning of the heart via a neurogenic pathway that induces protection via myocardial 
adenosine release and consequent receptor stimulation in the rat heart.10•11 Because BMOV, 
when administered intravenously after a total coronary artery occlusion, cannot easily reach the 
jeopardized myocardium before reperfusion has been reinstated (rats lack a significant 
coronary collateral circulation), we hypothesized that activation of a neurogenic pathway could 
have contributed to the protective actions of BMOV. However, in the present study we 
observed that the ganglion blocker hexamethonium had no effect on the cardioprotection by 
BMOV, suggesting that a neurogenic pathway is not involved in the cardioprotection by 
BMOV. 
Clinical relevance 
Ischemic heart disease, in particular myocardial infarction, has become the most 
important cause of heart failure in developed countries. Early restoration of blood flow to 
jeopardized ischemic myocardium is compulsory for salvaging as many cardiomyocytes as 
possible from cell death. Hence, reperfusion through thrombolysis or percutaneous coronary 
angioplasty is standard treatment in patients with an impending acute myocardial infarction. 
Despite its necessity, several investigators28,3°-33 have suggested that reperfusion causes 
irreversible myocardial damage by itself, beyond that inflicted by ischemia alone. This so-
called "lethal repeifusion injury" implies the death of cardiomyocytes, which are still viable at 
the onset of reperfusion, as a direct result of sequela initiated by reperfusion itself. The 
ultimate consequence is an extension of myocardial infarction. Since myocardial infarct size is 
a strong predictor of left ventricular dysfunction and mortality/4•35 research efforts have been 
aimed at developing pharmacological therapies to limit infarct size.27,36,37 However, most if not 
all of the cardioprotective agents developed to date require administration prior to the onset of 
the period of sustained ischemia in order to be effective. In patients that encounter a 
myocardial infarction as the first symptom of ischemic heart disease, pharmacotherapy can 
only be applied after a coronary artery has occluded. Hence, there is a need for agents that are 
protective even when given after the onset of ischemia or just before reperfusion. To our 
knowledge, BMOV when administered in a sufficiently high dose is the first compound to be 
equally cardioprotective when administered prior to reperfusion as compared to administration 
before ischemia. 
Conclusions 
The present study in an in vivo myocardial infarction model demonstrates that BMOV 
limits myocardial infarct size, principally by attenuating reperfusion-injury. The effect of 
BMOV does not depend on activation of a neurogenic pathway and suggests that BMOV acts 
directly on the heart. The observation that the tyrosine kinase inlnbitor genistein abolished the 
cardioprotection by BMOV is consistent with the compounds' purported tyrosine phosphatase 
inhibiting properties, which resulted in opening of K+ ATP channels. These findings also elude to 
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the importance of the status of phosphorylation of tyrosine residues and K+ ATP channels in the 
pathogenesis ofreperfusion injury. 
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Summary, general discussion 
and future perspectives 
Mechanistic and therapeutic aspects of ischemic myocardial preconditioning 
In this thesis are presented the results of our studies on the mechanism of ischemic 
preconditioning in the rat heart in vivo. In contrast to all other species used for experimental 
study, the major role of adenosine in triggering ischemic preconditioning has never been 
confirmed in rat hearts. We have therefore studied the role of adenosine by stimulating the 
adenosine A1- and A3-receptors in triggering classic ischemic preconditioning (Chapter 2). We 
further studied whether different ischemic stimuli, i.e. a single 15-min ischemic stimulus or a 
triple 3-min ischemic stimulus, activate separate intracellular pathways involving adenosine 
receptors, free radicals, multiple kinases and activation of ATP-sensitive potassium channels. 
In both stimuli, we have demonstrated a pivotal role of uncoupled mitochondria as a unifYing 
point (Chapter 3). Adenosine has been suggested to play a major role in inter-organ 
preconditioning. Therefore, we investigated the role of adenosine and its sites of action in 
inter-organ preconditioning by brief occlusion of the mesenteric artery (Chapter 4). Since the 
development of tolerance to cardioprotection by repeatedly applied preconditioning stimuli 
may interfere with therapeutical applications, we have further elucidated the underlying 
mechanism and search for means to circumvent development of tolerance (Chapter 5). Finally, 
we have shown that ischemia-reperfusion injury by 60-min coronary occlusion can be limited 
by administration of a tyrosine phosphatase inhibitor just prior to reperfusion (Chapter 6). 
Adenosine receptors and classical ischemic preconditioning in the rat heart 
The pivotal role of adenosine in eliciting preconditioning has been firmly established in 
most species used in experimental studies. However, in the rat heart its role had never been 
demonstrated and it was therefore concluded that adenosme does not play a role in myocardial 
infarct size limitation by ischemic preconditioning in rats.1 In previous studies in the rat heart, 
the duration of the ischemic stimuli never lasted longer than 3-5 minutes.Z4 Interestingly, 
Schulz et al. have shown in pigs that intracoronary infused adenosine deaminase was 
ineffective in attenuating infarct size limitation by a 3-min ischemic stimulus, but abolished the 
cardioprotection by a 10-min ischemic stimulus.5 Capitalizing on these previous studies, we 
hypothesized that adenosine could play a role in ischemic preconditioning in rats when 
ischemic stimuli of longer duration are employed. In chapter 2 we therefore investigated the 
role of adenosine in a stimulus consisting of a 15-min coronary artery occlusion which has 
been demonstrated to elicit potent cardioprotection in the rat heart.6 Pretreatment with non-
selective adenosine receptor blockade (with 8-SPT) abolished the cardioprotective effect of the 
15-min ischemic stimulus whereas cardioprotection by three cycles of 3-min coronary artery 
occlusion was not affected. Using selective A1 (low dose of 8-SPT) and selective A3 (MRS-
1191) adenosine receptor blockade, we demonstrated that A1 and A3 receptors contribute 
equally to the cardioprotection by 15-min coronary artery occlusion. These findings indicate 
that adenosine receptors trigger ischemic preconditioning in the rat heart when the ischemic 
stimulus is sufficiently long. 
In conclusion, the involvement of adenosine (and its receptors) in eliciting ischemic 
preconditioning is not species dependent, but depends critically on the duration of the ischemic 
preconditioning stimulus. 
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Mitochondrial uncoupling as a common (end)point of different cardioprotective signaling 
pathways 
Classic myocardial ischemic preconditioning has traditionally been considered to 
trigger a single transduction pathway involving the stimulation of G-protein linked receptors 
(i.e. by adenosine, bradykinin and catecholamines), and activation of protein kinase C resulting 
in opening of ATP sensitive potassium channels. As aforementioned, Schulz et al recently 
demonstrated that different ischemic stimuli may coexist since adenosine was not involved in 
preconditioning by a 3-min coronary artery occlusion but contributed to the cardioprotection 
by a 10-min coronary artery occlusion.5 In addition, Cohen et al reported in the rabbit heart, 
that in contrast to bradykinin, acetylcholine, opioids and phenylephrine, adenosine exerts 
myocardial preconditioning via a separate transduction pathway which does not involve 
opening of ATP sensitive potassium channels and the release of free radicals.7 In chapter 3 we 
demonstrate that infarct size limitation by the adenosine-dependent 15-min coronary artery 
occlusion was not affected by the free radical scavenger mercapto-propionyl-glycerine, 
whereas combined pretreatment with both the tyrosine kinase inhibitor genistein and the 
protein kinase C inhibitor chelerythrine abolished infarct size limitation. Moreover, the 
mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate also abolished 
cardioprotection by 15-min occlusion. Finally, we demonstrated that cardioprotection by 
adenosine infusion was abolished by genistein and chelerythrine, whereas cardioprotection by 
the selective mitochondrial ATP-sensitive potassium channel opener diazoxide was not 
affected. Thus in the rat heart, it appears that preconditioning by a single 15-min coronary 
artery occlusion elicits protection via adenosine, tyrosine kinase and protein kinase C and 
subsequently activation of mitochondrial ATP-sensitive potassium channels. 
Conversely, infarct size limitation by the adenosine independent triple 3-min ischemic 
stimulus was abrogated by either mercapto-propionyl-glycerine, genistein or chelerythrine 
hereby implicating a pivotal role for free radicals, tyrosine kinase and protein kinase C. But, in 
contrast to the single 15-min ischemic stimulus, both pretreatment with 5-hydroxydecanoate or 
the non-selective ATP-sensitive potassium channel blocker glibenclamide had no effect on 
cardioprotection by the triple 3-min ischemic stimulus. To further study the role of free 
radicals and the sequence in the signal transduction pathway, we intravenously infused 
menadione wich generates mitochondrial free radicals by complex Til inhibition. Indeed, 
menadione infusion limited infarct size to a subsequent coronary artery occlusion which was 
completely blocked by inhibiton of both tyrosine kinase and proteine kinase C, but unaffected 
by glibenclamide. It appears that preconditioning with a triple 3-min occlusion leads to release 
of free radicals, subsequently activating tyrosine kinase and protein kinase C without involving 
either adenosine or ATP-sensitive potassium channel opening. 
The preservation of myocardial energy demand in ischemic preconditioning has been 
demonstrated by the observation that the rate of ATP loss was reduced during the subsequent 
prolonged period of ischemia versus control hearts. 8 Moreover, opening of mitochondrial ATP-
sensitive potassium channels appears to play a major role in the signal transduction pathway in 
ischemic preconditioning.9 Therefore, after inducing the preconditioning stimulus in the in 
vivo rat heart, mitochondria from the area at risk zone were isolated to determine oxygen 
consumption in state 2 (succinate) and state 3 (succinate+ADP). Subsequently, the respiratory 
control index (RCI) was calculated from an oxygen change in state 3 over state 2. Respiratory 
control index was decreased by both the single 15-min stimulus and the triple 3-min stimulus 
versus sham treatment demonstrating an uncoupled state of the mitochondria. Most 
interestingly, both glibenclamide and mercapto-propionyl-glycerine not only abolished the 
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cardioprotection by the single 15-min and the triple 3-min preconditioning stimuli, 
respectively, but also prevented the decrease in the respiratory control index. It appears that 
either an adenosine dependent signal transduction pathway, subsequently opening 
mitochondrial ATP-sensitive potassium channels, or an adenosine independent signal 
transduction pathway, generating free radicals, both result in uncoupled mitochondria. 
In conclusion, different ischemic stimuli can activate different cardioprotective signal 
transduction pathways both leading to mitochondrial uncoupling as a common (end)point. 
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Figure I Adenosine released during small intestinal ischemia activates a neurogenic pathway, that 
preconditions the heart via myocardial Ar and A3 receptors. 
Adenosine receptors and inter-organ preconditioning at a distance 
Gho et al. previously demonstrated that 15-min of small intestinal ischemia followed by 
1 0-min reperfusion was also capable of limiting infarct size produced by a subsequent 
prolonged coronary artery occlusion.10 The authors observed that this phenomenon of inter 
organ preconditioning of the heart is induced via activation of a neurogenic pathway upon 
reperfusion. Based on these observations, Pell et al, implicated that adenosine released in the 
ischemic remote organ stimulated afferent nerves leading to myocardial protection. 11 In this 
chapter 4 we investigated whether activation of adenosine receptors are involved in the 
protection by small intestinal ischemia, and we determined the locations of the adenosine 
receptors i.e. myocardial and/or small intestinal. Both pretreatment with an A1-receptor 
selective low dose of 8-SPT and MRS attenuated infarct size limitation by interorgan 
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preconditioning with 15-min mesenteric artery occlusion. When 8-SPT and MRS were 
combined, the protection was abolished implying the involvement of both A1- and A3-receptors 
in myocardial preconditioning by 15-min intestinal ischemia. In addition, infusion of adenosine 
into the mesenteric artery limited infarct size by a subsequent 60-min coronary artery 
occlusion, which was abolished by pretreatment with the ganglion blocker hexamethonium. 
Moreover, a similar dose of adenosine, infused either into the portal vein or into the inferior 
caval vein, did not trigger cardioprotection which demonstrates that adenosine can elicit 
myocardial protection without directly reaching the heart via stimulation of small intestinal 
adenosine receptors and a neurogenic pathway. Finally, we demonstrated that hexamethonium 
when infused 5-min after the ischemic stimulus in the remote organ, did not affect 
cardioprotection suggesting that at this time point the neurogenic pathway is already activated. 
In contrast, infusion of a non-selective dose of 8-SPT also 5-min after the preconditioning 
stimulus, completely abolished infarct size limitation. 
In conclusion, locally released adenosine during small intestinal ischemia stimulates afferent 
nerves in the mesenteric bed during repeifusion initiating a neurogenic pathway that leads to 
activation of myocardial adenosine receptors. (fig. I) These findings suggest that adenosine 
and possible other cardioprotective agents can induce cardioprotection against ischemia 
without reaching the myocardial area at risk. 
Tolerance to multiple ischemic preconditioning stimuli 
Pharmacological exploitation of ischemic preconditioning to limit infarct size in the 
clinical setting is very promising. However, the therapeutical application may be limited by the 
development of tolerance to cardioprotection by repetitive brief ischemic stimuli. In conscious 
rabbits, Cohen et al12 demonstrated that myocardial protection to prolonged ischemia by a 
single ischemic stimulus of 5-min coronary artery occlusion waned when preceded by forty to 
sixty-five 5-min occlusions over a three to four day period, but could be reinstated after an 
ischemia-free interval. The mechanism of myocardial tolerance to ischemic preconditioning 
remains incompletely understood, but it may involve loss of adenosine production, a reduced 
adenosine receptor responsiveness or modifications in downstream signaling pathways. In 
chapter 5 we showed that classic preconditioning by either one or two 15-min classic ischemic 
preconditioning stimuli potently limited infarct size produced by a subsequent 60-min coronary 
artery occlusion. In contrast, ischemic preconditioning by six 15-min ischemic stimuli did not 
afford infarct size limitation demonstrating for the first time, that rats become tolerant to 
preconditioning after multiple ischemic stimuli. We first measured interstitial adenosine levels 
during repeated 15-min coronary occlusions by using a microdialysis probe. Adenosine levels 
were highly increased during the first ischemic episode whereas adenosine levels during the 
fourth episode were back to baseline level. We further investigated the occurance of reduced 
adenosine receptor responsiveness by preconditioning with multiple episodes of exogenous 
adenosine. Six episodes of 15-min adenosine infusions resulted in a blunted cardioprotective 
effect compared to one or two episodes implying a decreased responsiveness of adenosine 
receptors or down stream components. However, myocardium in which tolerance had 
developed after four episodes of 15-min coronary artery occlusions, two 15-min episodes of 
adenosine infusion was equally cardioprotective as two adenosine episodes by itself. This 
implies that tolerance after four episodes of classic preconditioning is not due to a reduced 
adenosine receptor responsiveness. Additionally, we demonstrated in myocardium that had 
become tolerant to four episodes of 15-min ischemia, that an alternative preconditioning 
stimulus was still able to elicit cardioprotection. Two episodes of interorgan preconditioning 
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stimuli, i.e. two 15-min of mesenteric artery occlusions, still limited infarct size to a 
subsequent 60-min coronary artery occlusion. Moreover, the adenosine-independent triple 3-
min ischemic preconditioning stimulus was also still cardioprotective although slightly less. 
In conclusion, the development of tolerance to classic ischemic preconditioning is due to a loss 
of adenosine production and not to a blunted receptor responsiveness. Moreover, tolerance 
does not lead to cross-tolerance to an alternative preconditioning stimulus. 
Inhibition of tyrosine phosphatase limits myocardial reperjusion injury. 
An increased tyrosine residue phosphorylation via increased tyrosine kinase activity has 
been implicated in the signal transduction pathway of cardioprotection produced by ischemic 
preconditioning.13•14 There is evidence that increased tyrosine residue phosphorylation 
increases cell survival. Moreover, a recent study reported that phosphatase inlubition can be 
highly effective in protecting isolated cardiomyocytes when administered late after onset of 
ischemia.15 Therefore in chapter 6 we tested whether myocardial reperfusion injury can be 
limited by inhibition of tyrosine phosphatase. For this purpose, the tyrosine phosphatase 
inhibitor bis(maltolato )-oxovanadium (BMOV), was infused either before a 60-min coronary 
occlusion or prior to onset of reperfusion. When infused before occlusion, BMOV dose 
dependently limited infarc size by 60-min coronary occlusion. Infusion of the tyrosine kinase 
inhibitor genistein 10 minutes before onset of reperfusion, completely abrogated infarct size 
reduction implying that the infarct size limiting effect by BMOV is due to reperfusion injury in 
a tyrosine kinase dependent way. Indeed, when BMOV was infused 10 minutes prior to 
reperfusion, infarct size limitation was equal to treatment with BMOV before occlusion. Since 
ATP-sensitive potassium channels are downstream targets of tyrosine kinase we tested the 
protective effects of BMOV during ATP-sensitive potassium channel inhibition with 
glibenclarnide. Subsequently, glibenclarnide completely abrogated infarct limitation by 
BMOV, demonstrating a pivotal role of ATP-sensitive potassium channels. Because BMOV 
was infused during late coronary artery occlusion, it may not have reached myocardial area at 
risk zone. In view of our results in chapter 4, we further investigated whether BMOV elicited 
cardioprotection at a distance via a neurogenic pathway similar to inter-organ preconditioning. 
However, the ganglion blocker hexamethonium had no effect on cardioprotection, so it appears 
that BMOV acted directly on the heart. 
In conclusion, inhibition of tyrosine phosphatase can protect against myocardial repeifusion 
injury via opening of ATP-sensitive potassium channels. 
Determinants of infarct size 
Within each preconditioning group, infarct size showed wide variability which was less 
in the control group. Variability in infarct size can be ascrtbed to variations in several known 
detenninants of infarct size such as body temperature, 16 systemic hemodynamics, occlusion 
time,17 collateral blood flow18 and size of area at risk.19'20 However, all experimental groups, 
either preconditioned or in control, were subjected to exactly the same index ischemia period. 
Myocardial temperature was carefully kept constant between 36.5 - 37.5 oc which excludes 
temperature as a possible factor for variability in infarct size. Moreover, in each study, heart 
rate-pressure product prior to onset of the 60-min coronary artery occlusion did not show any 
effect on infarct size, demonstrating that the variability in infarct size in the preconditioning 
groups is not due to hemodynamic changes or myocardial oxygen demands before occlusion. 
In dogs, infarct size variability is due to variable collateral blood flow, whereas rats are known 
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to have an insignificant collateral circulation.21 Therefore in rats, it is not necessary to 
incorporate collateral circulation as a covariate in infarct size. Since area at risk size is a major 
determent of left ventricular necrosis, infarct size is generally expressed as a percentage of area 
at risk. Nevertheless, the size of the area at risk has been shown to affect the degree of 
cardioprotection by ischemic preconditioning in dogs,22 rats23 and pigs.24 In these studies, the 
infarct size limiting effect of ischemic preconditioning shows a positive correlation with the 
size of area at risk, being most pronounced when area at risk is small. In contrast, infarct size 
in control hearts appeared independent of changes in area at risk. We have therefore examined 
whether the area at risk in our in vivo rat model has an affect on infarct size limitation by either 
the 15-min coronary occlusion, the triple 3-min occlusion and the 15-min mesenteric artery 
occlusion. In the control group, infarct area as a percentage of left ventricular mass showed a 
highly linear relation with area at risk as a percentage ofleft ventricular mass (figure 2A). 
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Figure 2A Relationship between the infarct size and the area at risk both presented as percentage of the left 
ventricular mass for the control group. The linear regression line shows a very strong relation. (1=0.92, 
P<O.OOJ) Intercept is almost completely through the origin, suggesting a low collateral circulation in rats. 
For dogs, it has been shown that the linear relation between infarct size and area at risk 
in control hearts has a positive intercept on the area at risk axis which can be ascribed to a well 
developed collateral blood flow. In our in vivo rat heart, the linear relation in control hearts, 
intercepted almost completely through the axis with a very slight positive intercept suggesting 
a low collateral circulation in the rat heart. However, in pigs which are known to have limited 
collateral circulation, infarct size also showed a positive intersep with area at risk.26 Since 
infarct size variations are limited in the control group, it is unlikely that wide infarct size 
variations in each preconditioning stimulus are due to collateral blood flow in our in vivo rat 
model. Additionally, in species like rabbits and pigs, the collateral flow to the area at risk is 
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negligible which results in less infarct size variability. To further investigate infarct size 
limiting effect of our ischemic preconditioning stimuli in relation to area at risk size, we 
plotted infarct size as a percentage of area at risk versus area at risk as a percentage of left 
ventricle mass (figure 2B to 2D). Confirming previous studies in dogs, pigs24 and rats/3 
control infarction showed no correlation. However, in contrast to the aforementioned studies in 
which the infarct size limitation of ischemic preconditioning depends on the size of area at risk, 
all ischemic preconditioning stimuli showed no correlation with area at risk size. Thus, the 
wide variability in all our ischemic preconditioning groups is most likely not due to the 
variations in area at risk size since there is no correlation with infarct size limitation. 
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Figure 2B Scatterplot of size of area at risk as a percentage of ventricular weight vs infarct size as a 
percentage of area at risk No correlation was found between variables in the control group. (? =0.01, 
P=0.81) In contrast to former reports in dogs, pigs and rats, no correlation was found in preconditioning by 
15-min coronary occlusion. (r2 = 0.002, P=0.84) 
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Figure 2C Scatterplot of size of area at risk as a percentage of ventricular weight vs infarct size as a 
percentage of area at risk. No correlation was found between variables in ischemic preconditioning by triple 
3-min coronary occlusion(? =0.01, P=0.81) 
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Figure 2D Scatterplot of size of area at risk as a percentage of ventricular weight vs infarct size as a 
percentage of area at risk. No correlation was found between variables in ischemic preconditioning by 15-min 
mesenteric artery occlusion (r2 =0.03, P=0.5) 
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Over the past three years, standard deviation in each preconditioning group remained 
constant when an experiment was randomly added. Therefore it can be concluded that mutual 
infarct size variation within each preconditioning group can be ascribed to a physiological 
phenomenon. The evolution of myocardial infarction over time, follows a sigmoidal course. 
Ischemic preconditioning results in a rightward shift indicating a delay in cell death (figure 3). 
After 60-min coronary occlusion, infarct size development in the rat heart is nearly complete as 
the slope of the curve is almost horizontal. However, in the preconditioning curve, the curve of 
infarct size development is stil very steep at 60-min coronary occlusion indicating a fast rate of 
cellular death at this time point Thus in our in vivo rat model, it appears that after ischemic 
preconditioning, wide variability in infarct size can be ascribed to the fast rate of cellular death 
at 60-min coronary occlusion. 
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Figure 3 Schematic presentation of infarct size development by sustained coronary artery occlusion. At 60-
min occlusion, the slope of the curve in the preconditioning group is much steeper versus the control group 
demonstrating an increased rate of cellular death at this time point. 
Suggestions for future research 
Intense research have yielded a vast amount of insight into the characteristics and 
mechanism of ischemic preconditioning. Moreover, several intracellular mechanisms 
responsible for the cardioprotection achieved with brief antecedent ischemia has been 
identified in virtually every species tested including human myocardium. Mechanistic studies 
have elucidated the underlying pathway(s) from the initial receptors to the incompletely 
understood end-effectors that are associated with this adaptation against prolonged ischemia. 
Subsequently, we not only learned many aspects of cellular physiology and molecular biology, 
but we have also identified a rational framework of pharmacological agents that mimic 
ischemic preconditioning. However, before the principles of ischemic preconditioning can be 
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added to the therapeutical arena, many aspects and questions need to be answered in greater 
detail. 
Mechanisms of the second window of protection by separate transduction pathways 
In this thesis we have shown that different ischemic preconditioning stimuli i.e. either 
an adenosine dependent stimulus by 15-min coronary artery occlusion or an adenosine 
independent stimulus by a triple 3-min coronary artery occlsusion, activate separate 
transduction pathways. In addition, the triple 3-min preconditioning stimulus limited infarct 
size by a subsequent coronary occlusion to a greater extent, also implying a separate 
mechanism. Ischemic preconditioning involves two phases of cardioprotection namely the first 
window of protection and a delayed second window of protection. 27 This thesis was focused on 
studying the first window of protection. Since all ischemic preconditioning stimuli confer 
delayed cardioprotection approximately 24-hours after the stimulus via transcription factors 
and protein synthesis, it would be interesting to elucidate the mechanisms of both ischemic 
stimuli (i.e. the single 15-min versus the triple 3-min stimulus) in the second window of 
protection, and to assess whether separate transduction pathways exert similar cardioprotection 
in the delayed phase. Moreover, separate transduction pathways may lead to synthesis of 
different proteins. 
The role of uncoupled mitochondria in myocardial protection against ischemia 
To date, the end-point of ischemic preconditioning has been in dispute. Three years 
ago, at the start of this thesis, the mitochondrial ATP-sensitive potassium channels were 
considered as potential end-effectors.28 However, they have currently been proposed as 
mediators29 and even as trigger.30 A recent study by Schwartz et al even demonstrated 
cardioprotection by a preconditioning stimulus without the opening of ATP-sensitive 
potassium channels.31 In our in vivo rat model, it appears that both the single 15-min 
preconditioning stimulus and the triple 3-min stimulus after activating separate pathways, unify 
into slightly uncoupled mitochondria. In chapter 3, both diazoxide and menadione have shown 
a strong infarct size limiting effect when infused before a 60-min coronary artery occlusion. 
The next step is to further investigate whether opening mitochondrial ATP-sensitive potassium 
channels or generation of free radicals respectively with diazoxide and menadione in vivo, lead 
to mitochondrial uncoupling. Other important targets to elucidate cardioprotection in relation 
to mitochondrial uncoupling are the uncoupling proteins which have been suggested to be 
activated by superoxide.32 Uncoupling proteins are a family of mitochondrial membrane 
proteins that are known to uncouple electron transport from ATP production. 33 
Finally, a very important potential target for further investigation is the mitochondrial 
transition pore which is a protein complex between the inner and outer mitochondrial 
membranes. Pore opening as a result of calcium overload and oxidative stress is followed by 
the release of pro-apoptotic proteins such as cytochrome-c.34•35 Preconditioning has been 
shown to reduce cytochrome-c release. Moreover, Baines et al has recently reported that 
protein kinase Q can directly interact with and inhibit the mitochondrial transition pore. 
Therefore, further elucidation of the mitochondrial transition pore in both the single 15-min 
and the triple 3-min ischemic may yield a better understanding of the mitochondrial role in 
cardioprotection. 
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Inter-organ preconditioning of the heart 
Despite accumulating evidence regarding the existence of inter-organ preconditioning, 
its exact mechanism remains incompletely understood. In contrast to classic preconditioning, 
the temporal profile of inter-organ preconditioning is unknown. In our rat model, a triple 3-min 
mesenteric artery occlusion did not confer cardioprotection whereas a triple 3-min coronary 
artery occlusion showed a strong infarct size limitation. Therefore, the minimal duration of 
preconditioning ischemia and its required reflow phase needs further investigation since it may 
not be similar to classic preconditioning. In addition, it also remains interesting to further study 
other possible charasteristics of inter-organ preconditioning such as the mechanism of the 
second window ofprotection.36 · 
In chapter 4 we demonstrated a pivotal role for the mesenteric release of adenosine 
which is responsible for the activation of a neurogenic pathway. Also bradykinine has been 
reported to elicit cardioprotection at a distance. Similarly, a role for calcitonin gene related 
peptide, of which the release the release can be modulated by adenosine has been implicated in 
cardioprotection by small intestinal ischemia.36 Therefore, further studies are required to 
elucidate other humoral factors and their sites of action in inter-organ preconditioning. 
Finally, in chapter 3 we have demonstrated that protection by classical ischemic 
preconditioning likely involves mitochondrial uncoupling which may play a pivotal role in 
inducing myocardial protection against ischemia. Similarly, it would be of interest to further 
investigate in our in vivo rat model whether a small intestinal ischemic preconditioning 
stimulus also involves mitochondrial uncoupling. 
Development of tolerance to classic ischemic preconditioning? 
Four episodes of 15-min coronary artery occlusion lead to development of tolerance in 
which infarct size limitation is abrogated. However, we have demonstrated that this does not 
lead to cross-tolerance for alternative preconditioning stimuli such as exogenous adenosine, 
mesenteric artery occlusions and a triple 3-min coronary artery occlusion. In addition, we 
could further study the development of tolerance by multiple episodes of the triple 3-min 
coronary occlusions or 15-min mesenteric artery occlusion and the occurance of cross-
tolerance for alternative stimuli. 
Finally, since mitochondrial uncoupling may be a unifying endpoint in ischemic 
preconditioning and therefore be responsible for the mechanism behind cardioprotection 
against ischemia, it would be interesting to further investigate whether mitochondrial 
uncoupling is also lost after development of tolerance by multiple ischemic preconditioning 
stimuli. 
Tyrosine kinase and myocardial reperfusion injury 
As aforementioned, mitochondrial permeability transition has been shown to be a 
critical event in both necrotic and apoptotic cell death.34'35 The exact nature of mitochondrial 
permeability transition in relation to apoptosis and/or necrosis is yet to be discovered. Protein 
tyrosine phosphatase is known to trigger apoptosis.37 It has been suggested that apoptosis plays 
a pivotal role during myocardial reperfusion injury which may be triggered via pro-apoptotic 
proteins released from the mitochondrial transition pore. Moreover, protein kinase Cc. has 
recently been demonstrated to inhibit the transition pore. 38 Therefore, a further goal of 
investigation would be the interaction of tyrosine kinase with the mitochondrial transition pore. 
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Mechanistic and therapeutic aspects of ischemic myocardial preconditioning 
In dit proefschrift staan de resultaten van de studies van bet Laboratorium voor 
Experimentele Cardiologie naar het mechanisme van ischemische preconditionering in 
genarcotiseerde ratten. De rol van adenosine in ischemische preconditionering is, in 
tegenstelling tot de andere proefdier modellen, nooit aangetoond in het in vivo rattenhart. 
Daarom hebben wij de rol van adenosine A1- en A3-receptoren bij het induceren van klassieke 
ischemisch preconditionering bestudeerd (hoofdstuk 2). Hierop volgend hebben wij onderzocht 
of verschillende ischemische preconditionerings stimuli ( een 15-min durende coronaire 
occlusie, of 3 cycli van 3-min coronaire occlusie) verschillende transductie paden induceren 
met betrekking tot adenosine-receptoren, vrije radicalen, kinase eiwitten en ATP-gevoelige 
kaliumkanalen. Wij hebben aangetoond dat ontkoppelde mitochondrieen een belangrijke rol 
spelen in beide ischemische preconditionerings prikkels (hoofdstuk 3). Er zijn studies die 
suggereren dat adenosine een belangrijke rol speelt bij inter-orgaan preconditionering. Daarom 
hebben wij onderzocht of adenosine een rol speelt bij inter-orgaan preconditionering door een 
15-min durende occlusie van de arterie mesenterica superior. Verder hebben wij gekeken op 
welke lokatie ( d.w.z. in het mesenterium, in de lever of in bet myocardium) adenosine een rol 
speelt in dit phenomeen (hoofdstuk 4). Omdat de ontwikkelling van tolerantie voor 
cardioprotectie na herhaalde ischemische preconditionerings prikkels de therapeutische 
applicatie kan vertragen, hebben verder gekeken naar mogelijk heden om deze tolerantie te 
kunnen omzeilen (hoofdstuk 5). Tenslotte hebben wij aangetoond dat reperfusie-schade na een 
60-min durende coronaire occlusie kan worden gereduceerd door infusie met een tyrosine 
phosphatase remmer vlak voor de reperfusie (hoofdstuk 6). 
Adenosine receptoren en klassieke ischemische preconditionering in bet rattenhart 
Bij de meeste diersoorten is de rol van adenosine in ischemische preconditionering 
duidelijk aangetoond. Echter, in bet rattehart heeft men de rol van adenosine nooit kunnen 
aantonen waarna men concludeerde dat deze in de rat geen rol zou spelen bij infarct schade 
beperking door ischemische preconditionering. In eerdere studies in de rat, heeft men altijd 
preconditionerings prikkels van 3-5 minuten gebruikt. Echter, Schulz et al. heeft in 
genarcotiseerde varkens aangetoond dat intra-coronair geinfundeerde adenosine deaminase niet 
in staat was de infarct schade beperking te blokkeren door een 3-min ischemische 
preconditionerings prikkel maar wel door een 10-min ischemische preconditionerings prikkel. 
Met bet oog op deze studies hebben wij daarom als hypothese gesteld dat adenosine in de rat 
wei een rol speelt bij ischemische preconditionerings pnKkels van langere duur. In hoofdstuk 2 
hebben wij daarom de rol van adenosine bestudeerd bij een prikkel van 15-min coronaire 
occlusie welke in de rat leidt tot potente infarct schade beperking. Voorbehandeling met de 
non-selectieve adenosine receptor blokker 8-SPT blokkeerde bet infarct beperkend effect van 
de 15-min durende preconditionerings prikkel. Echter, bet infarct schade beperkend effect van 
drie cycli van 3-min coronaire occlusie werd met dezelfde dosering niet geblokkeerd. Door 
middel van een A1 selectieve- (met een lage dosis 8-SPT ) en een A3-selectieve blokker, 
hebben wij aangetoond dat zowel A1- en A3-receptoren een gelijkwaardige rol spelen bij een 
ischemische preconditionerings prikkel van 15-min coronaire occlusie. Onze bevindingen 
suggereren dat adenosine receptoren ischemische preconditionering induceren in bet rattenhart 
wanneer de ischemische preconditionerings prikkel voldoende lang is. 
Concluderend kan gesteld worden dat de rol van adenosine (en adenosine receptoren) niet 
ajhankelijk is van de diersoort, maar van de duur van de ischemische preconditionerings 
prikkel. 
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Mitochondriale ontkoppeling als een gemeenschappelijk (eind)punt van verschillende 
cardioprotectieve signaal transductie paden 
Het wordt algemeen verondersteld dat klassieke ischemische preconditionering 
geactiveerd wordt via een enkele signaal transductie pad met betrekking tot G-eiwit gelinkte 
receptoren (voor adenosine, bradykinine, en catecholamines), activatie van proteine kinase C, 
en opening van ATP-gevoelige kalium kanalen. De eerder genoemde studie van Schulz et al. 
toonde aan dat verschillende ischemische preconditionerings stimuli naast elkaar kunnen 
bestaan aangezien adenosine niet betrokken is bij een 3-min coronaire occlusie, maar wei bij 
een 1 0-min coronaire occlusie. Hierop volgend, heeft Cohen et al. aangetoond in bet konijnen 
hart dat, in tegenstelling tot bradykinine, acetylcholine, opiaten en catecholamines, adenosine 
myocardiale preconditionering induceert via een altematieve transductie pad zonder generatie 
van vrije radicalen en ATP gevoelige kalium kanalen. In hoofdstuk 3 tonen wij aan dat de 
infarct schade beperking van de adenosine afhankelijke ischemische preconditionerings 
stimulus na 15-min coronaire occlusie niet kan worden gebokkeerd door de vrije radicalen 
scavenger MPG. Voorbehandeling met zowel de tyrosine kinase blokker genisteine en de 
proteine kinase C blokker chelerythrine blokkeerde de infarct schade beperking volledig. Ook 
de rnitochondriale ATP-gevoelige kalium kanaal blokker 5-HD was in staat de cardioprotectie 
van een 15-min coronaire occlusie te blokkeren. Ten slotte hebben wij aangetoond dat 
cardioprotectie na adenosine infusie wordt geblokkeerd door voorbehandeling met zowel 
genistein en chelerythrine terwijl de cardioprotectie van de rnitochondriale kalium kanaal 
opener diazoxide niet kon worden geblokkeerd. In de ratten hart blijkt preconditionering met 
een 15-rnin coronaire occlusie geinduceerd te worden via adenosine, tyrosine kinase en 
proteine kinase C hetgeen resulteert in opening van mitochondrial ATP-gevoelige kalium 
kanalen. 
Hierop volgend hebben wij aangetoond dat bet cardioprotectieve effect van de 
adenosine-onafhankelijke preconditionerings prikkel van drie cycli van 3-min coronaire 
occlusie kan worden geblokkeerd door zowel MPG, genistein en chelerythrine. Echter, 5-HD 
was, in tegenstelling tot de 15-min prikkel, niet in staat bet cardioprotectieve effect te 
blokkeren. Om de verdere rol van vrije radicalen in bet signaal transductie pad hebben wij de 
mitochondriale radicalen generator menadione geinfundeerd. Infusie van Menadione blijkt 
inderdaad in staat te zijn infarct schade te beperken tegen een hierop volgend 60-min coronaire 
occlusie. De cardioprotectie van menadione kon volledig worden geblokkeerd door genistein 
en chelerythrine maar niet door de non-selectieve A TP-gevoelige kalium kanaal blokker 
glibenclamide. Preconditionering na drie cycli van 3-min coronaire occlusie leidt blijkbaar tot 
generatie van vrije radicalen gevolgd door activatie van tyrosine kinase en proteine kinase C, 
zonder activatie van ATP-gevoelige kalium kanalen. 
Gedurende een lange periode van ischernie, is het myocardiale verbruik van ATP sterk 
vermindert na ischernische preconditionering in vergelijking met controle harten. Voor verdere 
studie hebben wij na toediening van een ischernische preconditionerings prikkel in het in vivo 
ratten hart de mitochondrieen van het risico gebied geisoleerd en gekeken naar de zuurstof 
consumptie in state 2 (succinaat) en state 3 (succinate+ ADP). Hieruit werd de respiratoire 
controle index (RCI) bepaald in state 3 over state 2. Zowel in de 15-min preconditionerings 
stimulus als in de 3 keer 3-min preconditionerings stimulus was de RCI Iicht gedaald in 
vergelijking met de controle groep. Na beide preconditinerings prikkels zijn de rnitochondrien 
dus Iicht ontkoppeld. Glibenclarnide en MPG blokkeerden de RCI dalingen respectivelijk in de 
15-min occlusie en de drie keer 3-min occlusie. Blijkbaar resulteren zowel een adenosine-
afhankelijke preconditionerings prikkel (met ATP-gevoelige mitochondriale kalium kanaal 
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opening), en een adenosine-onafhankelijke preconditionerings prikkel (met generatie van vrije 
radicalen), tot Iicht ontkoppelde mitochondrieen. 
Concluderend kan gesteld worden dat verschillende ischemische preconditionerings stimuli, 
verschillende cardioprotectieve transductie paden induceren. De signaal transductiepaden 
komen samen op het niveau van mitochondriale ontkoppeling. 
Adenosine receptoren en inter-orgaan preconditionering op afstand 
Een studie door Gho et al. heeft eerder aangetoond dat een 15-min durende occlusie 
van de arterie mesenterica superior gevolged door 1 0-min reperfusie ook in staat is bet hart te 
beschermen tegen ischemie. Dit phenomeen van inter-orgaan preconditionering van bet hart 
bleek te berusten op activatie van een neurogeen pad tijdens de reperfusie periode. Op basis 
van deze observatie, hebben andere onderzoekers aangetoond dat adenosine, vrijgekomen in 
een orgaan op afstand, afferente zenuwen prikkelt hetgeen leidt tot myocardiale bescherming 
tegen ischernie. In hoofdstuk 4 werd bestudeerd of adenosine receptoren betrokken zijn bij 
inter-orgaan preconditionering na een 15-min durende occlusie van de darm arterie. 
Vervolgens werd gekeken naar de lokalisatie van deze receptoren d.w.z. mesenteriaal en/of 
cardiaal. Zowel een A1 receptor selctieve dosis van 8-SPT als de A3-antagonist MRS 
blokkeerden bet infarct-reducerend effect van 15-min darm arterie occlusie. Infusie van 
adenosine in de arterie mesenterica bleek de infarct -schade van een hierop volgend 60-min 
coronaire occlusie te reduceren hetgeen kon worden geblokkeerd door de ganglion blokker 
hexamethonium. Een gelijke dosis adenosine welke in de vena porta werd geinfundeerd bleek 
geen cardioprotectief effect te induceren. Adenosine blijkt dus cardioprotectie te kunnen 
induceren via stimulering van mesenteriale adenosine receptoren gevolgd door activatie van 
een neurogeen pad. Aangezien hexamethonium op 5-min reperfusie na de preconditionerings 
prikkel geen effect had op bet cardioprotectieve effect terwijl 8-SPT dit effect volledig 
blokkeerde, kunnen wij concluderen dat ook myocardiale adenosine receptoren zijn betrokken 
bij inter-orgaan preconditionering van bet hart. 
Concluderend kan worden gesteld dat adenosine dat vrij komt tijdens een kortdurende darm-
arterie occlusie, afferente zenuwen kan stimuleren in het mesenterium tijdens repeifusie 
waarop een neurogeen pad wordt geactiveerd, hetgeen wederom leidt tot activatie van 
myocardiale adenosine receptoren. Deze bevindingen suggereren dat adenosine, en mogelijk 
ook andere cardioprotectieve agentia, cardioprotectie kunnen induceren zonder dat deze het 
risicogebied bereiken. 
Tolerantie voor preconditionering na multiple ischemische preconditionerings stimuli 
Farmacologische exploitatie van ischernische preconditionering lijkt zeer veel 
belovend. Echter, de therapeutische applicatie zou wei eens belemrnerd kunnen worden door 
de ontwikkeling van tolerantie voor cardioprotectie na herhaalde ischemische prikkels. In bet 
konijnhart is aangetoond dat in tegenstelling tot een enkele 5-min ischernische 
preconditionerings prikkel, veertig tot vijfenzestig 5-min ischemische preconditionerings 
prikkels niet leiden tot cardioprotectie. Het mechanisme van myocardiale tolerantie voor 
ischemische preconditionering is nog steeds moeilijk te omvatten. Het onderliggend 
mechanisme kan een verminderde adenosine produktie omvatten, een verminderde receptor 
activiteit, of andere componenten van bet signaal transductie pad. In hoofdstuk 5 hebben wij 
aangetoond dat zowel een enkele, als twee episoden van 15-min klassieke ischernische 
preconditionerings prikkels in staat waren om de infarct schade veroorzaakt door 60-min 
durende coronair occlusie te beperken. Echter, ischernische preconditionering door zes 
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episoden van 15-min coronaire occlusies bleek geen cardioprotecie te induceren. Hiemee werd 
voor het eerst in rattenharten aangetoond dat tolerantie kan optreden na herhaalde ischemische 
preconditionerings stimuli. Berst werd de interstitiele adenosine concentratie gemeten tijdens 
herhaalde 15-min coronaire occlusies d.m.v. de microdialyse techniek. Tijdens de eerste 15-
min occlusie was de adenosine concentratie duidelijk verhoogd, terwijl deze bij de vierde 15-
min occlusie op baseline niveau bleven. Zes episoden van adenosine infusies resulteerden in 
een Iicht verminderde cardioprotectie in vergelijking met een- of twee episoden van adenosine 
infusies, hetgeen suggereert dat er een verminderde respons optreedt van adenosine receptoren 
of verder op gelegen componenten in het signaal transductie pad. In myocardium waarin 
tolerantie is opgetreden na vier episoden van 15-min coronaire occlusie, bleken twee hierop 
volgende episoden van adenosine infusie een gelijke mate van cardioprotectie te induceren 
t.o.v twee enkele episoden van adenosine infusie. Dit suggereert dat het optreden van tolerantie 
na vier episoden van 15-min coronaire occlusie niet het gevolg is van een verminderde 
adenosine receptor gevoeligheid. Zowel inter-orgaan ischernische preconditionering, als drie 
cycli van 3-min coronair occlusies waren nog in staat om cardioprotectie te induceren. 
Concluderend kunnen wij stellen dat het optreden van tolerantie voor klassieke ischemische 
preconditionering het gevolg is van een verlies van adenosine productie, en niet het gevolg van 
een verminderde receptor gevoeligheid. Tevens leidt tolerantie voor klassieke ischemische 
preconditionering niet tot tolerantie voor een altematieve preconditionerings prikkel. 
Inhibitie van tyrosine fosfatase leidt tot beperking van myocardiale reperfusie schade 
Verondersteld wordt dat een verminderde tyrosine forforylering, hetgeen leidt tot een 
verhoogde tyrosine kinase activiteit, een belangrijke rol speelt in het mechanisme van 
ischemische preconditionering. Er zijn aanwijzingen dat een toegenomen tyrosine fosforylering 
leidt tot een betere eel overleving bij ischemie. Recent is aangetoond dat inhibitie van tyrosine 
fosfatase in een late fase tijdens ischernie nog altijd kan leiden tot cardioprotectie tegen 
ischernie in geisoleerde cardiomyocyten. In hoofdstuk 6 hebben wij onderzocht of myocardiale 
reperfusie schade kan worden beperkt door inhibitie van tyrosine fosfatase. Hiervoor werd de 
tyrosine fosfatase inhibitor bis(maltolato)-oxovandium (BMOV) gebruikt. BMOV werd voor 
een 60-min coronaire occlusie, en vlak voor de reperfusie geinfundeerd. Bij infusie vlak voor 
occlusie, bleeker een dosis afhankelijke infarct schade beperking op te treden. Wanneer hierbij 
de tyrosine kinase blokker genistein vlak voor reperfusie werd geinfundeerd, bleek de 
cardioprotectie volledig te worden opgeheven. Het blijkt derhalve dat BMOV myocardiale 
reperfusie schade beperkt op basis van een tyrosine kinase afhankelijke mechanisme. Wanneer 
BMOV 10-min voor de start van reperfusie werd geinfundeerd, bleek de infarct schade 
beperking gelijk te zijn t.o.v. behandeling met BMOV voor de 60-min occlusie. Aangezien 
ATP-gevoelige kalium kanalen downstream zijn gelocaliseerd van tyrosine kinase, hebben wij 
derhalve de effecten van BMOV bestudeerd tijdens inhibitie van ATP-gevoelige kalium 
kanalen. Het cardioprotectieve effect van BMOV bleek volledig te worden geblokkeerd door 
behandeling met glibenclarnide hetgeen een belangrijke rol voor ATP-gevoelige kalium 
kanalen suggereert. Aangezien BMOV in de late fase van de coronaire occlusie werd 
geinfundeerd, is het mogelijk dat deze cardioprotectie induceert zonder dat deze het risico 
gebied bereikt. Derhalve hebben wij onderzocht of het effect van BMOV te blokkeren is met 
voorbehandeling met hexamethonium. Deze bleek echter geen invloed te hebben op het 
cardioprotectieve effect van BMOV hetgeen suggereert dat deze direkt werkt op het hart. 
Concluderend kunnen wij stellen dat inhibitie van tyrosine fosfatase myocardiale repeifusie 
schade aanzienlijk kan beperken via tyrosine kinase en ATP-gevoelige kaliumkanalen. 
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